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Abstract
DNA methylation is essential for the survival and development of vertebrates. 
Methylated cytosine in the context of CpG-dinucleotides within the genome is 
recognized by proteins from the methyl-CpG DNA binding domain (MBD) family. 
When bound to methyl-CpG DNA, most MBD proteins can recruit histone deacetylase 
(HDAC) silencing complexes to the site of chromatin to remodel its structure, and this 
causes transcription repression. Loss of CpG-DNA methylation results in embryonic 
lethality in mice, but loss of methyl-CpG DNA recognizing MBD proteins produce a 
viable phenotype.
Our interest in MBD proteins arises from our discovery that a subset of them 
interact with RNA. Two MBD proteins (MBD2 and MeCP2) bind their RNA partners 
using a domain that contains arginine and glycine (RG) rich motifs. As proteins with 
RG rich motifs are often substrates of post-translational modifications catalyzed by 
Protein Arginine Methyltransferase (PRMT), I asked whether the two MBD proteins 
are methylated at their arginines, and the consequences of such modification.
By in vitro and in vivo labeling assays, I ascertained that MBD2 and MeCP2 
are substrates of PRMT, and that PRMT1 and PRMT5 are responsible for catalyzing 
different forms of methylation on the MBD2 protein. The relationship between the 
two PRMTs with regard to MBD2 methylation was characterized. Subsequently, I 
identified the significance of MBD2 arginine methylation. Biochemically, methylated 
species of MBD2 protein have less affinity for the HDAC silencing complex and 
methyl-CpG DNA. In cells, the loss in repression activity of arginine methylated 
MBD2 was demonstrated.
As MBD2 mediated repression activity can be relieved by arginine 
methylation, I propose that this mechanism might possibly explains the discrepancy 
between the phenotypes of CpG-DNA methylation null and MBD null mice. This 
study provides the first evidence that PRMT participate in the DNA methylation 
system of chromatin control.
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Chapter 1 Introduction
Chapter 1 Introduction
1.1 Epigenetic control
Following the completion of Human Genome Project in 2003, scientists have 
the blueprint of every gene that constitutes a human being. However, this information 
is insufficient to decipher the mystery of how a single cell, upon fertilization, divides 
into different cells of specialized functions, expressing only a particular subset of 
genes in different space and time, and yet containing the same DNA sequence (191).
Changes in the phenotype of the cell/organism can be achieved without any 
alteration in the primary DNA sequence. This phenomenon is classified loosely under 
epigenetics, which was a term first introduced in the 1950s (155). To date, epigenetics 
has been used to describe the stable, heritable and yet reversible alterations in gene 
expression not involving mutations in the DNA sequence (92, 101).
Various epigenetic factors exist and most of them function interdependently 
to result in the phenotype of the cell. They include, DNA methylation, post-translation 
modification of core and variant histones, non-coding RNA and the overall structure of 
chromatin (147). While examples are aplenty, I focus on the epigenetic mechanisms in 
vertebrates that are related to this study.
1.2 CpG-DNA methylation
The symmetric methylation at the 5-position of the cytosine base of DNA in 
the context of CpG-dinucleotides is the most abundant covalent modification of the 
eukaryotic genome (79). In the human somatic cell, 70-80% of CpG-DNA are 
methylated (20, 61). Non-methylated CpG are generally located around transcription 
start site of genes (100, 192), particularly of those with tissue specific or house­
keeping functions (8).
1.2.1 Heritability and reversibility of DNA methylation
When DNA sequences containing methylated CpG are integrated into the 
genome of cells, the epigenetic mark can be passed on for about 100 generations (202). 
The methyl-CpG landscape of the genome changes as totipotent embryonic stem cells
13
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differentiate into tissue specific cells with specialized functions. Although this 
developmental process is considered irreversible as methyl-CpG patterns are stably 
inherited after differentiation, experimental manipulations have successfully reset the 
methyl-CpG pattern of terminally differentiated cells at specific promoters and render 
it more embryonic-like (51).
Using monoclonal antibodies against methyl-CpG and performing bisulphite 
sequencing of the genome, it is able to study how CpG methylation changes 
throughout the life cycle of an organism (152, 175). In mice, the genome wide 
demethylation of methyl-CpG DNA can occur twice. This demethylation occurs first 
in germ cell development when methyl-CpG of the haploid genome is demethylated 
and then remethylated at maturation (187). The second occurrence is after 
fertilization, when the paternal genome is rapidly demethylated and the maternal 
genome becomes passively demethylated after a few cell divisions (152). Methyl-CpG 
gradually reappears in the embryonic genome after the fifth cell division and increases 
until the end of blastula stage at which the amount of methyl-CpG remains stable 
(200).
The fact that paternal DNA in the mouse zygote undergoes active 
demethylation without DNA replication had spurred researchers on in the search for 
CpG-DNA demethylating enzymes. Although a strong candidate protein was reported 
as the possible enzyme (MBD2, see Chapter 1.4.2)(19), the report has yet been 
reproduced by a different laboratory to date (40).
1.2.2 DNA methyltransferases
While methyl-CpG DNA demethylating enzymes are not identified, advances 
have been made on enzymes that catalyze the methylation of CpG-DNA; these 
enzymes are named DNA methyltransferase (DNMT). The first mammalian DNMT 
was cloned in 1988 (17) and five DNMT with conserved catalytic domain have been 
characterized, they are: DNMT1, 2, 3a, 3b and 3L (18) (Figure 1-1).
14
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A ctivity
DNMT1 I LI Maintenancecxxcxxc catalytic
DNM T2 tRNA
DN M T3a I 
DN M T3b I------------
PHD/CXXC
PHD/CXXC
De novo
DNM T3L I W
PHD/CXXC
Modulates 
DNMT3a & 3b
Figure 1-1 The DNMT protein family.
Five DNMT protein shares the conserved catalytic domain (Green). The PHD/CXXC 
(plant homeodomain-like) zinc linger domain (Red) and the activities of each DNMT 
are indicated. DNMT3L does not contain catalytic activity but is a co-factor of the 
DNMT3a and DNMT3b.
Even before their discovery, predicted activities of DNMT were categorized 
into maintenance or de novo DNA methylation (93, 190). Now, DNMT1 is regarded 
as the maintenance methyltransferase as it methylates cytosines on the newly 
synthesized DNA strand to duplicate the CpG-methylation pattern of the parental DNA 
strand in proliferating somatic cells (79, 136). Although proteolytically cleaved 
DNMT1 also displayed strong de novo DNA methyltransferase activity (18), absence 
of the enzyme in cells does not affect the ability of the genome to derive methyl-CpG 
from non-methylated double stranded DNA by de novo methylation (132).
In the search for genes encoding de novo methyltransferases in cells, 
DNMT3a and DNMT3b were identified (173). Cells lacking both enzymes fail to 
demonstrate de novo methylation activity against retroviral reporter DNA that is 
integrated into the genome (172). In embryos, the CpG-methylation ability of 
DNMT3a and DNMT3b depends on their interaction with a regulatory factor, 
DNMT3L (28). This protein shares a homology with DNMT3a and DNMT3b in the 
PHD zinc finger domain (1) but lacks conserved critical residues in the 
methyltransferase motif and has no DNA-methylation activity both in vitro and in vivo 
(84, 214) (Figure 1-1). Similar to DNMT3L, DNMT2 proteins does not to show any 
DNA methylation activity (174) and is recently identified to be a tRNA 
methyltransferase (80).
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Genetic removals of DNMT have illustrated the importance of these proteins. 
Mice embryos with deletion of DNMT1 in both alleles do not survive beyond E l l  and 
display severe stunning and developmental delay (138). DNMT3a homozygous 
mutants mice are normal at birth but die after few weeks and are significantly smaller 
than normal mice of the same age while DNMT3b mutants are bom dead and their 
embryos exhibit multiple developmental defects. Embryos of DNMT3a and DNMT3b 
double mutation are found to have more severe defects resembling those of DNMT1 
mutants (172). Targeted disruption of DNMT3L produce viable mice but adult 
homozygous males suffer from hypogonadism and homozygous females produce ova 
that cannot survive longer than 9.5 days (28).
Human diseases also arise from aberrant expression of DNMT genes. 
Reduced levels of DNMT1 in T-cells cause the autoimmune disease SLE {Systemic 
lupus erythematosus) and mutations of the DNMT3b gene result in the autosomal 
recessive disease ICF {Immunodeficiency, centromeric instability and facial 
anomalies) syndrome. In both instances, the cells affected display global or partial 
genome hypomethylation (191). Abnormal de novo methylation of CpG-DNA in the 
genome can be observed during establishment of primary cells in culture (101) and has 
been widely correlated to oncogenesis as many tumor suppressor genes are reported to 
be methylated in cancer cells.
Apart from disease, normal methylation of CpG-DNA in the mammalian 
genome is known to be essential for imprinting (137), transposon silencing (225), X 
chromosome dosage compensation (13) and chromosomal stability (60). The role of 
CpG-DNA methylation from the evolutionary standpoint has been argued to either 
serve as a host defense strategy against parasitic self-replicating DNA sequences (235) 
or to prevent the expression of irrelevant genes that would otherwise interfere with the 
agenda of the cell (21). Whichever theory is correct, they both still support the fact 
that methyl-CpG DNA mediates these phenomena by means of chromatin silencing.
1.3 Chromatin silencing mediated by DNA methylation
Methylation of CpG-DNA was correlated with transcription repression since 
the 1970s when methyl-CpG was found to be enriched in constitutive heterochromatin
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(159). Studies of differential methylation of {3-globulin genes from different chicken 
cell types revealed that DNA hypomethylation correlated with increased gene activity 
(186). The strongest clue provided then was observed in cells treated with 5-aza- 
cytidine; a potent DNA methylation inhibitor that triggered the reactivation of 
previously silenced genes in these mouse embryonic cells (104).
1.3.1 Factors repelled by methyl-CpG
The methyl-CpG mark on the genome can be interpreted by binding factors 
that are either repelled or attracted by it to regulate chromatin activity (115). CTCF 
protein is an example of a DNA binding factor that is sensitive to methyl-CpG. 
Genomic imprinting program of cells have instructed the expression of H19 gene only 
from the maternally inherited chromosome and Igf2 gene from the paternal. This 
specificity is caused by CpG-methylation of the paternally inherited chromosome at 
the particular locus while the same position on the maternal chromosome remains 
unmodified (Figure 1-2). Only the non-methylated locus of the maternal chromosome 
is able to recruit the CTCF protein that acts as an insulator to prevent the maternal Igf2 
promoter from gaining access to the transcriptional enhancers that are shared with the 
H19 promoter. On the CpG-methylated paternal locus, CTCF is not present and the 
Igf2 promoter interacts with the enhancers for transcription and thereby shutting down 
the expression of HI 9 gene (134).
Direct occlusion of transcription machinery from reconstituted chromatin can 
also be observed when a single CpG base within the upstream control elements of the 
ribosomal RNA gene is methylated (199). Binding of transcription activators to 
promoters of neurofibromatosis gene in vitro are also inhibited by methylated CpG 
DNA (149).
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Figure 1-2 Regulation of gene expression by imprinting.
Differential methylation of paternal (Blue) and maternal (Red) locus result in the ability 
of CTCF protein to control the accessibility of enhancers (Green) to interact with 
promoters of imprinted genes (White boxes).
1.3.2 Factors attracted by methyl-CpG
Among the protein factors that are attracted to methyl-CpG DNA, the proteins 
from methyl-CpG DNA binding domain (MBD) family are the most thoroughly 
characterized. MBD proteins are the major research interest for this study and will be 
discussed in the following sections.
Insights gained from biochemical and mechanistic properties of the MBD had 
lead to the discovery of other transcription repressors, notably the Kaiso. First 
identified as an interacting partner of the human pi 20 catenin, Kaiso is recognized as a 
transcriptional repressor after its ability to bind methyl-CpG DNA, and repress the 
expression of reporter plasmids in cells (183). Mouse Kaiso protein is also capable of 
binding specific non-methylated DNA sequences (55) but this interaction has not been 
reported to mediate repression. Genetic removal of Kaiso in mice yields healthy 
phenotypes (184) but inhibiting the expression of this protein in frog embryos resulted 
in severe developmental defects and apoptosis (195). In HeLa cell, Kaiso interacts 
with components of the chromatin remodeling complex at the promoter of specific 
genes to mediate transcription repression (236).
1.3.3 Chromatin remodeling implicated with methyl-CpG
Evidence gathered from repressive factors attracted to methyl-CpG DNA 
point towards changes in chromatin structure during the silencing process. Various
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levels of chromatin remodeling may exist and the most intensively studied are the 
post-translational modifications of histone tails. Residues in histones that can be 
modified include lysine, arginine, serine and threonine, and the modifications of lysine 
appear to be the most dynamic with the ability to accept an acetyl, methyl, ubiquitin or 
a sumo group (103, 212).
1.3.3.1 Histone deacetylation
Acetylation and deacetylation of lysines on histones are the earliest chromatin 
modifications linked with transcriptional control and this modification is considered a 
central switch regulating the interconversion between the permissive and repressive 
chromatin structure (223).
Early experiments using episomal chromosome, bearing methyl-CpGs in cells 
showed that addition of sodium butyrate, the histone deacetylase inhibitor, relieves 
methyl-CpG dependent transcriptional repression on the chromosome (96). 
Acetylation of the lysine residue on the N-terminal tail of the histone results in 
neutralization of the positive charge and this leads to weaker affinity of the histone to 
the negatively charged backbone of the DNA, thereby increasing the flexibility of the 
nucleosome structure. The presence of the acetyl group on the lysine residue and the 
increased chromatin flexibility facilitates the interaction of transcription factors and 
the outcome is positive transcription (109) (Figure 1-3).
Acetylation of lysine residue in the histone tail is carried out by histone 
acetyltransferases (HAT) and the antagonistic deacetylation reaction is carried out by 
histone deacetylases (HDAC). HAT are often associated with transcription activators 
while HDAC are found with repressors (168). Non-methylated CpG clustered around 
promoters of actively transcribed genes are associated with hyperacetylated histones 
and the local chromatin structure does not stain strongly with DAPI (4,6-diamidino-2- 
methylindole) (22) whereas regions of the chromosome enriched with methyl-CpG are 
transcriptionally silent and produce a bright DAPI staining pattern due to the 
chromatin structure. The size of acetylated or deacetylated regions of the chromatin 
can range from a single nucleosome to the entire chromosome as seen in X 
chromosome inactivation (119). The majority of methyl-CpG DNA dependent 
transcription repressors typically recruit HDACs to condense the site of chromatin and
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make it inhospitable for RNA polymerase transcription (Figure 1-3). For example, 
Kaiso is found to interact with HDAC3 in HeLa cells (236).
TranscriptionAc Ac Ac Ac HDACs
HATsAc Ac Ac Ac Ac
. HDAC 
complex.
repressors) Ac
Figure 1-3 Actions of HDACs and HAT.
(Top) The interconversion between the acetylated (permissive) and deacetylated 
(repressive) chromatin structure by histone de/acetylases.
(Bottom) methyl-CpG DNA based repressors often recruit HDAC silencing complex to 
certain sites of chromatin and cause formation of transcriptionally silent chromatin.
1.3.3.2 Histone lysine methylation
Methylation of lysines on histone is another modification that is strongly 
linked with transcription regulation. Generally, methylation of lysine 4, lysine 36 and 
lysine 79 of histone H3 correlates with transcription activation while methylation of 
histone H3 lysine 9 (H3K9), lysine 27 and histone H4 lysine 20 is associated with 
heterochromatin and transcription repression (126). Notably, H3K9 is also the site for 
acetylation and effects of H3K9 methylation are in direct contrast with the 
transcriptional activation function of acetylation (156).
Specific lysines in histones can exist in three methylated states, mono, di and 
tri. The number of methyl groups on the lysine residue is believed to determine the 
transcriptional status (150). The diversity of histone lysine methylation can be further 
illustrated by the identification of different enzymes that catalyze the same 
modification. For example, methylation of H3K9 can be mediated by five known 
methyltransferases (Suv39hl Suv39h2, G9A, Eset/SETDBl and EuHMTase) (212). 
An enzyme that removes methyl groups from the methylated H3K9 was also recently 
characterized (118). The methylation signals on H3K9 are recognized by three 
isoforms of heterochromatin proteins (HPla, P and y) and this interaction is thought to
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maintain the stable and heritable heterochromatin status (12, 122). Analysis of 
dimethylated H3K9 localizations in the genome shows that this modification is 
enriched in the inactivated female X chromosome and at the imprinted loci (181), 
whereas trimethylated H3K9 are concentrated in mouse pericentric heterochromatin 
(66). In both instances, the regions where methylated H3K9 are found coincide with 
methyl-CpG DNA.
1.3.3.3 Linking histone deacetylation and H3K9 methylation
Histone deacetylation directed by methyl-CpG DNA and H3K9 methylation 
are closely related mechanisms in transcription silencing and heterochromatin 
formation and both pathways show a certain degree of crosstalk. How one mechanism 
affects the other are still topics of intensive investigation, particularly in mammalian 
cells where various isoforms of DNMTs and histone methyltransferases exist to 
complicate the situation (212). H3K9 methylation is widely believed to be a 
prerequisite for CpG-DNA methylation as mouse cells derived from DNMT1 or 
DNMT3a/DNMT3b knockouts did not display mislocalization of trimethylated H3K9 
whereas depleting SuV39hl and SuV39h2, the enzymes responsible for H3K9 
trimethylation at pericentric heterochromatin, results in loss of DNA methylation at the 
specific loci (131).
It is still unclear how particular regions of chromatin are recognized and 
tagged by these histone methyltransferases and DNA methyltransferases to result in 
the eventual transcription silencing. It is only certain that these processes are mediated 
by protein complexes acting together to perform their specific task. There are various 
examples that illustrate the interactions between DNMTs, HP1 and histone 
methyltransferases (75, 131). Furthermore, DNMTs are reported to interact with 
HDACs and this suggests that besides their catalytic role, DNMTs may also have non- 
enzymatic role in mediating stable transcription silencing and this adds on to the 
complexity (115).
Regardless of the factors involved, transcription repression mediated by 
methyl-CpG DNA is usually dependent on the collaboration between various cellular 
machineries that maintain the dynamic chromatin structure in the silent state (101). 
While the detail mechanistic insights of how transcription silencing by
21
Chapter 1 Introduction
heterochromatin formation is achieved, I look at the first clearest evidence of how 
methyl-CpG DNA leads to the changes in chromatin structure; using the MBD family 
(212).
1.4 Methyl-CpG DNA binding domain protein family
The first specific binding factor of symmetrically methylated double stranded 
CpG-DNA was identified in 1989 from gel filtration studies which indicated that a 
protein complex of 400 to 800 kDa was responsible, and it was assigned as MeCPl 
(157). Repression activity of MeCPl was subsequently demonstrated in vitro and in 
vivo (29).
Shortly after the discovery, a similar approach identified a bona fide  methyl- 
CpG-DNA binding protein of 84kDa, and it was assigned as MeCP2. Antibodies 
raised against MeCP2 revealed that localizations of this protein coincide with the 
distribution of methyl-CpGs in mouse and rat genome (135). Using deletion assays, 
the minimal amino acid sequence within the MeCP2 that show preferential binding to 
methylated-CpG but not to non-methylated-CpG DNA was determined, and this 
sequence is defined as the methyl-CpG binding domain (MBD) (165). Further 
characterizations of MeCP2 also revealed a region of the protein that display 
independent transcription repression activity even when grafted onto irrelevant DNA 
binding protein and this region is named the transcription repression domain (TRD) 
(164).
By searching for sequences that are homologous to the MBD of MeCP2, 
additional members of the MBD family were identified. They are the MBD1 (53), 
MBD2, MBD3 and MBD4 (85) (Figure 1-4). The methyl-CpG DNA binding ability 
of these proteins were ascertained in vitro and MBD1, MBD2 and MBD4 are capable 
of binding DNA containing at least one methyl-CpG. The MBD3 protein is the only 
exception and it was illustrated to have different localization properties in the nucleus 
compared to MBD2, this is due to its inability to discriminate methyl-CpG from non- 
methyl-CpG DNA (85). Subsequent investigations revealed that inability of MBD3 in 
binding methyl-CpG varies from species to species; unlike the mammalian protein, 
MBD3 purified from Xenopus can bind methyl-CpG DNA. (224).
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Figure 1-4 The mammalian methyl-DNA binding domain (MBD) protein family
The MBD (Green) of each protein shares both amino acid and functional homology.
The transcription repression domain (TRD, Red) shares functional homology; it 
recruits histone deacetylase complexes to silence chromatin. The MBD of MBD2 
overlaps the TRD and is indicated by a black line. The MBD of mammalian MBD3 has 
amino acid substitutions that do not allow it to recognize methylated DNA. MBD4 is a 
DNA glycosylase.
MeCP2 and MBD 1-4 now form the founding members of the MBD family 
and more refined searches in the database had identified at least six novel members. 
Of which, three proteins had their MBD functionally verified (193). The MBD 
described here, together with their splice variants, illustrate the diversity of members 
within this family (10).
1.4.1 MeCP2
The first evidence of an MBD protein repressing transcription by chromatin 
remodeling comes from the study of MeCP2. In 1998, two laboratories reported the 
co-purification of MeCP2 with Sin3A protein in mammalian nuclear extracts (166) and 
Xenopus oocytes (105) (Figure 1-5). This interaction is mapped to the TRD described 
previously (164) and the purified MeCP2-Sin3A complex are found to posses histone 
deacetylase activity against synthetically acetylated histone peptide in vitro. In cells, 
the transcription repression activity of MeCP2 can be relieved by the presence of 
histone deacetylase inhibitor (105, 166).
Sin3A is a large multidomain protein that is postulated to be the scaffolding 
for assembly of other repressor complexes (119). Nucleosome remodeling factors 
involved with mouse Sin3A in vivo are: the core components of HDAC silencing
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complex that consists of two histone deacetylases (HDAC1 and HDAC2), two histone 
H4 interacting proteins (RbAp46 and RbAp48) (14), and many newly identified Sin3 
associated proteins (SAP) (58). SAPs identified to date include SAP 180, SAP 130, 
SAP45/SDS3, SAP30, SAP18 and SAP25 (208). Functions of most SAPs are not fully 
characterized, but SAP30 and SDS3 may act as the linker between Sin3A and other 
protein complexes (124) and SAP 18 is thought to enhance Sin3A repression activity 
(241). Besides MeCP2, other DNA binding proteins such as Ski, UME6, Mad/Mnt 
and NCoR/SMRT also target Sin3A complex to chromatin (119).
1.4.1.1 Novel interacting partners of MeCP2
More recent biochemical studies of MeCP2 illustrate that the protein is not an 
exclusive and stable partner of Sin3A-HDAC silencing complexes but is involved in 
numerous chromatin remodeling machineries (116). The TRD of MeCP2 has been 
proposed to target DNMT1 in place of Sin3A complex to hemi-methylated CpG-DNA 
to perform maintenance CpG-DNA methylation (113). MeCP2 also co-purifies with 
DNMT1 and SUV39H1, a H3K9 methyltransferase. The interaction of this 
MeCP2/DNMTl/SUV39Hl complex with another corepressor complex, CoREST, is 
thought to reinforce and propagate the state of silent chromatin (76, 144). A recent 
model also implicates the MeCP2-Sin3A as part of a larger chromatin remodeling 
complex, the SWI/SNF. The mechanism by which this complex represses
transcription is still unresolved (83).
1.4.2 MBD2 and MBD3
The MBD2 and MBD3 protein are the only two proteins from the MBD 
family that have homologues in organisms lower than vertebrates. Therefore, they are 
thought to be the ancestral proteins of the family. Genes coding for both proteins have 
identical genomic structure differing only in the size of their introns. Thus, both 
proteins might arise from a single gene duplication event (88).
The first characterization of the MBD2 coding sequence revealed an internal 
methionine codon that might be use as an alternative translation initiation site for a
24
Chapter 1 Introduction
shorter isoform of MBD2, this postulated isoform is termed MBD2b (85)1. In a 
subsequent report, an antibody was developed to reveal the presence of both MBD2 
and MBD2b proteins in HeLa nuclear extract (170); another recently developed 
antibody suggested that both proteins might exist in a 1:1 ratio2.
Biochemical analysis revealed that MBD2 is the specificity determinant for 
methyl-CpG DNA in the previously identified MeCPl complex, which also contains 
histone deacetylase activity for its transcription repression (170). Purification of the 
endogenous MeCPl complex in HeLa cells showed that it consists of MBD2 
interacting with the nucleosome remodeling and deacetylation (NuRD) complex to 
form the 1 MDa MeCPl (65)(see Chapter 1.4 and (157)).
Unlike the MeCP2/Sin3A, the molecular interaction between MBD2/NuRD is 
relatively more stable in vivo with majority of the MBD2 existing in the complex (65). 
However, similar to MeCP2/Sin3A, the MBD2/NuRD complex also contains the core 
components of HD AC silencing complex consisting of HDAC1, HDAC2, RbAp46 
and RbAp48 (Figure 1-5). Proteins unique to the NuRD include the Mi2 (an ATP 
dependent helicase activity) (65), MTA2 (a modulator of HD AC activities) (242) and 
two isoforms of a zinc finger protein p66 and p68 that are speculated to be essential for 
proper targeting of the NuRD complex to the genome (64). Interestingly, the 
mammalian MBD3, which does not bind methyl-CpG DNA, is an integral component 
of the NuRD (242) and co-exists with MBD2 in the MeCPl (219). However, a recent 
report that challenged the findings of the molecular interaction between MBD2 and 
MBD3 might redraw the position of MBD2 within the MeCPl complex if positively 
verified (125). Xenopus, MBD3 protein has specificity for methyl-CpG DNA and 
plays a more active role in the organism to direct the NuRD complex to methyl-CpG 
DNA (224).
1 For comparison o f MBD2 and MBD2b, see Figure 4-4.
2 Please refer to Sigm a, Anti-MBD2a,b (RA-18), Product Number M 7318.
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Figure 1-5 Components of chromatin remodeling complex on methyl-CpG DNA.
MeCPl and MeCP2 HDAC silencing complexes share the core component of histone 
deacetylation (Middle). Well-characterized members of both complexes are shown, and 
MBD2 and MeCP2 target these protein complexes to methylated DNA to mediate 
transcription repression. MeCPl complex consist of NuRD binding to MBD2.
While the majority of MBD2 are involved with NuRD, only a small fraction 
of cellular NuRD binds MBD2 (65). Other DNA binding factors that interact with the 
NuRD complex include the Drosophila hunchback protein and the mammalian Ikaros 
and Aiolos, which are all zinc finger protein (2).
/. 4.2.1 Novel interacting partners o f MBD2
Different from studies of endogenous MBD2 proteins, transiently 
overexpressed MBD2 in cells showed that the protein interacts with other chromatin 
remodeling factors. MBD2b, a predicted isoform of MBD2 that lacks the N-terminus3 
(85) is found to interact with the Sin3A complex via its TRD (23) (Figure 1-4). A 
novel MBD2 interacting partner MIZF (MBD2 interacting zinc finger) binds MBD2b 
and this interaction is postulated to direct sequence specificity in recognizing methyl- 
CpG DNA (206). Several groups illustrated that MBD2 can function as a transcription 
activator by its interaction with proteins such as the RNA helicase A (73) and the 
MBD/«, a novel protein identified by its interaction with MBD2 (133). Notably, a 
recent finding indicates that MBD2 interacts with TACC3 (transforming-acid-coiled-
3 For the map of MBD2b, refer to Figure 4-4.
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coil) and pCAF, the histone acetyltransferase to reactivate the transcription of 
previously silenced genes (7).
1.4.3 MBD1
MBD1 was thought to be a component of MeCPl complex (53) but 
subsequent experiments using antibodies against MBD1 showed that the protein does 
not co-purify with MeCPl, or affect its activity. There is no indication that MBD1 
interacts with MBD2 (169). Transcription repression activity of MBD1 displays 
variable sensitivity to histone deacetylase inhibitor. This suggests that MBD1 only 
relies partially on HDACs to mediate silencing (73, 169).
MBD1 is the only member of the MBD family that contains the cysteine rich 
(CXXC) motif found in DNA methyltransferase (DNMT1) and histone 
methyltransferase (MLL) (88) (Figure 1-1). The numbers of CXXC motifs present 
depends on the isoforms of the protein, and the motif directs sequence specificity. In 
some mammalian MBD1 isoforms, three CXXC are present and these enable the in 
vivo repression of reporter plasmids containing non-methylated CpG (74, 107).
Similar to MeCP2, MBD1 is reported to form a stable complex with another 
H3K9 methyltransferase, SETDB1. This association is found to direct histone lysine 
methylation to methyl-CpG DNA at specific genes throughout the cell cycle. During 
DNA synthesis, the MBD1-SETDB1 complex transiently interacts with chromatin 
assembly factor, the CAF1, which is bound to the replication fork machinery. This 
interaction is thought to target the MBD1-SETDB1 to methyl-CpG DNA to form 
stable heterochromatin (201).
1.4.4 MBD4
MBD4 is the odd member of the MBD family as transcription repression 
activity remained undiscovered for many years. Instead, MBD4 is considered as a 
DNA repair enzyme. This is because, although the protein recognizes double stranded 
methyl-CpG DNA, it displayed a stronger preference for double stranded methyl-CpG 
DNA when the methyl-cytosine on the complementary strand is deaminated to 
thymine. Furthermore, a DNA glycosylase domain is identified at the C-terminus of
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the MBD4, providing the ability to remove thymidine or uracil bases from damaged 
DNA strands (87) (see Figure 1-4).
As demaination of methyl-cytosine to thymine is the most common 
mutagenic base transition on the DNA (215), the repair function of MBD4 is much 
sought after because it represents a stabilizing agent of the genome. However, loss of 
MBD4 in mice that are deficient in mismatch repair activity does not increase tumor 
onset. This downplays the significance of this protein in defense of the genome 
against mutation (198).
The recently discovered transcription repression activity of MBD4 
demonstrated that the central region of the protein interacts with Sin3A and HDAC1 
( 120).
1.5 Relevance of MBD to mice
In comparison to the embryonic lethality, transposon reactivation and loss of 
imprinting observed in DNMT knockout mice (79), mice with deletion of genes 
encoding for the MBD proteins generally produced viable and subtle phenotypes.
Loss of MBD in mice typically affects brain functions. This is best 
exemplified by MeCP2 knockout mice that display dysfunctional motor neurons and 
neurological symptoms after birth. These symptoms are similar to Rett’s syndrome, a 
human neurodevelopmental disorder (38, 82). Rett’s syndrome almost exclusively 
affects female patients and this correlates with the fact that MeCP2 is an X-linked 
gene. Male MeCP2 mutant mice can only be generated by conditional knockout as 
deletion of the only copy of the gene in the X chromosome resulted in embryonic 
lethality (218). The majority of Rett’s patients are found to have mutations in the gene 
coding for MeCP2 and the mutations are commonly found within coding sequence for 
MBD and TRD (4) (Figure 1-4). As MeCP2 is most abundant in brain (164), failure to 
repress superfluous gene expression in the organ might be a plausible explanation 
(229).
Adult mice with deletion of the MBD1 have a smaller hippocampus, a region 
where the protein is highly expressed. Neuronal stem cells cultured from these mice
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show a decreased potential in neuronal differentiation and increased genomic 
instability. Consistent with these findings, these MBD1 knockout mice exhibit spatial 
learning difficulties (243).
MBD2 homozygous deletion mice are viable and healthy except for the fact 
that the females have behavioral defects in nurturing their pups (86). A slightly more 
distinct phenotype involving MBD2 mutants was reported in a subsequent study in 
which these mice were crossed with intestinal tumor prone mice; it was found that the 
lifespan of their offspring increases when gene dosage of MBD2 decreases. This 
suggests that MBD2 might play a role in tumorigenesis (197).
The only lethal phenotype that is caused by the deletion of a MBD family 
member comes from mice with homozygous MBD3 deletion; embryos of these mice 
were retarded and were reabsorbed at E8.5. This demonstrates the importance of the 
MBD3 protein in embryonic development (86). Since the mammalian MBD3 does not 
bind methyl-CpG DNA (85), the severity of this mutation cannot be considered as the 
loss of factors that specifically recognize methyl-CpG DNA. This mutation most 
probably reflects on the loss of activity of the NuRD complex as targeted deletions of 
the other integral chromatin remodeling complex components produced similar 
embryonic lethal phenotypes (52, 123).
Studies of MBD4 gene deletion in mice by various groups produced 
inconclusive evidence of whether the loss of the DNA mismatch repair protein 
increases tumorigenesis or genomic instability in mice. However, all reports agreed on 
the observed rise in cytosine to thymine base transition (158, 198, 230). Investigations 
of these MBD4 knockout mice did not include the characterization of the behavioral or 
neurological aspects of this mutation.
1.5.1 Are MeCP2 and MBD2 functionally redundant?
The mild phenotypes of these MBD mutants compared to the DNMT mutants 
lead to the questions of whether the diverse members from MBD family play 
important roles in gene regulation. Double deletion mutant mice of MBD2/MeCP2 do 
not have altered survival or disease onset (82). This suggests that the proteins might 
not have a central role in controlling developmental gene expression. In the MeCP2
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and MBD2 homozygous mutant mice, X chromosome inactivation and genomic 
imprinting appear normal (82, 86, 155). This could be due to the fact that DNMTs 
themselves posses alternative function such as targeting of chromatin remodeling 
complexes4 (115), and the existence of MBD proteins are for fine-tuning of 
transcription repression, or that these MBD proteins are functionally redundant (88).
7.5.7.1 Genes controlled by MeCP2
Early biochemical characterization suggested that these proteins function as 
global transcriptional repressors (105, 166, 170) but microarray analysis of the general 
transcriptional profile from brain tissue of MeCP2 mutant mice affected by Rett’s 
syndrome did not reveal the much anticipated genome wide gene misregulation. In 
fact, only slight changes were found when the transcription profiles of these mice were 
compared to wild-type mice (221). Therefore, approaches that are more precise were 
employed to identify the particular subset of genes controlled by the MBD proteins.
Using chromatin immunoprecipitation (ChIP), MeCP2 is found on the 
promoter of DLX5, an imprinted gene that is only expressed from the maternal allele. 
In MeCP2 null mice, it is found that the imprinting phenomenon is absent at the DLX5 
locus and a two-fold increase in the transcripts was observed. Derepression of only 
one allele should not cause drastic changes in expression levels. Thus, a modest 
increase is expected (95). On the other hand, imprinted genes such as UBE3A and 
GABRB3 were found to have decrease expression in MeCP2 deficient cells but the 
changes are not linked to misregulation of imprinting (196).
7.5.7.2 Genes controlled by MBD2
MBD2 control of gene expression is probably crucial during cellular 
developmental stages. During T cell maturation, naive T-helper cells have the 
potential to differentiate into interferon-y producing Thl and interleukin-4 producing 
Th2 cells. T cells from MBD2 -/- mice express these cytokines at aberrant levels and 
this results in a difference in susceptibility to pathogens compared to wild-type mice 
(98). Although genes that control the lineage specificity of these T cells were found to
4 Refer to Chapter 1.3.3.3.
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be appropriately repressed in the MBD2 mutant mice, ChIP analysis had identified that 
the MBD2 interact with the transcriptionally silent promoter of interleukin-4 and 
production of the cytokine was only possible when MBD2 is displaced by a 
transactivator protein, GATA3 (99). The data suggest that MBD2 might have a subtle 
role in controlling specific cellular development. Another study that supports this 
hypothesis uses MBD2 -/- mice to demonstrate the indirect overexpression of 6- 
globulin gene, which was otherwise specifically controlled in erythrocyte development 
(194).
Various other ChIP investigations had also located MBD2 on the promoter of 
genes such as GSTP1 (140), pl6/INK4A and pl4/ARF, which are all implicated with 
cancer (146). In all cases, treatment of cells with DNA methylation inhibitor and 
histone deacetylation inhibitor reverses the MBD2-mediated repression.
L 5. L 3 Genes controlled by various MBD proteins
In some instances, different members of the MBD family can be found on the 
same locus on methylated DNA. Both MeCP2 and MBD2 bind the promoter of 
MDR1, a gene that encodes a protein that confers drug resistance to cancer cells (57). 
The promoter of metallothionein stress response genes has been associated with 
MBD2, MBD4, MBD1 and MeCP2, while the former two proteins bind and mediate 
repression only when the promoter is CpG-methylated, the latter two interact and 
repress irrespective of the CpG- methylation status (148).
1.5.2 What are the specificity of MeCP2 and MBD2
Initial attempts to characterize the MBD using in vitro binding assay or 
immunofluorescence to locate the proteins on the genome were not sensitive enough to 
conclude whether these proteins have different sequence recognition specificity (85). 
However, more advanced experimental data accumulated over the years have 
suggested that these MBD are unevenly distributed along the genome and tend to 
cluster along precise chromosomal loci (10).
While most research concentrates on genomic screening and ChlPs to identify 
MBD target sequences, the direct characterization of MBD methyl-CpG DNA binding 
properties increases the understanding of these proteins tremendously. Measurement
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of the MBD association with methyl-CpG DNA shows that each member of the family 
has a different affinity towards the same sequence of methylated DNA and that the 
spacing between methyl-CpGs along the DNA is critical for the interaction (67). A 
more recent investigation on the binding selectivity of these protein illustrated that the 
efficiency of binding of MeCP2 to methyl-CpG is dependent on the presence of an 
adenine or thymine adjacent to the CpG sequence. Genetic depletion of MeCP2 
enables MBD2 to occupy its binding sites on methyl-CpG DNA but not vice versa 
(117). This supports the theory that MBD2 is the ancestral protein of the MBD family, 
possessing wider substrate specificity compared to the newly evolved MBD proteins 
that have more specialized functions (88).
Other than stably facilitating interactions between chromatin modifying 
complexes and methyl-CpG DNA, MBD proteins themselves can be governed by the 
dynamic equilibrium of cellular signaling to fine tune gene expression (88). The 
clearest example to date is shown by experiments in cultured mammalian neurons, 
where MeCP2 binds the promoter of bone-derived neurotrophic factor (BDNF) gene 
and represses transcription. When the cells are treated with a membrane depolarizing 
agent, MeCP2 becomes phosphorylated and lose its affinity for methyl-CpGs, resulting 
in BDNF expression (39, 151). Since then, the role of BDNF in the pathogenesis of 
Rett syndrome has been positively verified (36).
Therefore, it is only through the careful characterization of the molecular 
properties of MBD proteins and investigations of how they control their target genes 
that we can understand the phenotypic differences between DNMTs and MBDs 
deletion mice, and how these systems of chromatin control work together to govern the 
overall cellular gene expression program.
1.6 Aim of this study
Our laboratory’s interest in studying the components of chromatin control 
comes from our recent discovery that a subset of DNMT and MBD proteins has 
intrinsic RNA binding properties (102). While the functional significance of MBD2- 
RNA interaction is not known, MeCP2 is shown to modulate alternative splicing of
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reporter genes through its RNA dependent interaction with the Y-box binding protein, 
YB1 (238).
MBD2 414
gaRgggRgRgrwkqaaRgggvcgRgRgRgRgRgRgRgRgRgRgri
492MeCP2
gRgspsrreqkppkkpkspkapgtgRgRgRpkgsgtgR
Figure 1-6 MBD2 and MeCP2 contain RG domains.
The RG domain of both proteins are illustrated (Yellow box) and the possible R are in 
red.
Within the MBD proteins, the MBD2 and MeCP2 bind RNA with the highest 
affinity and the physiological RNA target of MBD2 has been identified. It was found 
that MBD2 interacts with 7SK non-coding RNA in cells and that the interaction is 
dependent on the arginine and glycine (RG) rich domain within the MBD2 (114). 
While the RNA binding domain for MeCP2 was not fully characterized by Jeffery & 
Nakielny (102), it is highly postulated to be located in a similar RG domain found in 
the protein (Figure 1-6).
Although the RG domain of MeCP2 is less extensive than that of MBD2 
(Figure 1-6), compared to the former, MeCP2 seemed to have a more conserved RG 
domain across species (Figure 1-7). Therefore, it would be interesting to characterize 
the functions of the RG domain of these two proteins and possibly address whether the 
RG domains of MBD proteins were acquired, or were lost during evolution. This may 
in turn unravel novel functions of MeCP2 in the pathology of Rett’s syndrome.
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Figure 1-7 Comparison of N-terminus halves of MBD2 (residue 1-180) and MeCP2 (residue 1-240) 
sequences across different species. The RG domain indicated in Figure 1-6 is highlighted by the 
Red box.
RNA binding proteins with RG repeats are often targets of a novel post- 
translational modification catalyzed by a family of enzymes termed the protein 
arginine methyltransferases (PRMTs) (126, 141, 163), I test whether the arginines in 
the RG domain of MBD2 and MeCP2 can be post-translationally modified (see Figure 
1-6). Moreover, I investigate which enzymes might catalyze such post-translational 
modifications and explore the biological consequences of these modifications at 
molecular and cellular level.
1.7 The PRMT family
Although it was established almost 40 years ago that arginine residues within 
proteins can be post-translationally modified with methyl groups (176), the enzymes 
that catalyze the modifications have only recently been identified (78, 89, 139). To
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date, nine PRMTs have been identified (47) and genes encoding arginine 
methyltransferases can be found in species such as Caenorhabditis elegans, yeast, 
plants, Drosophila, Xenopus and mammals (9, 16, 27). Preliminary studies indicate 
that these PRMTs are ubiquitously expressed, and have alternative splice variants to 
achieve some degree of tissue specificity (204).
Proteins from the PRMT family share a strikingly conserved catalytic core 
that binds to protein substrate and S-Adenosyl-methionine (SAM), the methyl donor. 
The SAM binding regions of PRMTs catalytic core are closely related to those found 
in nucleic acid and small molecule methyltransferases (154) and consists of the 
signature post I, post II and post III motifs. The protein substrate-binding region is 
only unique to PRMTs family members, the amino acid sequences fold into a p-barrel 
domain (239, 240) (Figure 1-8). Outside the catalytic core, the PRMTs contain 
additional domains such as the SH3, zinc finger or Fbox domain (47, 205, 217).
The fact that most PRMTs appear in screens designed to investigate diverse 
cellular process suggests that they play a variety of roles, particularly, in signal 
transduction (126, 154). The mammalian PRMT1 was first discovered as the 
interactor of the products of immediate early TIS21 and leukemia-associated BTG1 
gene, both of which modulate PRMT1 activity (139). PRMT4 is found in a complex 
with GRIP1, the p i60 steroid receptor coactivator and therefore the enzyme is also 
termed the co-activator associated arginine methyltransferase (CARM1) (37). 
PRMT5, also known as JBP1 (Janus kinase binding protein 1) was initially identified 
as the interacting partner of Janus kinase (182) while PRMT7 was isolated in a genetic 
screen enriching for suppressor elements which confer resistance against cytotoxic 
agents (81). Subjecting the highly conserved PRMT catalytic core to homology 
searches has led to the identification of PRMT2, PRMT6, PRMT8 and PRMT9 (47, 
69, 128, 205) and PRMT3 was uniquely identified by its interaction with PRMT1 
(217).
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PRMT Type
Post 1, II & III p-barrel
1 1
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2 II 1
Zn2+
3 1 1 ■ H H H ■ ■ ■ 1
4 1
5 II
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7 1 II
8 1
Fbox Zn2+
9 i m I I  I II
Figure 1-8 The protein arginine methyltransferase (PRMT) family.
A family of nine enzymes that catalyze methylation of arginines in proteins and contains 
a conserved catalytic domain (Black box) has been characterized. Their catalytic 
activity can be classified as type I or type II. Sequences outside the catalytic domain are 
unique to PRMT and may contain additional SH3 (Yellow), zinc finger (Green) and 
Fbox (Blue) domain.
1.7.1 Catalytic activity of PRMTs
Similar to lysine residues, there are three levels at which arginine residues can 
be methylated (see Chapter 1.3.3.2). The PRMTs are classified into two groups 
according to their catalytic end products on the target arginine residues. Both type I 
and type II PRMTs catalyze the modification of guanidino nitrogen atom on arginine 
residues to form a N -monomethylarginine, but type I PRMT proceeds with a further
P  P
reaction to generate an N ,N asymmetric dimethylarginine, and type II PRMT 
produces N°,NG symmetric dimethylarginine (Figure 1-9). PRMT1, PRMT3, 
PRMT4, PRMT6 and PRMT8 are classified under type I PRMT and PRMT5, PRMT7 
and PRMT9 belong to the type II grouping. No activity has yet been reported for 
PRMT2 (16, 126, 154) (Figure 1-8).
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Figure 1-9 Products of PRMT catalysis.
Both types of PRMT catalyze the formation of monomethylarginine. Type I PRMTs 
can proceed to form asymmetric dimethylarginine whereas type II PRMTs proceeds to 
form symmetric dimethylarginine.
Resolved crystal structures of the PRMTs show that these proteins dimerize to 
become catalytically active (228). Deletion of the region in PRMT1 responsible for its 
dimerization resulted in its inability to bind SAM, which abolished the enzymatic 
activity (239, 240). The ability of PRMT1 to interact with PRMT3 and PRMT8 might 
also be attributed by the dimerization of the enzymes for active complex formation 
although further investigations are required to confirm this (128, 217).
Biochemical characterization of PRMT5 also indicates that the enzyme exists 
as homo-oligomers in cells and that the association is mediated by disulphite and non- 
covalent interactions. In sucrose density gradients, oligomers of PRMT5 co-migrate 
with its methyltransferase activity (188). This theory is further supported by the 
identification of two catalytic regions found in PRMT7, both of which are essential for 
its enzymatic activity (161) (Figure 1-8).
Dimerizations of the PRMTs are also believed to facilitate the formation of 
dimethylarginine end products. Monomethylated arginine substrates are postulated to 
transfer from the active site of one monomer directly into the active site of another 
without dissociation from the active catalytic complex (126).
1.7.2 Peptide motifs recognized by PRMTs
Despite the high degree of amino acid and structural conservation in the 
catalytic core, members of the family can recognize and modify different amino acid
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motifs in the context of arginine (16, 126). The most distinctive arginine containing 
motifs that are targets of PRMT usually contain a glycine residue adjacent to the 
arginine in the sequence of RGG, RG or GR. Proteins harboring RXR motifs, where 
position X can be occupied by a small residue such as alanine, serine, or proline are 
also possible recognition targets of PRMTs (210).
Most type I PRMTs generally prefer arginine and glycine containing peptides 
as substrates (16, 128) and PRMT3 additionally modifies arginine residues within 
RXR motifs (24, 210). Currently, PRMT4 is the only exception in type I PRMT 
showing a higher degree of specificity. PRMT4 does not display affinity for RG 
containing sequences in proteomic screens. Alignment of peptide sequences 
methylated by PRMT4 has derived a loose consensus motif of RPAAPR (127). The 
crystal structure of the PRMT1 substrate binding domain revealed three peptide 
binding channels, possibly explaining the ability of a single PRMT protein to 
recognize different motifs on their substrates (126, 239).
For type II PRMTs, both PRMT5 and PRMT7 display efficient methylation 
for substrates containing a stretch of (RG) repeats but these sequences are not modified 
by PRMT9 (47, 129). Interestingly, while arginines in RG repeat sequences can be 
mono, asymmetrically and symmetrically methylated, arginines in RGG repeat are 
only reported to be mono and asymmetrically methylated (154). However, current 
data relies heavily on in vitro assays to determine the types of modifications and we 
await in vivo findings. With the increase in numbers of physiological PRMT 
modification reported, examples of RGG repeat being symmetrically modified may 
appear (153).
1.7.3 Reversibility of arginine methylation
One important feature of the regulation of cellular processes via post- 
translational modifications is that these changes are dynamic and reversible (e.g. 
de/acetylation and de/phosphorylation) (109). While knowledge of proteins that 
remove acetyl or phosphate groups from amino acids are abundant, enzymes that 
remove methyl groups from lysine or arginine remained elusive until two years ago 
(54, 207, 227).
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Figure 1-10 Demethylation of arginine.
Conversion of arginine and mono-methylated arginine to citrulline (Solid black arrow), 
and pathways that are speculated to exist to regenerate unmodified arginine residue 
from methylated species (Dash arrows).
For histone lysine methylation, the dimethyl group on histone H3 lysine 4 
(H3K4) is demonstrated to be removable by an amine oxidase to give an unmodified 
lysine. Depletion of the enzyme increases H3K4 methylation in cells and led to the 
corresponding transcription activation (207).
However, for arginine methylation, several observations suggested that the 
reversal of this modification seems more complicated. Firstly, peptidyl arginine 
deiminase 4 (PAD4), the deiminase implicated with arginine is only reactive towards 
unmodified or monomethylated arginine residues but not dimethylarginine residue (54, 
227). Secondly, the end product of PAD4 deimination is citrulline, and the reaction 
that converts the citrulline within a protein back to an arginine residue is not identified 
(16) (Figure 1-10). Due to the differences between the chemical properties of 
citrulline and arginine, the “demethylated” PRMT substrate is predicted to have 
impaired activity with respect to functional arginine residues (63).
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Therefore, the identification of either an amine oxidase that can convert 
methylated arginine to an unmodified state or an amino transferase that can convert 
citrulline back to an arginine residue will enhance our understanding in biological 
functions of arginine methylation (54) (Figure 1-10). Prior to that, investigations are 
carried out by comparing functions between methylated and unmethylated PRMT 
substrates.
1.8 Implications of PRMTs modifications
Arginine, being positively charged, often mediates hydrogen bonding and 
amino aromatic interactions with proteins and nucleic acids (24). While addition of 
methyl groups to arginine does not alter its overall charge, it does increase the bulk 
and hydrophobicity of the residue. This can affect molecular interactions in either a 
positive or a negative manner (16, 77, 126, 154). To date, arginine methylation of 
proteins has been implicated in a variety of biological processes such as RNA 
processing, signal transduction, DNA repair and transcription regulation (16, 126). In 
most reports, involvement of PRMTs is largely inferred by the identification of 
proteins belonging to particular cellular processes as being substrates of PRMTs, and 
the molecular basis of the modifications remains unexplored (63). Therefore, the 
following examples are chosen based on the clarity of the molecular details of how 
arginine methylation affects the function of its target protein.
1.8.1 Arginine methylation modulates protein-protein interaction
RNA binding proteins such as heterogeneous nuclear ribonucleoproteins 
(hnRNPs) A l, A2, K, R and hnRNP U represent the major targets of PRMT. They 
contain RGG motifs and have been positively identified to be methylated (90, 141). In 
the nucleus of HeLa cells, hnRNP accounts for 65% of asymmetric dimethylarginines 
within the total pool of proteins (141). Although the significance of arginine 
methylation in RNA binding proteins is not well understood, it is proposed that the 
modification serves as the maturation signal. Many RNA binding proteins are 
mislocalized in their hypomethylated state (143, 211).
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While the RGG motifs present on these proteins are known to be capable of 
mediating RNA interactions, mutations in the RGG motif of the hnRNP Al decreases 
its ability to self associate (110).
Sam68, another RNA binding protein that is identified as a physiological 
target of PRMT1 contains asymmetrically modified dimethylarginine in its RGG 
motifs (48). Besides binding RNA, Sam68 is also the adaptor protein for Src kinase 
and its proline rich motifs adjacent to the RGG motif is known to facilitate interacting 
with a number of proteins containing SH3 and WW domains. In vitro studies using 
asymmetrically arginine methylated Sam68 peptides revealed that arginine 
methylation inhibits the interaction of proteins that are based on the proline rich-SH3 
domains binding but does not affect protein interactions mediated by proline rich-WW 
domain binding (15).
The integral components of the pre-mRNA splicing machinery consist of 
seven RNA binding proteins. Four of the proteins are symmetrically methylated at the 
RG or GR motifs by PRMT5. They are, the SmB, SmB', SmDl and SmD3 (30, 31, 
70). The efficient assembly of Sm proteins forms the core particle for RNA splicing 
and this is dependent on the interaction of these proteins with the SMN (survival of 
motor neuron) protein. The Sm-SMN association is mediated by the RG rich motif 
located at the C-terminal tail of most Sm proteins (71). It is found that SMN prefers 
binding to symmetric dimethylated Sm proteins and this interaction is mediated by a 
region in the SMN that contains Tudor domain. Convincingly, peptides containing 
symmetric dimethylarginine can compete with Sm proteins for the interaction with 
SMN but similar peptides containing mono or asymmetric dimethylarginines cannot 
(30, 70). Therefore, symmetric arginine dimethylation, in this case, serves to increase 
the interaction with proteins containing Tudor domain.
1.8.2 Arginine methylation modulates protein-nucleic acids interactions
Despite the prevalence of RNA binding proteins reported as PRMT 
substrates, there is a lack of strong evidence to address the roles of arginine 
methylation in protein-nucleic acid interactions (154). In salt elution columns, 
methylated species of hnRNP Al proteins is found to have less affinity towards the 
RNA or single stranded DNA. They eluted from the immobilized nucleic acids at
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slightly lower salt concentration (< 45 mM) compared to their unmethylated 
counterpart (185). The fragile X mental retardation protein (FMRP) binds mRNA and 
regulates translation. Within the FMRP, there are RGG motifs that contain 
asymmetric dimethylarginine. Artificially methylating the RGG motifs of 
recombinant FMRP proteins with PRMT1 resulted in a 60% decrease in association of 
FMRP with its interacting RNA (213).
Subtle effects of arginine methylation in modulating protein-nucleic acids 
interactions probably suggest that the modification serves to increase the specificity of 
the proteins towards their nucleic acid target (33, 153). The diverse secondary and 
tertiary structures of RNA that are not governed by Watson and Crick base pairing 
gives rise to a huge variety of surfaces for RNA-protein interactions (106). As 
arginine is one of the most common residues that functionally contacts RNA, methyl 
groups added to the residue might disrupt hydrogen bonding by steric hindrance. On 
the other hand, increasing the hydrophobicity of the arginine by methylation might 
also favor the ability of the residue to interact with the aromatic bases on RNA 
molecule (16). However, these hypotheses need to be supported by experimental data, 
as few reports exist to explore the issue.
Other than studying how arginine methylation can affect RNA binding 
properties, the reverse can also be investigated (153). In vitro methylation efficiency of 
substrate proteins within cell lysates can be positively or negatively altered when the 
cell lysate was treated with RNase prior to the labeling assay (68). Indeed, there are 
reports of PRMTs substrates losing potential to accept methyl groups when bounded to 
RNA, examples include the yeast Hrplp (222) and NS3 protein encoded by Hepatitis 
C virus (189).
1.8.3 Arginine methylation and transcription
1.8.3.1 Arginine methylation of histone
Histones were the first proteins identified to contain methylated arginines 
(176), but investigations on how histone arginine methylation can regulate 
transcription begins only after the discovery of PRMTs. Currently, PRMT1, PRMT4 
and PRMT5 are known to modify histones (16).
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PRMT1 methylates histone H4 on arginine 3 (H4R3). This methylation 
facilitates the subsequent modification of the histone tail by HAT. Therefore, it has 
been correlated with transcription activation (226). The H4R3 residue, together with 
the histone H3 arginine 8 is also reported to be targets of PRMT5 (62, 177). However, 
there is no convincing evidence regarding the presence of symmetric
dimethylarginines on these residues in vivo. This is because major conclusions were 
either based on in vitro methylation of histone peptide (178) or recognizing
symmetrically methylated histone with antibodies generated against asymmetrically 
methylated arginine (62, 153). PRMT4 methylation of histone has also generated 
equally contradictory findings; histone H3 arginine 2, arginine 17 and arginine 26 are 
reported to be specific substrates of the PRMT in vitro (203) and H3R17 in particular, 
is strongly linked with transcription activation (145). However, antibodies generated 
to specifically recognize asymmetrically methylated H3R17 revealed that the residue 
remains asymmetrically methylated in PRMT4 knockout mouse cells (233).
1.8.3.2 Arginine methylation of transcription factors
While PRMT modification of histone remains confusing, findings that are 
more comprehensible are available to support the significance of PRMTs in
transcription regulation. The cyclic AMP responsive element binding (CREB) protein 
is controlled by intracellular signaling to associate with its target DNA sequences, and 
this mediates gene expression. CREB recruits transcription co-activators such as CBP 
(CREB binding protein) or p300 to the site of chromatin, and these CBP/p300 proteins 
posses HAT activities. The CBP/p300 co-activators families are the first set of 
transcription factors reported as targets of PRMT (232). It is now a fact that PRMT4 
modifies these proteins in at least three sites, leading to different downstream 
molecular and cellular effects (153).
Methylation of arginine residues in the CREB-interacting domain of 
CBP/p300 proteins result in the inability of the co-activators to bind CREB and 
mediate transcription activation (Figure 1-11). In cells, increasing expression of 
exogenous PRMT4 resulted in a corresponding decrease in transcription of reporter 
genes. This effect cannot be reproduced by PRMT4 catalytic mutants, implying that 
the arginine methyltransferase activity is required for this regulation (232).
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The second site on the CBP/p300 that contains methylarginines is found near 
the C-terminus of the CREB-interacting domain. In this instance, arginine methylation 
is postulated to be a prerequisite for CBP to co-operate with GRIP1, a set of 
hormonally induced transcriptional activators (Figure 1-11). Substitutions of the 
arginines involved resulted in the loss in GRIP 1 mediated transcriptional activation but 
the CBP-CREB activation pathway remains unaffected (37, 42).
Opposite effects on p300-GRIPl interaction are observed when arginines 
within the C-terminus of CBP/p300 are methylated (Figure 1-11). The C-terminus of 
these proteins is the binding domain for GRIP1 and methylation of one particular 
arginine residue resulted in the loss of interaction between p300 and GRIP1, and 
mutating the arginine residue to lysine abolished p300 co-activation activity (130).
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Figure 1-11 PRMT4 methylation of CBP/p300.
Basic map of the CBP/p300 proteins with the functional histone acety(transferase 
domain (Gray box) and each co-activator interacting domain are labeled (Top). Arrows 
indicate sites of arginine methylation by PRMT4 and their effects (Bottom). Sites that 
are required for hormone dependent transcription activation are indicated in Blue box.
1.8.3.3 Arginine methylation o f transcription elongation factors
Besides modulating gene expression by controlling transcription activation, 
PRMTs are also implicated in transcription elongation. SPT5 is a transcription 
elongation factor that determines the processivity of transcription by binding to RNA 
polymerase II (RNAP II). When RNAP II and SPT5 are not phosphorylated, SPT5 
negatively regulates the basal level of transcription. Upon phosphorylation of SPT5
44
Chapter 1 Introduction
and RNAP II, SPT5 switches from inhibitory to stimulatory mode and positively 
regulates transcription elongation.
SPT5 is reported to be a substrate of PRMT1 and PRMT5 in vivo and 
methylation of arginines within SPT5 is thought to decrease its association with RNAP
II. Substitutions of the arginines involved resulted in the increased association of 
SPT5 with its target promoters and enhancement in RNAP II/SPT5 transcription 
elongation activity (121).
A following study also identified FCP1 phosphatase, the enzyme that recycles 
RNAP II by dephosphorylation, as a substrate of PRMT5 but the significance of this 
modification remains unknown (3).
1.9 Roles of the PRMTs
1.9.1 In animal models
As a wealth of literature emphasizes the importance of PRMTs based on their 
molecular functions in cells, mice with deletion of PRMT genes are the best models 
used for studying the importance of this family of proteins for the development of 
animals (16). Mouse PRMT1 -/- embryos did not survive more than 6.5 days and were 
reabsorbed. However, deletion of the PRMT1 gene still permits cell survival as 
PRMT1 -/- blastocyst maintain in culture are similar to those from wild-type in terms 
of growth rate and morphology (180).
Consistent with reports of PRMT1 being the major type I arginine 
methyltransferase, PRMT activity in the mutant blastocyst is reduced by 84% and the 
asymmetric dimethylarginine content of cellular proteins is reduced by 50% (180, 
216). Further analysis of these mutant blastocysts revealed that the loss of PRMT1 
activity cannot be compensated by other type I PRMTs (179).
Homozygous mice with targeted disruption of PRMT4 died at birth and the 
embryos isolated were smaller and displayed breathing difficulties (233). Further 
analysis of the embryos also revealed an underdeveloped thymus containing fewer 
cells suggesting a role for PRMT4 in early T cell development (111). Mouse 
embryonic fibroblasts (MEF) of the PRMT4 -/- mutants were obtained and PRMT4
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substrates were assayed for the loss of asymmetric dimethylarginines. While p300 
becomes hypomethylated in the absence of PRMT4, histone H3 R17 is still recognized 
by the antibody specific for the methylated arginine (see Chapter 1.8.3.1). To 
ascertain whether the CBP/p300 hormonal induced transcription activation is 
dependent on its modification by PRMT4 (Figure 1-11), the MEF cells were 
transfected with estrogen responsive reporter and reporter expression was determined 
to be significantly lower than wild-type cells. The loss in expression can be rescued 
by adding exogenous PRMT4 (233).
Recently, the synergy between p300 and PRMT4 is implicated with another 
transcription regulator, nuclear factor kappaB (NF-kB). These three proteins form a 
complex in vivo and the enzymatic activities of PRMT4 and p300 are required to 
enhance the expression of a subset of genes controlled by NF-kB. In addition, these 
genes are misregulated in PRMT4 knockout MEF after NF-kB induction (50).
1.9.2 In human disease
As some PRMTs are known to be involved in nuclear receptors mediated 
transcription activation (42, 233), overexpression of these enzymes might result in 
hormone dependent cancer formation (16). It is observed that PRMT4 have aberrant 
expression in human prostate carcinoma (94) and inhibitors against PRMT1 and 
PRMT4 activity suppress hormone dependent transcription activation activity (41).
Increased arginine methylation of PRMT substrate proteins are also identified 
as a possible causes of human diseases. In multiple sclerosis, arginines in myelin basic 
protein (MBP) are observed to have higher levels of deimination and methylation 
(112). The pathology of this disease reveals that the autoimmune response triggered 
by methylated species of MBP causes damage to the components of the nervous 
systems. Similarly, hypermethylation of Sm proteins is also known to cause the 
autoimmune disease lupus erythematosus (34).
1.10 Studying the effects of arginine methylation on MBD
Being RNA binding proteins (102) as well as factors that bridge the 
association between methyl-CpG DNA and chromatin remodeling complexes, MBD2
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and MeCP2 present themselves as good candidates for investigations into whether they 
can be controlled by PRMT. The emerging examples that illustrate how PRMT can 
participate in diverse cellular processes have led us to question whether the MBD can 
provide the first molecular evidence between CpG-DNA methylation and arginine 
methylation.
Here, I report that MBD2 and MeCP2 are methylated on arginines in vivo and 
I identify the PRMTs responsible for the modification of MBD2 in cells. I also show 
that MBD2 methylation regulates its affinity for co-repressor complex and methyl- 
CpG DNA. Consistent with the molecular effects of arginine methylation, MBD2 
methylation blocks its transcription repression activity in cells. PRMTs function in 
this regulatory network as repressors of a repressor.
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Chapter 2 Results I - Are MBD proteins methylated?
2.1 MBD proteins are methylated in vitro
2.1.1 Recombinant MBD2 and MeCP2 can be methylated.
To address whether the amino acid sequences of MBD2 and MeCP2 can be 
post-translationally modified by methyltransferases, recombinant forms of the proteins 
were produced in bacteria for in vitro methylation assay. These proteins served as 
good substrates because arginine methyltransferase activity is not reported in bacteria 
cells (141).
H2N
HO-
H<5 OH HO OH
SAM SAH
MBD2
F/L
MeCP2
F/L
SAH
97  —  
66 —
SAH
45 —
45 —
29 —
3H Fluorograph 3H Fluorograph
Figure 2-1 GST-MBD proteins are methylated in vitro.
(Top) Structure of the methyl donor (SAM) and the inhibitor (SAH).
(Bottom) Full-length GST-MBD2 and GST-MeCP2 proteins were subjected to protein 
methylation assay by incubating with rabbit reticulocyte lysate at 37°C for 90 min. The 
reactions were stopped by addition of SDS-PAGE sample buffer, resolved by SDS- 
PAGE and subjected to Fluorography. Arrows indicate the migration of the full-length 
proteins.
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Full length GST-MBD2 and MeCP2 were tested for their ability to accept the 
3H-methyl group from S-adenosyl-methionine (SAM), the universal methyl donor for 
all methyltransferase reactions (Figure 2-1, Top). In this experiment, the source of 
methyltransferases was provided by rabbit reticulocyte lysate, which is known to 
contain PRMT activities (141). After the transfer of methyl group to substrate 
proteins, SAM is converted to S-adenosyl-homocysteine (SAFI), the potent end 
product inhibitor of all methyltransferase reactions (162). Therefore, to demonstrate 
that the 3H-label is incorporated into the proteins in Figure 2-1 (Bottom) were 
catalyzed by methyltransferases and not by other metabolic enzymes, SAH was 
included as a control. Only in the absence of SAH, MBD2 and MeCP2 were labeled 
by methyltransferases present in the lysate.
2.1.2 Recombinant MBD2 and MeCP2 are methylated at the N-terminus
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Figure 2-2 MBD2 and MeCP2 are methylated at N-terminus.
(Top) The GST-MBD proteins were expressed as N and C-terminus parts; position of 
black vertical lines separates the terminus.
(Bottom) The recombinant proteins are subjected to the in vitro methylation assay as 
for Figure 2-1, and the products were visualized by Coomassie and Fluography.
As the arginine and glycine repeats of both MBD2 and MeCP2 proteins are 
located nearer to the N-terminus, I tested whether the N-terminus halves of the 
proteins are the sites for methylation. The MBD proteins were expressed as GST- 
tagged N and C-terminus fusion proteins (Figure 2-2, Top), and were subjected to the
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in vitro methylation assay using methyltransferase from Ramos cell lysate. The 
experiment was repeated with cell lysate from HeLa, 293T, Neuronal 2A and PC 12 
cells, and the outcome was consistent with Figure 2-2 (Data not shown). The N- 
terminus halves of both proteins containing the RG domain are the major 3H-labeled 
products in the absence of SAH.
However, as the mammalian cell lysates used were robustly methylating the 
N-terminus halves of the two proteins, especially GST-MBD2, the SAH present was 
not able to fully suppress the methyltransferase activities. A titration assay was 
performed to determine the optimum SAH concentration required in future assays (see 
Figure 6-1 in Chapter 6.1), and all subsequent assays use 100 pM SAH.
2.2 MBD proteins are methylated in vivo
Since recombinant MBD2 and MeCP2 proteins can be methylated by 
methyltransferases in vitro, I investigated whether methylated arginines were indeed 
present in the RG domain of these proteins purified from cells. This can be achieved 
by various approaches, such as mass spectrometry analysis or in vivo labeling 
experiments.
2.2.1 Immunopurifying endogenous MBD2 for mass spectrometry analysis
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Figure 2-3 Large-scale immunopurification of MBD2 protein from Ramos cells5.
MBD2 proteins were immunopurified using the optimized conditions stated in Figure 
6-2 and the purified products were analyzed by Western blot (Right) or sliver staining
5 For details of conditions used for immunoprecipitation of MBD2 protein in this experiment, refer to 
Chapter 6.2.
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(Left). The silver stained band migrating at the same position as MBD2 in the Western 
blot was excised and analyzed by mass spectrometry. (*) Denotes antibody heavy chain.
The MBD2 protein was chosen for the mass spectrometry analysis as the 
primary amino acid sequence shows that the RG domain of MBD2 is more extensive 
than MeCP2 (Figure 1-6). Furthermore, compared to GST-MeCP2 N-terminus, GST- 
MBD2 N-terminus is also more robustly labeled in the in vitro methylation assay 
(Figure 2-2). This indicates that the MBD2 protein might have higher methylarginine 
content.
Using immunoprecipitation conditions optimized in Figure 6-2 and Figure 6-3 
(see Chapter 6.2), endogenous MBD2 protein was isolated from 5 X 108 Ramos cells 
(Figure 2-3). From the silver staining, it was observed that the immunoprecipitations 
the presence of antibody without lysate (Lane 1 and 3) were cleaner compared to those 
in the presence of antibody and lysate (Lane 2 and 4). A distinct band of 45 kDa in 
lane 2 and 4 was confirmed to be a non-specific interaction of (3-actin with goat 
antibodies. However, as lane 7 of the Western blot revealed a satisfactory yield of 
MBD2 protein, bands in lane 4 that correspond to the migrating positions of MBD2 
proteins were excised and identified by mass spectrometry analysis. Although 
endogenous MBD2 was identified upon mass spectrometry analysis, peptide sequences 
of both P-actin and goat IgG heavy chain were also present. Therefore, it was 
unfeasible to analyze for the presence of methylarginines in the endogenous MBD2 
proteins purified.
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2.2.2 Post-translational labeling of transiently expressed MBD
2.2.2.1 Transient expression o f MBD proteins
4% input FLAG-IP BSA (ug)
MeCP2
(minor) MeCP2(major)
MBD2
116
97
Figure 2-4 Purification of MBD proteins expressed in mammalian cells.
293T cells were transiently transfected with plasmids encoding the indicated FLAG- 
tagged proteins for 48 hr. The cells were then lysed and immunoprecipitated with 
FLAG antibodies and eluted with 3x FLAG peptide. Eluted FLAG-proteins were 
resolved by SDS-PAGE and visualized by Coomassie.
MBD proteins with purity of > 90% can be prepared by immunopurifying the 
FLAG-tagged proteins from transiently transfected 293T cells (Figure 2-4). As the 
FLAG-proteins were eluted from the agarose-conjugated antibodies by 3X FLAG 
peptide competition, problems of contaminating antibody heavy chain in the sample 
was avoided. The indicated MBD2 band was excised and analyzed by mass 
spectrometry for the presence of methylarginines. However, the result was 
inconclusive, as enzymatic digestion of the MBD2 band was not able to release MBD2 
peptides at the RG domain. It is believed that the stretch of amino acid was either too 
large, or too hydrophobic to be resolved by the mass spectrometry.
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Figure 2-5 In vivo labeling of MBD proteins.
(Top Left) The scheme of the labeling experiment.
(Top Right) Lysate from cells treated with protein synthesis inhibitors cyclohexamide 
(CX) and chloramphenicol (CP) have translation effectively knocked down.
(Bottom) 293T cells were transiently transfected with plasmids expressing the indicated 
FLAG-proteins. The cells were treated with the indicated radioactive methionine labels 
and in the absence (Top) or presence (Bottom) of CX/CP. FLAG-proteins were then 
purified from total cell lysate by immunoprecipitation with anti-FLAG antibody, and 
methylated proteins were analyzed as for Figure 2-1. (*) Denotes antibody heavy chain.
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Besides showing the presence of methylarginines in MBD purified from 
mammalian cells, the methyltransferase activities acting on the two proteins can be 
demonstrated in live cells (48). FLAG-tagged MBD2 and MeCP2 were expressed in 
293T cells, and the cells were used directly for the in vivo labeling experiments (Figure 
2-5, Top Left).
3H-methyl methionine or 35S-methionine, two cell-permeable radioactive
labels, were included as the only source of methionine in the medium. When protein
synthesis inhibitors were absent, the 35S-methionine was readily incorporated into all
cellular proteins by translation. In the presence protein synthesis inhibitors, translation
was effectively blocked (Figure 2-5, Top Right). Under these conditions, 3H-methyl
 ^ #
methionine can still be converted by cellular metabolism to H-SAM, which serves as 
the in vivo methyl donor.
From the labeling reactions, it was observed that only wild-type MBD2 and 
MeCP2 were accepting the 3H-signal when translation ceased (Figure 2-5, Bottom, 3H- 
Fluorograph). This indicates that the labeling is a post-translational event. The 
arginine residues in the RG repeats of the MBD proteins are the most likely methyl 
accepting sites because removal of the RG repeat domain (MBD2-RG and MeCP2-RG 
6) prevents 3H-label incorporation.
2.3 Identifying methyltransferase interactors of MBD2 and MeCP2
As it is now clear that the MBD proteins are modified by methyltransferases 
in cells, and the sites of post-translational modifications were mapped to the RG 
domains, I used an interaction assay to identify the specific arginine 
methyltransferases catalyzing these modifications.
6 The amino acid sequences of the RG domains removed from the two proteins are illustrated in Figure
2-6, top panel.
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GST-MBD2 RG domain GST-48-gvrregargggrgrgrwkqaargggvcgrgrgrgrgrgrgrgrgrgrgrpqsggsgl-104
GST-MeCP2 RG domain GST-154-dfdftvtgrgspsrreqkppkkpkspkapgtgrgrgrpkgsgtgrpkaaaseg-206
GST-GAR GST-1-mkpgfsprgggfggrggfgdrggrggrggfgggrgrgggfrgrgrgggggggggggggrggggfhsggnrgrgrg
gkrgnqsgknvmvephrhegvficrgkedalvtknlvpgesvygekrvsisegddkieyrawnpfrsklaaai-148
MBD2 MeCP2 GAR
substrate RG RG
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Figure 2-6 RG domain of MBD proteins are sufficient for methylation.
(Top) The RG domains of MBD proteins and fibrillarin (GST-GAR) were expressed as 
GST-proteins in bacteria. Amino acid sequences for each of the substrates are 
indicated, and the relative positions of the residues are shown as numbers.
(Bottom) The indicated proteins were subjected to methylation by HeLa cell lysate as 
for Figure 2-1. (*) Indicates the relative position of the proteins in the gel.
To create baits for identification of the interacting methyltransferase(s), the 
RG domains of MBD2 and MeCP2 proteins were expressed as GST-tagged proteins 
(Figure 2-6, Top). I needed to ascertain whether the RG domain alone was sufficient 
for interaction with, and could be modified by, the methyltransferase(s), or whether the 
interacting sites for the methyltransferase(s) is not dependent on the RG domain.
Therefore, proteins were tested for their capacity to be methylated by an in 
vitro methylation assay (Figure 2-6, Bottom). GAR (Lane 7 and 8), the RG containing 
domain of fibrillarin protein (217), was included as the positive control. To ensure 
that there was no auto-methylation of lysate proteins, controls without substrate were 
included (Lane 1 and 2). As expected, the RG domains of MBD2, MeCP2 and GAR 
were labeled by methyltransferases in HeLa lysate (Lane 3, 5 and 7). Therefore, the 
RG domains of the MBD proteins were considered suitable baits for the pull down 
assays.
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2.3.1 GST pull down assay using N2A and PC12 cell lysates
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Figure 2-7 Identifying the interacting partners of the RG domain of MBD proteins 1.
GST protein or the GST-tagged RG domain of MeCP2 and MBD2 proteins were 
incubated in the absence or presence of methy lation inhibitor and/or the indicated cell 
lysates, and the samples were prepared and analyzed as for Figure 6-4.
Mammalian cell lysates that posses in vitro methyltransferase activity towards 
MBD2 and MeCP2 proteins were used for GST pull down assays. In the initial 
experiments, HeLa and Ramos cell lysate were incubated with the RG domain of the 
two MBD proteins, and 35 proteins enriched in the interaction assay were sent for 
identification by mass spectrometry analysis. None of the interacting proteins was 
identified as a methyltransferase (see Figure 6-4 in Chapter 6.3).
As deficiency or mutations in the MBD proteins was linked to 
neuropathological disease/symptoms (4, 86), I repeated the pull down assay using 
transformed cell lines of neuronal origin (Figure 2-7). While the experimental setup 
and controls were similar to the previous experiment8, I also wanted to test the 
hypothesis that SAH might affect the affinity of interaction between the target 
methyltransferases and the RG domain proteins, since it inhibits methyltransferase 
activity. However, addition of SAH did not produce any visible difference in the co-
7 For details of the conditions used for GST pull down assay, refer to Figure 6-4. in Chapter 6.3.
8 Refer to Figure 6-4.
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purifying protein bands compared to samples without SAH (5 vs 6, 8 vs 9, 14 vs 15 
and 17 vs 18). Again, distinct bands were selected and analyzed by mass spectrometry 
but no methyltransferase was identified.
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RG RG 
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Figure 2-8 The RG domain of MBD interacts with methyltransferase.
The recombinant proteins captured after incubating with PC12 cell lysate as for Figure 
2-7 were subjected to methylation assay by incubating at 37°C for 90 min in the 
presence of 3H-SAM. The interacting methyltransferase present catalyzed the addition 
of 3H-methyl groups to the recombinant protein, and the reactions were stopped and 
visualized as for Figure 2-1.
Due to the inability of the pull down assays to isolate specific 
methyltransferases, I asked whether the targeted methyltransferases were binding to 
the GST-bait. To ensure that this was the case, the experiment in Figure 2-7 was 
repeated (note similar lane numbers). Instead of visualizing the protein complexes by 
SDS-PAGE/Coomassie, the presence of methyltransferase activity was tested by 
adding 3H-SAM to the purified complex (Figure 2-8).
From the Fluorography, it was confirmed that the GST-RG domain was 
attracting methyltransferase(s) that catalyze the addition of radioactive methyl groups 
to the recombinant substrate when a methyl donor was supplied (Lane 14 and 17).
I can also conclude that the presence of SAH in the lysate during the pull 
down assay had a detrimental effect on the interaction between the methyltransferase
and the RG domain proteins (14 vs 15 and 17 vs 18). This is because the samples were 
washed extensively in SAH-free buffer before the methylation assay to prevent carry­
over of the inhibitor.
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Figure 2-9 Optimization of washing conditions for the GST pull down assay.
(Top) GST-tagged RG domain of MBD2 was subjected to pull down assay using Ramos 
cells lysed in buffer containing 100 mM NaCI. The complexes were captured as for 
Figure 6-4, and were washed extensively (6 times) with the indicated concentrations of 
NaCI. 90% of the proteins were analyzed by Coomassie, while the remaining samples 
were assayed for co-purifying methyltransferase activity as for Figure 2-8.
(Bottom) The pull down experiment was repeated using GST-MBD2 N-terminus as the 
bait, and was analyzed as above.
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Since the methyltransferase activity can be purified using the pull down 
experiments, a cleaner purification with fewer non-specific proteins might improve the 
chances of identifying the methyltransferase by mass spectrometry. The pull down 
assay was performed as before (Figure 6-4), but the stringency of the washes were 
enhanced by increasing the ionic strength of the wash buffer (Figure 2-9). To check 
that the increased stringency of the wash did not remove the desired 
methyltransferase(s), duplicates of the samples were assayed by in vitro methylation.
Interestingly, increasing the NaCI concentration reproducibly increases the 
purified methyltransferase activity (Figure 2-9, Top). This might be due to the 
removal of non-specific proteins that were masking the sites of methylation on the 
GST-MBD2 RG domain. From the Coomassie gel (Figure 2-9, Top), it was observed 
that GST pull down samples washed in 800 mM NaCI (Lane 6) contained the fewest 
contaminating protein bands and had uncompromised methyltransferase activity. 
Therefore, this condition was chosen for further assays.
For washes with a higher concentration of NaCI, although higher 
methyltransferase activity was observed (Lane 8 and 10), the purified samples 
produced more Coomassie bands compared to those prepared in 800 mM NaCI. This 
could be a result of protein aggregation under high salt conditions.
I also tested whether the washing conditions optimized for the GST-MBD2 
RG domain can also be applied to the larger GST-MBD2 N-terminus bait (Figure 2-9, 
Bottom). Similarly, washing the complexes with 800 mM NaCI (Lane 14) produced 
the least number of contaminating bands in the silver staining, but contained the 
highest methyltransferase activity compared to other samples (Lane 11-13).
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2.3.2 The RG domain of MBD2 interacts with PRMT1 and methylosome 
components
GST
MBD2
F/L
GST
MBD2
RG
dom ain
lysate
116
97
66
45 —
29 —
C oom assie
Figure 2-10 GST pull down using full-length and RG domain of MBD2.
GST-tagged MBD2 proteins were used in pull down assays with Ramos cell lysate 
containing 800 mM NaCI, the complexes were incubated and captured as for Figure 6-4, 
and were washed extensively in buffer containing 800 mM NaCI. The purified 
complexes were eluted with SDS-PAGE sample buffer and resolved by SDS-PAGE. The 
indicated bands were analyzed by mass spectrometry.
Using the optimized conditions previously worked out (Figure 2-9), the pull 
down assay was repeated for MBD2 protein (Figure 2-10). Three distinct bands were 
purified by the GST-MBD2 RG domain protein, and the identity of the bands is 
reported in Table 2-1.
Bands Protein Accession
number
a Eukaryotic transcription elongation factor 6
450348
b MEP50 13129110
c HMThnRNP 4504497/1808644
Table 2-1 Results of mass spectrometry analysis.
Identity of protein bands from Figure 2-10 reported by mass spectrometry analysis.
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From Table 2-1, band (a) was not a methyltransferase and was also reported 
in the previous experiments (Figure 6-4 and Figure 2-7). Hence, the significance of 
this interaction was not explored.
Band (b), the MEP50 protein, is also known as methylosome protein 50 and is 
a component of the large (20S) PRMT complex that consists of PRMT5, pICIn and 
MEP50 (72). For band (c), the full name of the protein is human methyltransferase 1 
(HMT1) hnRNP methyltransferase-like 2, which is also known as protein arginine 
methyltransferase 1 (PRMT1). The peptide sequences of the three proteins identified 
in Table 2-1 revealed that they were of human origin and this correlated with the 
source of cell lysate used.
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Figure 2-11 MBD2 interacts w ith components of the methylosome.
The indicated GST-tagged MBD2 proteins were used in pull down assays as in Figure 
2-10, and interacting proteins were assayed for the presence of methylosome 
components by Western blot with the indicated antibodies.
Since MEP50 protein was identified in the pull down assay, I tested whether 
PRMT5 and pICIn interact with GST-MBD2. Instead of using mass spectrometry 
analysis, protein complexes purified from pull down assays were subjected to Western 
blotting using antibodies raised against the two proteins (Figure 2-11).
MBD2 protein that contains the RG domain interacts with PRMT5 and pICIn 
(Lane 3, 5 and 9), and GST-MBD2 C-terminus (Lane 7) was the only construct that 
did not interact with the methylosome proteins. This is consistent with the fact that in 
vitro arginine methylation was not reported in that section of the protein (see Figure 
2-2).
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2.4 MBD2 interacts with PRMT1 and PRMT5 in vivo
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Figure 2-12 Endogenous MBD2 co-purifies with methyltransferase activity.
Control antibodies or antibodies against MBD2 were added to Ramos cell lysate in a 
buffer containing 800 mM NaCI, and binding was carried out at 4°C for at least 4 hr.
The antibody-MBD2 complexes were captured by Protein G agarose and were washed 
extensively in the lysis buffer. 50% of the purified complexes were eluted and analyzed 
by Western blot (Left). (*) Denotes antibody heavy chain. The remaining antibody- 
MBD2 complexes were subjected to methylation assay by addition of 3H-SAM to detect 
for the presence of interacting methyltransferase (Right). The reactions were stopped 
and visualized as for Figure 2-1.
The in vitro GST pull down assay revealed that at least two PRMTs interact 
with MBD2 via the RG domain (Figure 2-10). However, as amino acid repeats in the 
context of RG are the favored recognition motifs for most PRMTs (163), and MBD2 
contains an extensive stretch of RG repeats, the authenticity of this molecular 
interaction required verification.
Using the optimized buffer system from Figure 2-9, I investigated whether 
endogenous MBD2 protein in cells can be immunopurified with methyltransferase 
activity. From Western blotting, I know that isolation of endogenous MBD2 protein is 
feasible using the high NaCI buffer (Figure 2-12). Thus, a duplicate of the 
immunopurified MBD2-protein complex was supplied with 3 H-SAM, as for Figure 
2-8, to probe for any co-purifying methyltransferase activity.
From the Fluorography, a 3H-band corresponding to the size of MBD2 protein 
was observed. As this band is the only enriched protein in the MBD2 
immunopurification, it is believed to be the endogenous MBD2 methylated by the co- 
purifying PRMT(s).
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Figure 2-13 Co-immunoprecipitation of PRMTS and MEP50 with endogenous MBD2.
(Top) MBD2 was immunopurified from Ramos cell lysate as for Figure 2-12. MBD2- 
complexes eluted with SDS-PAGE sample buffer were analyzed by Western blot with 
the indicated antibodies.
(Bottom) Western blot was exposed for 1 min. Arrow indicates position of pICIn.
Since endogenous MBD2 co-purified methyltransferase activity, the isolated 
MBD2-protein complexes were tested for the presence of the PRMTs by Western blot. 
In Figure 2-13, MBD2 displayed a positive interaction with PRMT5 and MEP50 (Lane 
3), whereas hnRNP Al, a well-characterized PRMT1 substrate found in the nucleus of 
cells (141), did not (Lane 5).
As for pICIn, although it is present at high levels in the cell lysate (Lane 6), 
and displayed a strong positive interaction with PRMT5 (Lane 11), the existence of 
pICIn in an endogenous MBD2-protein complex appeared minimal or insignificant 
(Lane 8).
63
Chapter 2 Results I
IP
3a.c
45
29
CMam
<
Q.
Zacc
9  —
1 2  3 4
PRMT1 
hnRNP A1
W estern
Figure 2-14 Endogenous MBD2 does not co-immunopurify strongly with PRMT1.
MBD2 proteins were immunopurified from Ramos cell lysate as for Figure 2-12. 
MBD2-complexes eluted with SDS-PAGE sample buffer and analyzed by Western blots 
with the indicated antibodies. PRMT1 Western was exposed for 1 min.
When the endogenous MBD2 complexes were probed for the presence of 
PRMT1 by Western blot (Figure 2-14, Lane 3), the interaction was weak and 
inconclusive. This is because PRMT1 was also observed in the control goat antibody 
immunoprecipitation (Lane 2). However, the PRMT1 substrate hnRNP A1 (141, 179), 
also did not co-purify with the methyltransferase.
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Figure 2-15 MBD2 proteins overexpressed in vivo co-purify with PRMT1 and PRMT5.
FLAG-proteins were immunoprecipitated with FLAG antibody, eluted with FLAG 
peptide, and normalized by titration against BSA in SDS-PAGE/Coomassie. 
Normalized protein complexes were analyzed for co-purifying PRMTs by Western blot 
with the indicated antibodies. 1% input represents pooled lysate used from all 
transfections.
As it was reported that the majority (> 90%) of MBD2 in cells exists in the 1 
MDa MBD2/NuRD complex (65), expressing excess MBD2 in cells might increase
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the amount of the free protein and allow for its interaction with the PRMTs. FLAG- 
MBD protein complexes purified from transfected 293T cells were tested for the 
presence of co-purifying PRMTs.
From the Western blot (Figure 2-15), it was observed that full-length MBD2 
protein interacts with PRMT1 and PRMT5, but not PRMT3 and PRMT4 (Lane 3). 
This interaction is exclusive to the RG domain because an MBD2 mutant with the 
domain deleted (MBD2-RG, Lane 2) did not show any interaction with the two 
PRMTs.
MBD3, a protein sharing 70% sequence similarity with MBD2 in the MBD 
domain (85) interacts with PRMT5 but not PRMT1 (Lane 4). Although the presence 
of PRMT5 in the MBD3 immunoprecipitate could be due to their co-existence in the 
Brgl complex in cells (56, 177), I can not rule out the possibility of an artifact, as 
PRMT5 was observed to non-specifically bind FLAG-agarose beads in some instances 
(Data not shown).
2.5 Characterizing the species of methylarginine present on MBD2 
and MeCP2
PRMTs have been shown to associate stably with proteins without catalyzing 
modifications on their interacting partners (6, 178). Therefore, I needed to check 
whether the interacting PRMTs were catalyzing the formation of their specific 
methylated arginines products in the RG domain of the MBD2 protein.
In the study of PRMTs, the most difficult aspect is to determine the 
methylation status of arginine present on the substrate proteins (11, 220). This is due 
to the chemical similarities between an unmodified arginine residue and each species 
of methylarginine, which makes it difficult to generate antibodies that do not cross 
react. Therefore, any methylarginine specific antibodies used in this study needed to 
be carefully tested. For MBD2, since it is found to interact with both type I and type II 
PRMTs (PRMT1 and PRMT5 respectively), I would expect the two forms of 
dimethylarginines (asymmetric and symmetric respectively) to be present on the 
protein. For this reason, greater care was required to address the issue.
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In the case of MeCP2, the interacting PRMT was still not identified. 
However, if I were able to determine the specific species of dimethylarginines present 
in the protein, I might be able to establish the particular type of PRMT that is 
responsible for catalyzing this modification. This would enable me to concentrate on a 
smaller subset of PRMT proteins.
2.5.1 Characterizing the antibodies that recognize methylarginine
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L-methionine
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m ethy ltransferase
'A d en o sy l
m ethionine
sy n th e ta se
S-(5'-Adenoysl)-
L-hom ocysteine
(SAH)
Methionine
betaine
hom ocysteine
lethyltransferase
A denosyl 
hom ocysteine 
hydro lase  y
Adox
H om ocysteine
Figure 2-16 The methylarginine content of PRMT substrates can be depleted by using 
methyltransferase inhibitor.
Regeneration cycle of the universal methyl donor for all methyltransferases and the 
inhibitory effect of Adox in the cycle (43).
To generate MBD proteins with or without methylarginine contents, 
transfected 293T were treated with the cell permeable methyltransferase inhibitor, 
Adox. In cells, Adox prevents the regeneration of SAM by binding to Adenosyl 
homocysteine hydrolase. This causes the accumulation of intracellular SAH and 
inhibits all methyltransferase reactions (Figure 2-16). In this study, the in vivo post- 
translational labeling of MBD2 protein is consistently abolished by the addition of 
Adox9.
9 For an example illustrating the effects of Adox on the in vivo methylation o f MBD2, refer to Figure
3-11, Lane 1 & 2).
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With the ability to control the methylarginine content of proteins, 
commercially available antibodies can be tested against MBD2 and MeCP2 purified 
from cells. The outcome of the Western blot will be informative as to whether these 
antibodies are specific for methylated arginines or whether they are cross-reacting with 
unmodified arginine residues. The list of commercially available antibodies selected 
for screening the MBD proteins are listed in Table 2-2.
Antibody Cat no. Antieen SDecies Cross
reaction
ComDa
7E6 ab412 MMA and
Asym
DMA
Mouse unknown Abeam
21C7 ab413 Asym
DMA
Mouse Sym DMA 
(unknown)
Abeam
16B11 ab414 MMA Mouse Sym DMA 
(unknown)
Abeam
5D1 ab415 MMA Mouse Sym DMA 
(unknown)
Abeam
Asym24 07-414 Asym
DMA
Rabbit No Upstate
Sym 10 07-412 Sym DMA Rabbit No Upstate
Syml 1 07-413 Sym DMA Rabbit Unknown Upstate
Table 2-2 List of all commercially available antibodies that detect methylated arginine 
residues.
The characteristics and cross reactivity are based on information from the 
manufacturer. (MMA = monomethylarginine, DMA = dimethylarginine, Asym = 
asymmetric and Sym = Symmetric)
The cross reactivity and specificity of these antibodies were determined in the 
following experiments.
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FLAG IP
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Figure 2-17 Screening mouse methylarginine antibodies against MBD proteins.
293T cells were transiently transfected with plasmids expressing the indicated FLAG- 
proteins for 30 hr and fresh medium with or without Adox were added to the cells for 
another 18 hr. The FLAG-proteins were purified and normalized as for Figure 2-15, 
and were analyzed by Western blots with the indicated antibodies stated in Table 2-2.
Films for 7E6 and 21C7 were exposed for 20 sec, and for 16B1 and 5D1, exposure was >
2 min.
For Figure 2-17, the four proteins tested were prepared from cells treated with 
or without methylation inhibitor. Two of the proteins, (MBD2-RG; Lane 1,2 and 
MeCP-RG; Lane 5,6) were shown to be immune to protein methylation (see Figure 
2-5), and therefore should not be recognized by the antibodies. Even if
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methylarginines were indeed present in these -RG mutants, the Adox treated samples 
should not be detected in the Western blots (Lane 2 and 6).
In this experiment, the only samples that are expected to react with the 
antibodies were the wild-type MBD2 and MeCP2 proteins prepared from cells raised 
in Adox free medium (Lane 3 and 7). However, none of the antibodies used in Figure 
2-17 seemed to be exclusive for these two samples (Lane 3 and 7). All proteins were 
recognized by 7E6 and 21C7 antibodies while 16B1 and 5D1 antibodies required 
lengthy exposure to reveal the non-specific bands and were thus considered unsuitable.
FLAG IP
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Figure 2-18 Screening rabbit methylarginine antibodies against MBD proteins.
FLAG proteins were prepared and purified from 293T cells as in Figure 2-17, and were 
screened for methylated arginines with the indicated antibodies stated in Table 2-2. All 
fdms were exposed for 20 sec.
Proteins prepared in Figure 2-17 were also tested with antibodies raised in 
rabbits immunized with peptides containing dimethylarginines. From the Western 
blots in Figure 2-18, it was observed that the Asym24 and Sym 10 antibodies were 
specifically detecting wild-type MBD2 protein prepared from cells cultured in the
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absence of Adox (Lane 3). The antibodies did not recognize the same protein prepared 
from Adox treated cells (Lane 4). This illustrates the ability of the two antibodies to 
discriminate between methylated and unmethylated arginine residues.
MBD2 protein with a deletion of the RG domain (MBD2-RG, Lane 1) was 
not recognized by the antibodies. This supported the findings in Figure 2-5, where I 
found that dimethylarginines were either non-existent or were present at an 
insignificant level in the C-terminus region of MBD2.
All variants of MeCP2 (Lane 4-8) were recognized non-specifically by the 
Sym 11 antibody, and were not detected by Asym24 and Sym 10. Judging from the 
antigens used to generate the Asym24 and Sym 10 antibodies (Figure 2-19, Top), it is 
not surprising that methylated MeCP2 (Figure 2-18, Lane 7) could not be detected. 
This is because the immunogen used for Asym24 and Sym 10 antibodies are based on 
peptide sequences with a row of at least 4 consecutively methylated RG repeats. Even 
if the RG domain of MeCP2 was fully methylated, they might escape detection by the 
antibodies, as there are only 3 consecutive RG repeats present on this protein (see 
Figure 1-6). MBD2, on the other hand, contains 10 consecutive RG repeats in the RG 
domain.
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KG RasDMAG *G RasDMAG R ^dmaq PPPPP R“ °MAG RosDMAG RasDMAG R*»dmaG
Sym10
K RsDMAG RsDMAG rsDMAg  R*°maG
FLAG IP
CO CM CM
Q  Q  Q  Q
E 00 IB o
<n S  5  5
45—
29—
14 —
45— —
29—
14 —
45—
29—  
14 ----
—
FLAG
Asym24
Sym10
1 2  3 4
Western
Figure 2-19 Asym24 and SymlO antibodies are specific for arginine methylated MBD2.
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(Top) The antigens used for generation of the antibodies, and the position and type of 
modification of the arginine residues are indicated, (as = asymmetric, s = symmetric.
DMA = dimethylarginine.).
(Bottom) Plasmids encoding the indicated FLAG-proteins were transfected into 293T 
cells in the absence of Adox and the proteins were purified and normalized as for Figure 
2-15. The proteins were tested for methylated arginines with the indicated antibodies.
Specificity of Asym24 and Sym 10 antibodies for MBD2 was reconfirmed 
using MBD3 and SmDl, a protein reported to contain both species of 
dimethylarginines (Figure 2-19, Bottom) (31, 160). Both dimethylarginine antibodies 
did not recognize MBD3 (Lane 2) and MBD2-RG (Lane 4), but they detected the 
modified arginine residues on MBD2 protein (Lane 3), as observed previously (see 
Figure 2-18).
Although SmDl proteins purified from the nuclear fraction were known to 
contain asymmetric dimethylarginines in mass spectrometry analysis (160), they were 
not recognized by the Asym24 antibody (Lane 1). This could be due to a bias of the 
purification scheme that might enrich for the cytosolic fraction of SmDl that 
exclusively contains symmetric dimethylarginine. Alternatively, the proportion of 
asymmetrically methylated arginines in SmDl might be too low for detection. The 
latter explanation is more appealing, because MBD2, the nuclear protein (85, 99) and 
was easily purified in the experiment using the high salt lysis buffer (800 mM NaCI). 
Furthermore, symmetric dimethylated species of SmDl can also be found in the 
nuclear fraction, and the knowledge of its existence precedes the discovery of 
asymmetrically dimethylated SmDl by years. These studies support the prevalence of 
the symmetric dimethylated species of SmDl.
While I cannot confirm whether Asym24 or Sym 10 antibodies are only 
specific for their intended species of dimethylarginines, the uncertainty was partly 
resolved by the Asym24 Western blot on SmDl proteins. Amino acid sequences of 
the RG domain in SmD 1 and MBD2 are very similar in comparison (9 consecutive RG 
in SmDl and 10 in MBD2). If Asym24 antibodies were to cross react with symmetric 
dimethylarginines, they should detect SmDl proteins in the Western blot. However, 
since the specificity of the two dimethylarginine antibodies is of utmost importance, 
further experiments were designed to address this point.
71
Chapter 2 Results I
2.5.2 MBD2 proteins expressed at endogenous levels contain methylated 
arginines
In previous experiments, the Asym24 and Sym 10 antibodies were tested 
against overexpressed MBD2 purified from cells. As overexpression of proteins might 
sometimes disrupts cellular systems and lead to aberrant post-translational 
modifications, I generated stable cell lines that express controllable levels of FLAG- 
MBD2 and FLAG-MBD2(-RG) only upon tetracycline induction.
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Figure 2-20 MBD2 expressed at endogenous levels is methylated.
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Human (293T) cells from the Flp-In™ T-Rex™ system were transfected with plasmids 
containing the FLAG-MBD2 or FLAG-MBD2 (-RG41)10 genes driven by a tetracycline 
inducible promoter.
(Top) Transfected cells were selected with antibiotics to obtain stable colonies (see 
Chapter 5.4.3.2) and these cells were titrated for tetracycline induction. Bradford 
normalized total cell lysates were prepared from the induced stable cells and HeLa cells 
to analyze for the expression level of MBD2. ( f )  Indicates the tetracycline 
concentration selected for induction of each stable cell. Ran levels indicate protein 
loading.
(Bottom) FLAG-MBD2 proteins were purified from the selected tetracycline induction 
( t )  as for Figure 2-5 and analyzed by Western blot with the indicated antibodies 
(Bottom). (*) Denotes antibody heavy chain.
To show that MBD2 is unequivocally methylated in vivo, the FLAG-MBD2 
proteins were expressed at levels comparable to endogenous MBD2 in HeLa cells 
(Figure 2-20, Top). These FLAG-MBD2 proteins were purified and were tested with 
the dimethylarginine antibodies. Again, full-length MBD2 but not MBD2-RG was 
determined to contain both asymmetric and symmetric dimethylarginines (Figure 2-20, 
Bottom).
2.6 Partial removal of the type I and type II PRMT specific for 
MBD2
It was demonstrated that removal of methylarginine content of MBD2 by 
Adox enabled us to test the ability of the antibodies to discriminate unmodified 
arginine residues from methylated arginine (Figure 2-16). However, to test if the 
Asym24 and SymlO antibodies can differentiate between the two species of 
dimethylarginine residues, a more sophisticated system was needed.
To specifically remove the asymmetric dimethylarginine content of MBD2, 
the type I PRMT (PRMT1) responsible for this modification had to be removed from 
the cells. The same logic was applied to remove symmetric dimethylarginines by 
targeting PRMT5. PRMT knockout mice cells are most suitable for this purpose. 
However, only the attempt to delete PRMT1 in mice was documented, and the 
phenotype of PRMT1 -/- mice was embryonic lethal (180). Therefore, to obtain 
cellular systems that allow the study of the effects of PRMTs on MBD2, the siRNA
10 In subsequent characterization, a better defined MBD2 mutant with deletion o f the entire RG domain 
was created (MBD2-RG41, Figure 3-6). The amino acids that are removed from this MBD2 protein is 
illustrated in Figure 3-5.
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approach was employed to reduce the normal levels of the two PRMTs in 293T cells. 
mRNA sequences of human PRMT1 and PRMT5 were analyzed by Extractor 5 
software to select suitable regions of the sequence for design of siRNA .
Gene Clone
Number
siRNA se q u e n c e Target 
sequence in 
mRNA (bp)
PRMT1 A 3 ' -TTTCGAATGATGAAACTGAGG 145-167
B 3 ' -TTCTAGCAGTTTCGGTTGTTC 379-401
C 3 ' -TTTCGGTTGTTCAATCTGGTA 389-411
D 3 ' -TTTGTCGACCAGTGGTTGCGG 721-743
PRMT5 A 3 1-TTCTTCCCTAAAGGACAAGAA 808-830
B 3 ' - TTTCGAAAGAGGTACCTAAGC 342-364
C 3 ' -TTTCCTGGGGTAGTTTATGAG 1074-1096
D 3 ' -TTCCCTGACCTTATGCGATTA 315-337
p53 - 3 ' -TTGAGGTCACCATTAGATGA 774-796
Table 2-3 Design of siRNA sequences.
siRNA sequences designed based of mRNA sequences of human PRMT1 and PRMT5. 
Only the reverse strand of the targating sequences are shown. The vector encoding 
siRNA against p53 transcripts was included as a control (32).
48 hrs post transfection
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Figure 2-21 Transient expression of siRNA in 293T cells.
293T cells were transfected with plasmids encoding siRNA sequences specific for 
PRMT1 or PRMT5 (see Table 2-3) and were maintained in culture for 48 hr (Top) or 72 
hr (Bottom). The cells were then lysed and the lysate were normalized by Bradford.
74
Chapter 2 Results I
Normalized lysates were subjected to Western blot with the indicated antibodies.
Western blot of Ran protein levels indicates loading control and a stable clone of 293T 
cell producing siRNA against p53 was included as control for siRNA knockdown. Lane 
18 for the PRMT1 Western is a membrane transfer error.
The sequences were cloned into pRetro. Super plasmid for transient 
transfection in 293T cells. In cells, the constitutive HI RNA promoter in the vector 
drives the transcription of short hairpin RNA (shRNA), which will be processed into 
the siRNA sequences listed in Table 2-3 (32).
At 48 hr post transfection, the endogenous levels of PRMT1 and PRMT5 
were compared (Figure 2-21, Top). The pRetro.Super vector plasmid was included as 
the negative control because it does not generate any siRNA against protein 
transcripts. From the Western blots, there was a decrease of PRMT1 levels in cells 
transfected with the plasmids encoding PRMT1 siRNA (Lane 2-5), and similar 
PRMT5 decrease was observed for PRMT5 siRNA plasmids (Lane 6-9). However, 
the extent of knockdown was inadequate.
The minimal decrease in the PRMT protein levels might be attributed to the 
stability of the PRMT protein present prior to the knockdown. Therefore, the 
transfection was repeated and proteins were analyzed 72 hr post-transfection (Figure 
2-21, Bottom). Instead of the pRetro.Super negative control, a plasmid encoding 
siRNA against p53 was included; p53 levels in cells transfected with this plasmid 
displayed distinct and significant knockdown (Lane 10). At 72 hr post transfection, 
there was a more effective knockdown of PRMT 1 and PRMT5 proteins (Lane 11-14 
and Lane 15-18 respectively) compared to the 48 hr time point.
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Figure 2-22 Generating the siRNA stable clones.
(Top) 293T cells were transiently transfected with plasmids encoding the indicated 
siRNA and were selected with puromycin. Positive clones were continuously selected 
for 1 month and were assayed for knockdow n of targeted proteins as for Figure 2-21.
(Bottom) After two months of selection, the clones that displayed the highest level of 
protein knockdown were kept for further analysis.
Since PRMT1 and PRMT5 proteins appeared to be stable and required a 
longer time for the siRNA to be effective, stable cell lines producing the siRNA were 
generated to target the two PRMTs. siRNA sequences that displayed the highest level 
of knockdown of proteins in the 72 hr transient transfection were chosen to make the 
stable cells.
Transfected 293T cells were selected for 1 month with puromycin and were 
assayed for the endogenous level of target proteins (Figure 2-22, Top). The level of 
protein knockdown was very high in p53 siRNA cells (Lane 2 and 3); this is consistent 
with the findings of other laboratories (32). For the PRMTs, clone A of PRMT1 
siRNA cell line (Lane 4) and clone A of PRMT5 siRNA cell line (Lane 7) were 
observed to produce the highest level of knockdown of their respective target protein. 
Thus, these cells lines were further selected for another month before the reanalysis of 
their protein levels (Figure 2-22, Bottom). After two months, knockdown of PRMT1 
and PRMT5 (Lane 4 and 7) proteins were more than 50% and were therefore used for
76
Chapter 2 Results I
further experiments. A stable clone containing the empty pRetro.Super vector plasmid 
(Lane 1) was also generated during the process to serve as the negative control in 
future experiments.
2.7 Analyzing the methylarginine content of MBD2 produced from 
PRMT1 and PRMT5 deficient cells
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Figure 2-23 In vitro methylation assay using lysates from siRNA clones.
Cell lysates from siRNA stable clones in Figure 2-22 were normalized by Bradford assay 
and Western blot (Top), and were used as the source of methyltransferase for in vitro 
methylation of the GST-MBD2 N-terminus protein as for Figure 2-1 (Bottom).
To test whether the reduced PRMT levels in the lysate drastically affect the 
protein methyltransferase activity on recombinant MBD2 proteins, the in vitro 
methylation assay was performed (Figure 2-23, Bottom).
From the Fluorograph, it was observed that most lysates were able to 
methylate the GST-MBD2 N-terminus protein, and only the methyltransferase activity 
in the PRMT1 siRNA cell line was affected. This was expected, as PRMT1 is the 
predominant arginine methyltransferase in mammalian cells (180, 216). However, as 
in vitro methylation assay using bacterially produced MBD2 might not represent the
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complex regulation of MBD2 arginine methylation in cells, the in vivo methylation 
reaction was performed in the siRNA clones.
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Figure 2-24 In vivo labeling assay using siRNA stable clones.
siRNA stable clones in Figure 2-22 were transfected with the indicated MBD constructs 
and cells were labeled with 3H-methionine in the presence of protein synthesis inhibitors 
as for Figure 2-5. The proteins were FLAG immunoprecipitated, peptide eluted and 
normalized by Coomassie. Normalized protein (Top) was subject to Fluorography 
(Bottom) to detect the amount of 3H-methylated arginine present.
Full-length MBD2 and MeCP2 were transfected into the siRNA clones and 
were post-translationally labeled in the cells (Figure 2-24). I included MeCP2 to 
check whether depletion of the PRMTs can have an effect on the methylation of the 
protein (Lane 7 and 8).
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Although there was a reduction in 3H-label on MeCP2 protein produced in 
PRMT5 knockdown cells (Lane 8), the protein produced in the p53 knockdown 
background showed a similar level of reduction (Lane 6). For MBD2 protein, the 
results were also not as clear cut, since, unexpectedly, FLAG-MBD2 labeled in the 
PRMT knockdown background (Lane 3 and 4) did not have a reduction in H- 
methylation signal compared to in the control background (Lane 1 and 2).
Unlike inhibition of the in vivo labeling by Adox (Figure 2-16), where almost 
all methyltransferase activity in the cells was abolished, the siRNA clones only 
partially removed the PRMTs. The remaining PRMT1 and PRMT5 protein in the cells 
might still be able to saturate the available sites of methylation on the MBD2 proteins, 
and therefore produce no difference in the amount of labeling. This is possible 
because scintillation counting of the overexpressed MBD2 and MeCP2 proteins 
labeled in cells revealed that only 1:100 (molecule/molecule) of the total protein 
contained 3H. However, as the protein synthesis inhibitors are toxic to the cells, the 
time given for posttranslational labeling of the proteins was never extended beyond 3 
hr to increase the methylation.
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Figure 2-25 MBD2 expressed in PRMT deficient cells has reduced methylarginine 
content.
FLAG-MBD2 proteins were transiently transfected in to siRNA clones in Figure 2-22, 
and were purified and normalized as for Figure 2-15. Normalized proteins were 
analyzed with Coomassie (Top) and Western blot (Bottom) for the presence of 
methylarginine.
Using the Asym24 and SymlO antibodies against purified MBD2 provides a 
more comprehensive assessment of the methylarginine content of the MBD2 proteins. 
In this instance, the siRNA clones were maintained under normal growth conditions 
throughout, and the FLAG-MBD2 and FLAG-MBD2-RG proteins were purified 48 hr 
post-transfection (Figure 2-25).
MBD2 with removal of RG domain was not recognized by the antibodies; this 
is similar to previous observations (Lane 1-4). Full-length MBD2 protein from the 
pRS or the p53 deficient cells was not affected in methylarginine content (Lane 5 and 
6). The asymmetric dimethylarginine content of MBD2 from PRMT1 deficient siRNA 
cells (Lane 7) was completely abolished when compared to cells of control (pRS), p53
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or PRMT5 deficient background (Lane 5, 6 and 8). As for the symmetric 
dimethylarginine content, it was observed that this modification was not only reduced 
in MBD2 produced in PRMT5 deficient cells (Lane 8), but was also reduced in that 
produced in PRMT1 deficient cells (Lane 7). This is unexpected and I speculate that 
there might be some regulation, or sequential order for arginine methylation of MBD2 
protein to occur.
Even though the result was surprising, the question of whether the two 
antibodies are specific for their intended species of dimethylarginine was answered. 
When PRMT5 levels in cells were reduced, symmetric dimethylarginine levels on 
MBD2 were also reduced, whereas asymmetric dimethylarginines on MBD2 were not 
affected (Lane 8, Asym24 Western).
As for the SymlO antibody, if it non-specifically recognizes the asymmetric 
dimethylarginine modifications present on MBD2 proteins, the band in lane 8 of the 
SymlO Western blot should be stronger compared to the band in lane 7. This is 
because there are more asymmetric dimethylarginines present on the protein sample 
(Lane 8).
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Figure 2-26 Reduction of PRMT1 in cells do not decrease MBD2-PRMT5 interaction.
FLAG-MBD2 proteins were transiently transfected to siRNA clones in Figure 2-22 and 
were purified and normalized as for Figure 2-15. Normalized proteins complexes were 
analyzed with Western blot for the presence of co-purifying PRMTs.
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To understand how knocking down PRMT1 resulted in a decrease of 
symmetric methylation in MBD2 proteins, the MBD2 produced in PRMT deficient 
siRNA cells was tested for their ability to co-immunoprecipitate PRMTs (Figure 2-26).
As shown previously (Figure 2-15), MBD2 without the RG domain was 
incapable of binding PRMTs (Lane 1-4). Full-length MBD2 produced in PRMT1 
deficient cells (Lane 7) displayed a decrease in the amount of co-purifying PRMT1. 
Likewise, co-purifying PRMT5 was distinctly decreased in cells deficient of the 
enzyme (Lane 8).
Since there was a decrease in symmetric dimethylarginines on MBD2 
produced in PRMT1 deficient cells (Figure 2-25, Lane 7), I would expect to see a 
decrease in the levels of co-purifying PRMT5 (Figure 2-26, Lane 7). However, this 
was not observed. Therefore, I was only able to conclude that in PRMT1 deficient 
cells, PRMT5 was binding to MBD2 proteins but was unable to add symmetric 
dimethylarginine to the protein. To further understand the relationship between 
PRMT1 and PRMT5 in methylation of MBD2 protein, the PRMT1 knockout 
embryonic stem cells was employed.
2.8 Analyzing MBD2 produced from cells without PRMT1
As mice with PRMT5 -/- genotype are not available and PRMT1 mutant mice 
are embryonic lethal (180), characterization of the MBD2 proteins can only be carried 
out with PRMT1 -/- embryonic stem (ES) cells. These ES cells were difficult to 
manipulate for protein expression but are a good source of MBD2 protein (Figure
2-27, MBD2 western, Lane 1 -4). Therefore, endogenous MBD2 protein was purified 
from these cells.
Ceil lysate
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Figure 2-27 Analysis of PRMT levels in wild-type and PRMT1 -/- embryonic stem cells.
Bradford normalized ES cells were analyzed by Western blots with the indicated 
antibodies to detect for the presence of the proteins.
In the PRMT1 -/- ES (prmtl) cell lysates (Lane 2 and 4), the PRMT1 protein 
was not observed in the Western blot as expected. There was also an unexpected 
increase in PRMT5 protein level in the lysate compared to wild-type (Lane 1 and 3); 
this phenomenon was not reported previously, as researchers using the cells were 
seldom studying PRMT5.
With careful normalization of the samples for the Western blot, I determined 
that MBD2 protein levels in prmtl cells (Lane 2 and 4) were slightly lower than wild- 
type cells. Furthermore, the MBD2 protein bands from prmtl cells also seemed to 
migrate faster in SDS-PAGE gels. As arginine methylation does not drastically affect 
the overall charge or molecular weight of the target protein (77), arginine methylated 
proteins and their unmodified counterparts are generally believed to migrate similarly 
during one dimensional gel electrophoresis (97). However, the MBD2 protein 
contains an extensive RG domain that can be asymmetrically and symmetrically 
methylated, and since this is unique amongst most arginine methylated proteins, 
further tests were done to confirm the difference in migration of the two MBD2 
proteins11.
11 For details of test performed to illustrate the difference in migration, refer to Figure 6-5 in Chapter 
6.4.
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2.8.1 MBD2 from prm tl ES cells do not contain asymmetric dimethylarginine
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Figure 2-28 Analysis of the asymmetric dimethylarginine content of MBD2 from 
PRMT1 knockout cells.
(Top) Endogenous MBD2 protein was purified from wild-type and prmtl ES cells (3 X 
108) cultured under normal growth conditions. The purified MBD2 and control samples 
were analyzed by Western blot for the presence of asymmetric dimethylarginines using 
the Asym24 antibody.
(Bottom) After Asym24 Western blot, the membrane was stripped and reprobed with 
antibody against iMBD2 protein.
(*) Denotes antibody heavy chain.
To thoroughly understand the relationship between PRMT1 and PRMT5 in 
methylation of MBD2 and the modifications present on MBD2 from the wild-type and 
prmtl cells, endogenous MBD2 proteins were purified and analyzed for their 
asymmetric dimethylarginine content (Figure 2-28).
From the Asym24 Western blot, the lysate of prmtl ES cells contained less 
protein carrying the asymmetric dimethylarginine modification (Lane 2) compared to 
lysate from wild-type ES cells (Lane 1). This probably reflects the loss of asymmetric 
dimethylarginine content in the cellular PRMT 1 substrates proteins.
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At the position where MBD2 migrates, the only band that was detected to 
contain asymmetric dimethylarginines was from the immunoprecipitation of MBD2 in 
wild-type ES cells (Lane 4). To ensure that the band observed was MBD2, and that 
the protein was indeed isolated from prmtl ES cell lysate (Lane 6), the same blot was 
stripped and reprobed with antibodies recognizing MBD2. It was observed that MBD2 
protein was purified from both cell lysates by immunoprecipitation. Therefore, I 
concluded that MBD2 purified from prmtl ES cells did not contain asymmetric 
dimethylarginines.
This finding is similar to the previous experiment using PRMT1 deficient 
siRNA cells where there was an observable reduction in the asymmetric 
dimethylarginine content of the purified FLAG protein (Figure 2-25). To ascertain 
whether symmetric arginine methylation of MBD2 in prmtl ES cells will be similar to 
those in PRMT1 siRNA cells, the immunoprecipitation was repeated and the MBD2 
protein was probed with the antibody specific for symmetric dimethylarginine.
2.8.2 MBD2 from prm tl ES cells have higher symmetric dimethylarginine 
content
0.8%
lysate
IP
WT ES prm tl
WT prm tl
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W estern
MBD2reprobe
Figure 2-29 Analysis of the symmetric dimethylarginine content of MBD2 from PRMT1 
knockout cells.
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Endogenous MBD2 protein was purified as for Figure 2-28 and analyzed for the 
presence of symmetric dimethylarginine using SymlO antibodies.
From the SymlO Western blot (Figure 2-29), it was found that MBD2 
immunopurified from prmtl ES cells (Lane 6) contains higher content of symmetric 
dimethylarginine compared to protein from wild-type ES cells (Lane 4). The amount 
of immunoprecipitated MBD2 protein from both cell lines appeared similar when the 
Western blot was reprobed with MBD2 antibody. This result directly contradicts the 
findings from the siRNA cells (Figure 2-25), where a reduction in PRMT1 levels in 
cells caused an observed reduction in the PRMT5 ability to symmetrically methylate 
arginine residues in MBD2.
When comparing the normalized lysates of both ES cell lines in the SymlO 
Western blot (Lane 1 and 2), it was observed that total proteins in prmtl ES cells 
generally contains more symmetric dimethylarginines. As complete knockout of 
PRMT1 in ES cells resulted in an increase in PRMT5 protein levels (Figure 2-27), this 
might explain the increase in symmetric arginine methylation of all PRMT5 substrate 
proteins. Like the other cellular proteins observed in Lane 2, MBD2, a PRMT5 
substrate protein, was most probably affected in the same manner.
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Chapter 3 Results II - Functions of MBD2 methylation
3.1 Functional analysis of MBD2 arginine methylation
As the RG domains of the two MBD proteins are methylated in vivo, and the 
PRMT activity on MBD2 is characterized, further experiments were designed to 
investigate the effects of arginine methylation on the functions of the proteins.
Various roles of MBD2 in cells were reported in the literature, including the 
demethylation of methyl-cytosine in CpG-DNA (19), transcriptional activation (7, 
133) and transcriptional repression (65, 170). Among these reports, evidence 
presented on the transcriptional repressor function is the most substantial. This is 
because in HeLa nuclear extracts the majority (> 90%) of endogenous MBD2 stably 
interacts with the HD AC silencing complex (NuRD) to form the 1 MDa MeCPl (65, 
157, 242) (Figure 1-5). Considering the ease in co-purifying components of the 
HDAC silencing complex with MBD2, I asked whether arginine methylation of 
MBD2 affects the stability of this interaction.
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3.2 Arginine methylation of MBD2 and interaction with HDAC 
silencing complex
3.2.1 MBD2 with reduced methylated arginine content has higher affinity for 
HDAC silencing components
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Figure 3-1 MBD2 with reduced methyl arginine content have has higher afflnity for 
HDAC silencing complex.
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FLAG-MBD2 proteins were transiently transfected in to siRNA stable cell lines (Figure
2-22) and were prepared as for Figure 2-15. Normalized proteins complexes were 
analyzed by Western blot for the presence of co-purifying HDAC silencing complexes 
(Bottom). Figure 2-25 is reproduced here (Top) to show the level of methylated arginine 
on MBD2.
As described previously (Figure 3-1, Top), expression of FLAG-MBD2 in 
PRMT deficient cells resulted in a decrease in methylarginine content of the protein. 
When the methylarginine deficient MBD2 (Lane 7 and 8) was tested for co-purifying 
HDAC silencing complex, it was observed that this protein displayed a higher affinity 
interaction compared to MBD2 with normal methylarginine content (Lane 5 and 6).
MBD2 protein with the RG domain deleted (-RG, Lane 1-4) also displayed a 
higher affinity interaction with the HDAC silencing complex regardless of the 
background of cells from which they were immunopurified. This is because the 
mutation in these MBD2 proteins made them impervious to PRMT modifications, and 
this overrides the effect of cellular background. Therefore, I conclude that arginine 
methylation of MBD2 protein disrupts its interaction with the HDAC silencing 
complex.
89
Chapter 3 Results II
3.2.2 MBD2 with reduced methylated arginine content copurifies with higher 
HDAC activity
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Figure 3-2 Measurement of histone deacetylation activity of MBD2-protein complexes.
(Top) The scheme of the histone deacetylation assay.
(Bottom) FLAG-MBD2 complexes prepared as for Figure 3-1 were incubated with 3H- 
acetyiated histone H4 peptide at 37°C for 3 hr with the indicated amount of protein (ng) 
and in the absence or presence of the HDAC inhibitor Sodium Butyrate (250mM).
Release of 3H-acetate (CPM) from the histone H4 peptide was determined by 
scintillation counting.
As the functional association of HDAC1, HDAC2, RbAp46, RbAp48 and 
MTA2 is essential for histone deacetylase activity (242), full-length MBD2 with 
reduced methylarginine content (Figure 3-1, Lane 7 and 8) was compared against 
normal MBD2 (Figure 3-1, Lane 5) for co-purifying histone deacetylase activity.
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The immunoprecipitated native protein complexes were incubated with 
histone H4 peptide H-acetylated in vitro, and the release of H-acetate groups into 
solution was measured (Figure 3-2, Top). In agreement with data obtained by Western 
blot (Figure 3-1), arginine methylation deficient MBD2 produced in PRMT1 and 
PRMT5 deficient cells co-purified with higher histone deacetylase activity.
3.2.3 MBD proteins and HDAC silencing complex interaction in cells treated 
with Adox
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Figure 3-3 Creating arginine methylation deficient MBD proteins by treating cells with 
methyltransferase inhibitors.
(Top) 293T cells were transfected with the indicated MBD plasmids for 36 hr and were 
treated with the indicated methyltransferase inhibitors for another 12 hr before 
harvesting. Expression levels of the MBD proteins were checked in Bradford 
normalized lysate.
(Middle) FLAG-MBD proteins were prepared as for Figure 2-15 and were checked for 
methylation status using the Asym24 and SymlO antibodies.
91
Chapter 3 Results II
(Bottom) The co-purifying protein complexes were also checked for their interaction 
with HDAC silencing complex by Western blot with the indicated antibodies. 1% input 
represents the lysate from untreated cells used for immunoprecipitation of the protein.
As arginine methylation deficient MBD2 proteins have a higher affinity 
interaction with the HDAC silencing complex, I investigated whether unmethylated 
species of MeCP2 proteins would also produce the same effect.
Non-methylated species of both MBD proteins were produced by treating 
cells with methylation inhibitors, Adox or 5’-methyl-thioadenosine (Mta). To ensure 
that the expression level of the proteins are not affected by the inhibitors, normalized 
cell lysates were compared for their amount of FLAG proteins expressed (Figure 3-3, 
Top, Lane 1-6). FLAG protein levels were normal even in the presence of inhibitors 
and so FLAG immunoprecipitation was performed. These MBD protein complexes 
were analyzed for their methylarginine content and interacting HDAC silencing 
complexes.
When assessing the levels of arginine methylation on MBD2 protein (Figure 
3-3, middle, Lane 7-9), it was observed that Adox treated cells produced MBD2 with 
less methylarginine content compared to cells treated with Mta (Lane 8 vs. 9). As 
expected, these antibodies did not detect MeCP2 (Lane 10-12).
When the amount of HDAC complexes co-purifying with the MBD2 was 
determined (Figure 3-3, bottom), it was surprising to observe that hypomethylated 
species of MBD2 (Lane 15 and 16) were interacting less strongly with HDAC2 
proteins compared to untreated cells (Lane 14). There was also less MTA2 protein co- 
purifying with the MBD2 produced in Adox treated cells (Lane 15). This directly 
contradicts findings from using siRNA cells (Figure 3-1).
Sin3A is reported as an interacting partner of MBD2 (23), but I was unable to 
purify the MBD2-Sin3A complex. As for MeCP2, it is also reported to be in the same 
complex as Sin3a and HDAC2 (166), but in the experiment, I was only able to co- 
purify HDAC2 with the protein (Lane 18). This may be because the MeCP2-Sin3A 
complex does not exist stably (116). However, from the HDAC2 Western blot, it was 
observed that MeCP2 protein produced in cells treated with methylation inhibitors 
(Lane 19 and 20) also revealed a decrease in the level of co-purifying HDAC2 protein.
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3.2.4 Adox disrupts the stability of the HDAC silencing complex
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Figure 3-4 Adox affects NuRD integrity.
(Top) Control and 293T cells treated with Adox for 16 hr were lysed, normalized with 
Bradford, and subjected to immunoprecipitation for endogenous HDAC silencing 
complexes using the indicated antibodies. The im mu noprecipitated complexes were 
analyzed by Western to detect for presence of co-purifying MTA2 protein. As the 
MTA2 signal is weak in Western blots, a longer exposure of the same blot was included.
(Middle) Adox affects MTA2 protein levels. 293T cells were subjected to an Adox 
titration assay for 16 hr and were lysed, normalized with Bradford and assayed with 
Western blots to check the level of each HDAC silencing complex component.
(Bottom) MTA2 levels in siRNA stable clones remain unchanged. siRNA stable clones 
as in Figure 2-22 were cultured under normal conditions and were subjected to Western 
blots with the indicated antibodies. Western blot of Ran indicates protein loading.
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To determine whether using the methylation inhibitors or the siRNA cells is 
more representative of the physiological state of unmethylated MBD proteins, the 
effect of Adox on the integrity of the HDAC-silencing complex was studied (Figure
3-4).
First, I asked whether the integrity of MTA2-HDAC silencing complex 
remains the same after the cells were treated with Adox. Endogenous HDAC1, 
RbAp46, and MTA2 proteins were immunoprecipitated from 293T cells cultured in 
the absence or presence of Adox, and the protein complexes were assayed for the 
presence of co-purifying MTA2 (Figure 3-4, Top).
Immunoprecipitations of HDAC1 and RbAp46 from cells treated with Adox 
generally displayed a decrease in level of co-purifying MTA2 protein (Lane 4 and 6) 
compared to those from untreated cells (Lane 3 and 5). Since the cell lysates used for 
the immunoprecipitations were normalized by protein level, there should be no 
difference in the level of MTA2 protein purified with the MTA2 antibody (Lane 7 and 
8). However, a slight difference was observed and longer exposure (1 min) of the 
Western blot revealed that lysate of cells treated with Adox displayed reduced MTA2 
protein (Lane 1 vs. 2) as well.
Since MTA2 protein level was affected by the treatment of cells with Adox, 
the stability of other HDAC silencing components in the presence of Adox was also 
assayed. 293T cells were titrated in culture with an increasing concentration of Adox, 
and normalized lysates were assayed for the levels of various proteins (Figure 3-4, 
Middle). While the stability of most of the proteins was unaffected by Adox (Lane 9- 
12), the level of MTA2 protein was reduced when Adox concentration exceeded 20 
pM (Lane 11), which is the usual concentration administered to cells. Therefore, I 
conclude that MBD2 produced in Adox treated cells are not suitable for assessing the 
levels of co-purifying HDAC-silencing complex. This is because the instability of one 
component protein most probably affects the integrity of the whole silencing complex.
The same comparison was also carried out from normalized lysate of the 
siRNA clones (Figure 3-4, Bottom). It was observed that the level of MTA2 and other 
cellular proteins was not affected by the genetic background of the cells. This
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strengthens the conclusions in Figure 3-1 because the integrity of HDAC silencing 
complex components in the siRNA cells is not affected.
3.2.5 MBD2 hypermethylated on arginine copurifies less HDAC silencing 
components
3.2.5.1 Increasing the methylarginine content o f MBD2 by increasing the amount 
of PRMT in cells
Since MBD2 protein with less methylarginine content tends to have higher 
affinity for HDAC silencing complex, the reverse was also tested by increasing the 
methylarginine content of MBD2. To achieve this, the level of PRMT in cells was 
increased by transfecting 293T cells that were expressing MBD2 proteins with the 
PRMT plasmids (see Figure 6-6 in Chapter 6.4). However, although there was an 
increase in PRMT protein levels, there was no observable increase in the 
methylarginine content of MBD2.
3.2.5.2 Increasing the methylarginine content o f MBD2 by mutating the RG 
domain
Clone Residues 
name removed MBD2 RG domain (aa 48 -114)
RG
retained
MBD2(WT) 0 ...............gvrregargggrgrgrwkqaargggvcgrgrgrgrgrgrgrgrgrgrgrpqsggsglggdggggagg 14
MBD2 (-RG41) 41 gvrreg------------------------------------------------------ grpqsggsglggdggggagg 0
MBD2 (-RG36) 36 gvrregarggg----------------------------------------------- grpqsggsglggdggggagg 1
MBD2 (-RG18) 18 gvrregargggrgrgrwkqaargggvcgr--------------------- grpqsggsglggdggggagg 5
MBD2(-RG29a) 29 gvrrega— grgrgrwkqag-------------------------------- grpqsggsglggdggggagg 2
MBD2 (-RG26) 26 gvrregargggrgrgrwfcqag---------------------------------grpqsggsglggdggggagg 3
M8D2 (-RG23) 23 gvrrega------------------ rgggvcgrgrgrgrgrg-----------grpqsggsglggdggggagg 6
MBD2(-RG29b) 29 gvrrega---------------------------------------rgrgrgrgrgrgrpqsggsglggdggggagg 6
MBD2 (-RG14) 14 gvrrega------------------ rgggvcgrgrgrgrgrgrgrgrgrgrgrpqsggsgiggdggggagg 11
Figure 3-5 Mutants of the MBD2 RG domain generated in this study.
RG domain of the wild-type MBD2 protein (aa 48 -  110) and the 14 arginine residues 
within that fall in the context of RG. Sequences of the 8 MBD2 RG domain mutants are 
shown, black horizontal lines represent deleted residues and red letters represent 
substituted residues.
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All experiments suggested that methylation of arginine residues within the 
extensive RG domain of MBD2 protein is a tightly regulated event. In an attempt to 
create intermediates between the wild-type MBD2 with 14 possible arginines for 
methylation, and the MBD2-RG mutant12 containing no arginine for the modification, 
I modified the RG domain of the MBD2 protein to retain some arginine residues that 
are possible sites of PRMT modification (Figure 3-5). Unexpectedly, these proteins 
were found to have a higher stoichiometry of arginine methylation, and this is 
illustrated in the following sections. Biochemical properties of these hypermethylated 
mutants were also characterized.
12 Refer to Figure 2-5 and Figure 2-20 for MBD2-RG mutants that do not contain the 14 arginines that 
are required for accepting methyl groups from PRMT.
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Figure 3-6 Highly methylated MBD2 have less afflnity for the HDAC silencing complex.
(Top) 293T cells were transfected with plasmids encoding FLAG-tagged MBD2 and its 
RG deletion mutants described in Figure 3-5 for 48 hr. Cells were lysed and the
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Bradford normalized lysates were analyzed by Western blot for expression level of the 
proteins. Levels of RbAp46 protein indicate protein loading and FLAG represents the 
MBD2 proteins.
(Middle) FLAG-tagged MBD2 proteins were purified and normalized as for Figure 2-15 
and were tested for their methylation status and their affinity for components of the 
HD AC silencing complex. Coomassie staining indicates normalization of proteins.
(Bottom) 293T cells were also transfected with the indicated constructs and a duplicate 
set of the cells were treated with Adox prior to posttranslational labeling with 3H-L- 
methyl-methionine and CX/CP as for Figure 2-5. FLAG-proteins were prepared and 
normalized as in Figure 2-15 and were analyzed by SDS-PAGE, Coomassie stain and 
Fluorography.
The constructs encoding various RG domain mutants of MBD2 were 
expressed in 293T cells, and their expression levels were checked together with the 
endogenous RbAp46 to provide sample normalization (Figure 3-6, Top). The FLAG- 
MBD2 proteins were purified and were characterized (Figure 3-6, Middle and 
Bottom).
For methylarginine content, the two deletion mutants described previously 
that had all arginines removed (Lane 1 and 3) were not detected by the Asym24 and 
SymlO antibodies. Wild-type MBD2 protein was observed with normal levels of 
methylation (Lane 2). Methylarginine signal was not detected in MBD2 (-RG36) as 
there is only one RG motif, which is insufficient for detection by the antibodies (Lane
4).
However, for MBD2 -RG18, -RG29a and -RG26, which contain 5, 2 and 3 
RG repeats respectively (Lane 5-7), their asymmetric and symmetric dimethylarginine 
content was determined to be higher than the wild-type MBD2 (Lane 2). The 
significance of the Asym24 degradation band (in Lane 6 and 7) is not known.
To ensure that the observed increase in recognition of the hypermethylated 
MBD2 mutants by the methylarginine specific antibodies is a result of increased 
methyl arginine content of MBD2, and not due to the nature of mutation that created a 
better epitope, the in vivo methylation assay was performed (Figure 3-6, Bottom). 
Under normal conditions, there was no dramatic difference between the 3H-signal on 
the wild-type and mutant proteins (Lane 8-10). This is probably because the MBD2 
proteins have reached their maximum potential to be methylated in vivo. A duplicate 
set of transfected cells was also inhibited for arginine methylation by addition of Adox 
to the medium post transfection, and the inhibitor was removed prior to labeling. The
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Fluorograph shows that these hypermethylated mutants are indeed better acceptors of
'y
the H-methyl groups compared to wild-type MBD2 (Lane 11-13).
The hypermethylated MBD2 mutants, together with data gathered from 
siRNA knockdown cells (Figure 2-25) and PRMT1 knock out ES cells (Figure 2-29), 
confirm the complexity of this modification in MBD2 and suggest that within the pool 
of transiently expressed MBD2, only a fraction contains methylated arginine.
Using the array of mutants with varying methylarginine content, the amount 
of co-purifying HD AC complex was investigated (Figure 3-6, Middle). As expected, 
mutant proteins (Lane 1, 3 and 4) that contain either low or no methylarginine 
displayed higher affinity for HDAC silencing complexes compared to wild-type 
MBD2. Hypermethylated mutants (Lane 5-7) generally have less affinity for the 
complex, with the exception of MBD2-RG18 (Lane 5), where the amount of co- 
purifying proteins seemed higher than for wild-type MBD2.
Since mutants in Lane 5, 6 and 7 were highly methylated, the presences of co- 
purifying PRMTs within the complex were also probed. Although these mutants were 
highly modified by the PRMTs, they did not interact strongly with PRMT1 or PRMT5. 
Wild-type MBD2 is the only protein that is capable of positive interaction with the two 
methyltransferases (Lane 3). The presence of PRMT5 in Lane 4 and 5 seems to be a 
result of non-specific binding as subsequent purification of the two mutant proteins did 
not observe any co-purifying PRMT5 (Data not shown).
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3.2.5.3 Additional characterizations o f the RG domain mutants
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Figure 3-7 Highly methylated MBD2 have less affinity for HDAC silencing complex.
Experiment in Figure 3-6 was repeated to include remaining m utants stated in Figure
3-5. As normalization of FLAG proteins were not even (Top), they were repeated again 
and the Coomassie of the proteins were show n (Bottom).
As the MBD2-RG18 protein (Figure 3-6, Lane 5) is the only exception among 
the hypermethylated mutants with regard to the correlation between methylarginine 
content and interacting HDAC silencing complex, more mutants were tested.
Similar to the two mutants reported previously (Figure 3-7, Top, Lane 2 and 
3), partial removal of amino acids from the RG domain of MBD2 protein resulted in 
an increase in both species of methylarginine on the protein (Lane 4-6). Moreover, 
some mutations also resulted in protein degradation (Lane 2-5).
When the levels of co-purifying HDAC silencing complex proteins were 
analyzed (Figure 3-7, Bottom), the Coomassie stain revealed that protein levels of
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MBD2-RG14 were too low and thus no conclusions can be made regarding this 
mutant. However, all other highly methylated mutants of MBD2 (Lane 8-11) were 
displaying lower affinity of interaction compared to the wild-type MBD2.
3.3 Arginine methylation of MBD2 and interaction with nucleic 
acids
The MBD2 and MeCP2 proteins were first identified by their ability to 
specifically bind methyl-CpG DNA using the MBD-domain (29, 157). It was 
demonstrated in vitro that both MBD proteins were able to interact with a variety of 
double stranded DNA containing at least one methyl-CpG (85, 167). However, recent 
studies suggest that substrate specificity for MeCP2 in cells is different from MBD2 
(117).
The methyl-CpG DNA binding function of MBD proteins allows targeting of 
the HDAC silencing complex to particular sites of the genome and mediates 
transcriptional repression. Since the interaction between MBD2 and the HDAC 
silencing complex is affected by arginine methylation, the effect of arginine 
methylation of MBD2 on its interaction with methyl-CpG DNA was investigated.
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3.3.1 MBD proteins and methyl-CpG DNA interaction in gel shift assays
Methyl-CpG-DNA : GATCC GAC GAC GAC GAC GAC GAC GAC GAC GAC GAC GAC GA 
C : methyl-cytosine
Flag-MBD2
(•RG)
Flag-MBD2
(WT)
siRNA c lo n e s
U nbound 
32P methyl 
-CpG-DNA
Gel shift a ssay
Flag
MBD2
Flag
MeCP2
Adox
Unbound 
32P methyl-CpG-DNA
Gel shift a ssay
Figure 3-8 Interaction of arginine methylation deficient MBD2 with methyl-CpG DNA.
(Top) Sequence of one strand of the double stranded CpG-DNA used for the interaction 
assays is shown, and positions of methyl-cytosine are indicated in red. The 
complimentary DNA strand also contains the corresponding methyl-cytosine.
(Middle) MBD2 proteins from PRMT reduced background were prepared and 
normalized as for Figure 2-15. The normalized native proteins were incubated with the 
illustrated radiolabeled methyl-CpG DNA for 20 min and were resolved on 0.5% TBE 
agarose gels and autoradiograph to assay for shift in mobility of the nucleic acids.
(Bottom) MBD proteins purified from cells treated with control or methylation inhibitor 
were prepared and normalized as for Figure 2-15. Normalized FLAG proteins were 
used in gel shift assay as for above to detect for differential interaction with 
radiolabeled methyl-CpG DNA.
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MBD2 proteins raised from siRNA stable cells were tested for their ability to 
interact with radiolabeled double stranded DNA that contains 12 methyl-CpG on each 
strand (Figure 3-8, top). Similar to reports from co-workers (157), MBD2 interacts 
robustly with the methyl-CpG DNA in gel shift assays. Although it was illustrated 
here that the MBD2 mutant without methylarginine content (MBD2-RG) seemed to 
have higher affinity of interaction with methyl-CpG DNA, full-length MBD2 proteins 
obtained from PRMT reduced background did not display the same increase in affinity 
compared to proteins obtained from control siRNA cells (pRS) (Figure 3-8, middle). 
The results were also not reproducible in subsequent experiments (Data not shown).
The experiment was repeated with arginine methylation negative MBD2 and 
MeCP2 proteins raised from Adox treated cells (Figure 3-8, Bottom). While MeCP2 
interacted with the same affinity regardless of the cellular background, MBD2 isolated 
from Adox treated cells had slightly increased affinity for methyl-CpG DNA. 
However, the results were also not reproducible.
3.3.2 MBD proteins and double stranded RNA interaction in gel shift assays
Flag
MBD2
Adox
U nbound 
-32P dsRNA
Figure 3-9 Interaction of arginine methylation deficient MBD proteins with RNA.
Proteins isolated from cells treated with methylation inhibitor were prepared and 
normalized as for Figure 2-15. Normalized FLAG proteins were used in gel shift assays 
as for Figure 3-8 to detect for differential interaction with radiolabeled double stranded 
RNA.
Since MBD2 and MeCP2 proteins also interact with double stranded RNA in 
gel shift assays (102), I tested whether the methylated species of the MBD proteins 
display a different interaction affinity with RNA compared to unmethylated proteins
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(Figure 3-9). It was found that Adox treatment had no effect on the interaction of 
MBD proteins with double stranded RNA. A plausible explanation for this 
observation could be because throughout the purification of the proteins, no RNase 
treatment was included, the unspecific binding of cellular RNA to the MBD proteins 
made it impossible to measure the binding of radiolabeled RNA to the Adox treated 
proteins. If this is the case, it might also explain the observed higher degree of 
association between the radiolabeled double stranded RNA and MeCP2, which have a 
less extensive RNA binding domain (RG) compared to MBD2.
3.3.3 MBD2 and methyl-CpG DNA interaction in solution
The gel shift assays did not give a clear conclusion of whether arginine 
methylation of the MBD proteins resulted in a change of affinity of the proteins 
towards nucleic acids. Therefore, the experimental approach for addressing this issue 
was modified. Data from Chapter 3.2.5.2 suggested that the methylarginine content of 
wild-type MBD2 protein is much lower compared to the various MBD2 mutants that 
had a portion of the RG domain removed. Therefore, wild-type MBD2 raised from 
cells cultured without Adox might bind methyl-CpG DNA at a similar affinity 
compared to the same protein raised in Adox treated cells.
Since it was speculated that only a fraction of MBD2 purified is methylated 
on arginines, a solution binding assay that tracks the behavior of these MBD2 species 
might be more appropriate.
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Figure 3-10 MBD2-DNA solution binding assay.
(Top) The scheme of the binding assay.
(Middle) Basic proteins interact non-specifically with DNA. Biotinylated DNA were 
synthesized, annealed in vitro, and immobilized on strepavidin agarose. The FLAG 
proteins were prepared as for Figure 2-4 and were incubated with the immobilized DNA
105
Chapter 3 Results II
for 2.5 hr. The unbound fractions (UB) were collected and fractions bound to resin (B) 
were washed in buffer containing 350 mM NaCl and eluted with SDS-PAGE sample 
buffer. Both fractions were separated on SDS-PAGE and analyzed by Western blot 
with anti-FLAG antibody. Input represents the amount of FLAG proteins added to the 
resins.
(Bottom) tRNA decreases non-specific binding of FLAG-MBD2 protein to DNA. FLAG 
MBD2 was incubated with the indicated immobilized DNA as above, but the binding 
reaction was carried out in the presence of the indicated concentrations of tRNA. 100% 
of the bound fraction was washed, eluted and loaded on SDS-PAGE gel and analyzed by 
Coomassie and 10% of unbound fractions are shown. (*) Represents position of MBD2.
In Figure 3-10 (Top) the scheme of the solution binding assay is described; 
the total population of MBD2 protein was allowed to interact with the immobilized 
methyl-CpG DNA, and both bound and unbound fractions were compared for their 
methylarginine contents.
As the MBD2 proteins are basic, they might interact non-speciflcally with the 
acidic phosphate backbone of nucleic acids. Therefore, unmethylated CpG-DNA was 
used as the negative control (Figure 3-10, Middle). In the FLAG Western blot, 
although the MBD2 preference for methyl-CpG DNA was illustrated (Lane 2), the 
amount of MBD2 interacting non-specifically with CpG-DNA was undesirable (Lane 
3). The FLAG proteins in the unbound fractions (Lane 4 and 5) appeared low because 
only 10% of the total sample was loaded.
To prevent non-specific interactions, the incubation process was titrated with 
increasing amounts of tRNA (Figure 3-10, Bottom). From the bound fractions without 
tRNA (Lane 6 and 11), it was observed that MBD2 was binding to unmethylated DNA 
but had more affinity for methyl-CpG DNA. When the concentration of tRNA was 
increased, non-specific binding of MBD2 to DNA decreased (Lane 7-10 and 12-15). 
There was also a corresponding increase of MBD2 in the unbound fraction of 
unmethylated DNA (Lane 17-19). MBD2 that was exposed to methyl-CpG DNA was 
present at lower levels in the unbound fractions (Lane 21-23), and this might represent 
the pool of protein that was bound to the DNA but washed away before the recovery of 
the proteins. Since the tRNA prevents non-specific interaction of MBD2 with 
unmethylated DNA, it was included in all subsequent assays.
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Figure 3-11 Specific MBD2-methyl-CpG DNA interaction.
(Top) Co- and post-translationally labeled MBD2 as for Figure 2-5 were FLAG 
immunoprecipitated and eluted with 3x FLAG peptide. The labeled proteins were 
loaded onto the indicated immobilized DNA as for Figure 3-10 in the presence of 0.8 
mg/ml tRNA. 100% of the bound and unbound fractions were precipitated, and 
analyzed by Coomassie, 35S-Fluorograph or 3H-Fluorograph accordingly.
(Bottom) To reveal the species of dimethylarginine bound to DNA, proteins cultured 
under normal conditions were analyzed with Western blot with the indicated antibodies.
In both assays, Adox was included to produce non-methylated species of MBD2.
Using the optimized conditions, the ability of MBD2 to discriminate 
methylated from unmethylated-CpG DNA was illustrated (Figure 3-11, all 
Coomassie). In the 35S-Fluorograph, all MBD2 proteins were labeled regardless of 
Adox. It was observed that there was also no 35S-MBD2 signal binding to CpG-DNA 
(Lane 3 and 4), but at least 40% of total MBD2 protein interacted with methyl-CpG 
DNA (Lane 9 and 10). Being more sensitive than Coomassie, the 35S-Fluorographs 
further support the interaction specificity of MBD2 in this experiment.
When post-translationally modified proteins in the experiment were 
visualized (Figure 3-11, 3H-Fluorograph), the input fractions show that only proteins 
that were produced in cells cultured without Adox were labeled (Lane 1 and 7). As 
expected, the labeled MBD2 species only interacted with methyl-CpG DNA (Lane 9), 
but not CpG-DNA (Lane 3). However, it was difficult to interpret whether the 3H- 
arginine methylated MBD2 (Lane 9) or the unmethylated MBD2 (Lane 10) have better 
affinity for methyl-CpG DNA.
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The experimental setup was repeated with proteins produced in cells cultured 
under normal conditions, but in addition, a set of cells was treated with Adox (Figure 
3-11, Bottom, Lane 14, 16, 18, 20, 22 and 24). All protein fractions were analyzed by 
Coomassie and Western blot. As usual, Adox treated proteins were observed by 
Coomassie staining but were not detected by methylarginine antibodies. When the 
methylated species of MBD2 binding to methyl-CpG DNA were compared with the 
unbound fractions (Western blot, Lane 21 vs. 23) and the total population of the 
protein (Coomassie), the difference in elution pattern of the arginine methylated 
species of MBD2 was again difficult to deduce.
3.3.4 Arginine methylation controls the affinity of the MBD2 and methyl-CpG 
DNA interaction
Even with conditions that clearly defined the specificity of MBD2 affinity 
towards methyl-CpG DNA and not CpG-DNA, I was unable to determine whether 
arginine methylation resulted in a change in affinity between MBD2 and methyl-GC 
DNA. Therefore, the solution binding assay for MBD2 and methyl-CpG DNA was 
modified to account for the behavior of all MBD2 proteins added to the methyl-CpG 
DNA.
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Figure 3-12 Analysis of MBD2-methyl CpG DNA affinity using step salt elution.
(Top) Co-translationally labeled MBD2 prepared as for Figure 2-5 was FLAG 
immunoprecipitated and eluted with 3x FLAG peptide. The labeled proteins were 
loaded onto the indicated immobilized DNA as for Figure 3-10 in the presence of 0.25 
mg/ml tRNA. MBD2 proteins bounded to the DNA were salt eluted in steps using the 
indicated concentrations of NaCI (in mM). All elutions including the unbound fractions 
were precipitated and analyzed by Fluorography.
(Bottom) Arginine methylated MBD2 species have less affinity for methyl-CpG DNA.
To differentiate the affinity of methylated and unmethylated forms of MBD2 towards 
CpG-methylated DNA, FLAG MBD2 produced under normal conditions was incubated 
with the immobilized methyl-CpG DNA as for above. Coomassie and Western blots with 
FLAG antibody indicate the total population of MBD2 proteins and Western blots with 
methylarginine antibodies represent the modified species of MBD2.
In the previous experiment, (Figure 3-10, Bottom), it was observed that in 
presence of tRNA, washing the methyl-CpG DNA-MBD2 complex with 350 mM 
NaCI probably resulted in unwanted loss of proteins in the procedure, as the unbound 
fraction did not contain a significant amount of the remaining protein.
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To ensure that all MBD2 was analyzed, 35S-MBD2 was assembled onto CpG 
and methyl-CpG DNA. Unbound fractions were collected, and bound protein was 
eluted off the DNA with stepwise increase of NaCI concentration. All eluted fractions 
collected were analyzed by SDS-PAGE/Fluorography (Figure 3-12, Top). As 
observed, MBD2 did not interact with CpG-DNA and the majority of the protein was 
found in unbound fractions while the remaining protein was removed from the DNA 
by low salt buffer 200mM). On the other hand, the majority of MBD2 bound to 
methyl-CpG DNA was eluted off the DNA only when NaCI concentration reached 400 
mM to 600 mM NaCI.
The experiment for methyl-CpG DNA was repeated using MBD2 raised 
under normal conditions (Figure 3-12, Bottom). Similar to the Fluorography, results 
of the Coomassie gel revealed that elution of MBD2 peaks at 600 mM. The behavior 
of the methylated fraction of MBD2 was tracked by Western blot (Figure 3-12, 
Bottom). Unlike the total population of MBD2 (Coomassie stained or 35S-MBD2), 
the majority of asymmetrically and symmetrically arginine methylated species of 
MBD2 eluted at 400 mM NaCI instead of 600 mM. Therefore, I conclude that 
arginine methylation of MBD2 reduced its affinity for methyl-CpG DNA
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3.3.5 Control of MBD2 and methyl-CpG DNA association by arginine 
methylation is a mechanism exclusive to wild-type MBD2
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Figure 3-13 Step elution of hypermethylated MBD2 mutants from methyl-CpG DNA.
The experiment in Figure 3-12 was repeated to compare the elution of wild-type MBD2 and 
hypermethylated MBD2 mutants from Figure 3-5. Coomassie staining represents the total 
population of MBD2 and Western blots represent the modified species of MBD2.
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To check whether this effect of arginine methylation applies to the 
hypermethylated MBD2 mutants, I assembled the wild-type MBD2, MBD2-RG29a 
and MBD2-RG23 proteins onto methyl-CpG DNA, and eluted them using a more 
gentle salt gradient (Figure 3-13). Wild-type MBD2 exhibits a sharper elution peak 
between 600 and 700 mM NaCI in the Coomassie stained gel, and the majority of 
arginine methylated MBD2 elutes at 500 mM. Both hypermethylated mutants were 
observed to elute between 400 and 500 mM. This decrease in affinity could be 
attributed to the reduction in pi of the proteins as the highly basic RG domain is 
partially deleted. When the arginine methylated species of these hypermethylated 
mutants were visualized, there was no difference between the elution patterns of the 
methylated proteins (Western blot) compared to the total proteins (Coomassie). 
Therefore, I deduced that arginine methylation only controls the interaction between 
wild-type MBD2 and methyl-CpG DNA. Although hypermethylated, a disrupted RG 
domain in MBD2 does not affect its interaction with methyl-CpG DNA.
3.4 Arginine methylation of MBD2 and its behavior in cells
Since arginine methylation of MBD2 affects the affinity of its interaction with 
HDAC silencing complex and methyl-CpG DNA, I speculate that arginine methylation 
of MBD2 can also affect its transcriptional repression function in cells. To be able to 
utilize the MBD2 arginine methylation mutants in a transcriptional repression assay, 
the behavior of the proteins and their mutants in cells must be characterized.
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3.4.1 Subcellular localization of MBD2 and arginine methylation mutant 
proteins
HeLa
MBD2
(WT)
MB 02
(-RG41)
MB02
(-RG23)
MeCP2
(WT)
M«CP2
(R106W)
MBD3
FLAG FLAG DAPI
Figure 3-14 Immunofluorescence of MBD proteins.
HeLa cells were transfected with the indicated FLAG-MBD plasmids for 18 hr and were 
stained with anti-FLAG/FITC or DAPI. Scale bar: 10 pm (Bottom right)
Although the biochemical properties of MBD2 arginine methylation mutants 
are conclusive, their subcellular localization has yet to be addressed. Wild-type 
MBD2 is reported to localize in the nucleus of mammalian cells (85, 99). If any of the 
MBD2 mutant proteins fail to be imported into the nucleus, they will be unable to 
repress transcription.
Therefore, non-methylated (MBD2-RG41) and hypermethylated (MBD2- 
RG23) mutant protein was compared against wild-type MBD2 for their nuclear 
localization properties (Figure 3-14). Similar to wild-type protein, all MBD2 mutants 
localized in the nucleus. This indicates that they are at least structurally competent in 
terms of recognition and transport by nuclear import factors. As the MeCP2 and 
MBD3 were used as controls in subsequent assays, they were also included in this 
experiment. Similar to studies from co-workers, these proteins localize in the nucleus
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(135, 167). MeCP2 R106W, a mutation that cripples the binding affinity of the protein 
to methyl-CpG DNA in vitro (10), is also found in the nucleus.
3.4.2 Transcriptional repression activity based on methyl-CpG DNA binding 
and recruitment of the HDAC complex
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Figure 3-15 Repression activity of MBD2 on methyl-CpG DNA.
(Top) DNA methylation of a reporter plasmid. The pGL2-luciferase reporter plasmid 
was incubated in the absence or presence of DNA methylase M.SssI and the plasmid was 
precipitated and purified. Fspl was used to check for completion of the methylation 
reaction.
(Bottom) Arginine methylation deficient MBD2 has higher repression activity than 
methylated MBD2. HeLa cells were transfected with the unmethylated or the 
methylated luciferase reporter plasmid, the renilla control plasmid, and the indicated 
FLAG-MBD plasmids. 24 hr after transfection, cells were assayed for their firefly 
luciferase and renilla luciferase activity and relative luciferase unit (RLU) is expressed 
as a function of firefly/renilla luciferase. To obtain the relative transcriptional activity 
in presence of the indicated MBD, the ratio of RLU of cells transfected with methylated 
plasmid and unmethylated plasmid was taken. Each value represents an average from 
3 independent experiments.
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The repression activity of MBD towards methylated CpG-reporter-DNA can 
be demonstrated in cells (29, 86). In a repression assay described by Hendrich et al., 
expressing exogenous wild-type MBD2 protein in MBD2 knockout mice cells rescued 
the repression of a methylated reporter plasmid. In their experiment, reporter DNA, 
either methylated or unmethylated at CpG-dinucleotides, was transfected into cells 
together with the MBD2 constructs. The ratio between the gene products from the 
methylated and unmethylated reporter represents the repression activity of the 
exogenous proteins targeted to methyl-CpG DNA in cells.
Similar to their experiment, I used the pGL2-promoter reporter plasmid 
produced in DNA-methylation deficient E. coli cells and subjected them to mock or 
CpG-DNA-methylation using M.SssI, a methylase that modifies cytosine in the 
context of CpG in double stranded DNA (171). After methylation, the plasmids were 
checked by digesting with Fspl (methylation sensitive restriction enzyme) (Figure 
3-15, Top).
The methylated or unmethylated plasmids were transfected with the MBD 
constructs into HeLa cells and the expression of reporter genes was quantified (Figure 
3-15, Bottom). In HeLa cells, the endogenous transcription repressors present were 
able to restrict the expression of the methylated reporter plasmid to 16% of the 
unmethylated plasmid (no MBD). With co-expression of exogenous repressor (MBD2 
WT), the expression was reduced to 9.5% and a further reduction to 7.1% can be 
achieved in cells co-expressing MBD2-RG41. This suggests that the arginine 
methylation deficient MBD2 mutant has slightly higher repression activity. The 
mammalian MBD3, which does not bind directly to methyl-CpG DNA (85) (see 
Chapter 1.4.2), did not significantly reduce expression of the reporter when co­
expressed.
Although the experiment was consistently reproduced, the increase in 
repression activity of the MBD2-RG41 protein compared to the WT never exceeds 1.4 
fold. To demonstrate a greater difference in repression activity, the expression level of 
the MBD proteins in HeLa cells was taken into consideration.
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Figure 3-16 Expression levels of MBD proteins are different in HeLa.
(Top) HeLa cells were transfected with different amount of the indicated FLAG-MBD 
plasmids for 48 hr and Bradford normalized cell lysates were used to determine the 
expression level of MBD proteins by Western blot with FLAG antibody.
(Bottom) Relative transcription activity of the MBD proteins was determined as for 
Figure 3-15. Transfection of MBD2-RG41 and MBD3 were fixed at 250 ng of plasmid 
and values represent 3 independent experiment. For wild-type MBD2, expression of the 
protein was titrated in cells with increasing ng of plasmid, each value represents one 
transfection.
When expression of the MBD proteins were checked in HeLa cells by 
titrating the amount of plasmid in transfections (Figure 3-16, Top), it was observed 
that wild-type MBD2 protein were generally expressed at higher levels compared to 
MBD2-RG41. MBD3, the negative control for the experiment had the lowest level of 
expression among the 3 proteins.
To ensure that the relative transcription assay is correlative to the levels of 
MBD repressors proteins present in cells, the experiment was titrated with increasing 
amount of wild-type MBD2 plasmids (Figure 3-16, Bottom). Although the assay had 
showed a similar trend of MBD3 being the least capable of repression, and MBD2- 
RG41 had the highest repression activity, expression of wild-type MBD2 plasmid in 
the system did not show a dose dependent increased in repression.
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3.4.3 Methyl-CpG-dependent transcriptional repression assay in MBD2 -/- cells
A possible reason why expression of the methylated reporter plasmid is not 
responsive to the dosage of wild-type MBD2 might be due to the presence of 
endogenous repressor proteins masking the effects of the MBD2. When the same 
experimental setup was performed in 293T cells, it was impossible to illustrate a 
difference in repression activity between wild-type MBD2 and MBD2-RG41 (Data not 
shown). I speculate that this might also be due to the presence of saturating 
endogenous methyl-CpG DNA dependent repressors.
The original design of the relative transcription assay was to illustrate that 
cells derived from MBD2 -/- mice were unable to repress transcription of CpG- 
methylated reporter plasmid as well as wild-type cells (86). Therefore, the MBD2 
knockout cells were obtained and used for the experiment to check whether there 
would be more difference in repression activity with respect to MBD2-RG41 and wild- 
type MBD2 protein.
mtf (cell lysates)
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WT mbd2 WT mbd2 WT mbd2 WT mbd2
Western MBD2
Relative expression of luciferase gene in presence of MBD proteins 
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Figure 3-17 Using MBD2 knockout cells for repression assay.
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(Top) Mouse tail fibroblast (mtf) cells from MBD2 knockout mice were compared to 
wild-type mice cells for the presence of MBD2 protein. The indicated amounts of 
Bradford normalized cell lysate were analyzed by Western blot with antibodies against 
MBD2.
(Bottom) Both cell types were transfected with reporter plasmids to assay for relative 
transcription in the presence of MBD as for Figure 3-15.
Cell lysate from the MBD2 knockout mice cells was checked for the presence 
of endogenous MBD2. Similar to the report by Hendrich et al. (2001), targeted 
disruption of the MBD2 allele produced a truncated protein of 25 kDa (86), whereas 
the wild-type cell line was producing the normal MBD2 protein doublet observed in 
Western blots (Figure 3-17, Top).
Applying the relative transcription assay to MBD2 knockout fibroblast (mbd2 
mtf, Figure 3-17, Bottom), I again observed that MBD2-RG41 reduced expression of 
the methylated reporter to a lower level (9.0%) compared to wild-type MBD2 (14%). 
Wild-type MeCP2 also demonstrated higher repression of the methylated reporter 
(8.0%) when compared to MeCP2 R106W, a mutant incapable of binding methyl-CpG 
DNA (10), which allowed the methylated plasmid to express at 15.8%.
When the experiment was done with wild-type fibroblasts (WT mtf), the 
methylated reporter was generally expressed at lower levels compared to in the MBD2 
knockout fibroblast. This is because endogenous MBD2 protein was contributing to 
the repression of the reporter. No conclusion can be drawn from these cells as there 
was no difference in repression activity between the wild-type MeCP2 and the 
dominant-negative MeCP2 R106W.
For the data from MBD2 knockout fibroblasts, the difference in repression for 
wild-type MBD2 and MBD2-RG41 was similar to that obtained from HeLa cells. 
These experiments suggested that the MBD2-RG41 mutant, which cannot be modified 
by arginine methylation is more competent in mediating transcription repression.
However, since the assay was illustrated to be not quantitative (see Figure 
3-16), it was not optimized further. A different reporter assay to measure the 
repressive strengths of the MBD2 protein and its mutants is required.
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3.4.4 Transcription repression activity based on interacting HDAC complex
The relative transcription assay used previously measures the functional 
activity of both the MBD and TRD domains of the exogenous MBD2, and this is 
highly relevant to this study. However, the data was obtained by indirect calculation 
of the ratio between the expression of CpG-methylated and non-methylated reporter 
plasmids in different transfections, and values were not correlative to the dosage of 
MBD2. Therefore, a more direct approach that measures the repression activity of 
MBD2 with respect to its TRD domain in cells was employed.
3.4.4.1 Hypermethylated MBD2 mutant has impaired repression activity
Using the cell based tethering assay, MBD2 fused to Gal4 DNA-binding- 
domain protein was illustrated to be capable of repressing reporter plasmid with a 5X 
Gal4 binding site upstream of the promoter in a HDAC dependent manner (22, 170).
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Figure 3-18 pG5 DNA polymerase 0 luciferase transcription assay.
(Top) 293T cells were transfected with pG5 DNA polymerase P luciferase reporter 
plasmid, pRL-TK renilla reporter plasmid and the plasmids encoding the Gal4 proteins. 
RLU (firefly/renilla) for the indicated time points were obtained.
(Middle) The repression activity of wild-type MBD2 was compared against the 
hypermethylated mutant MBD2-RG23. All values obtained are an average of 3 
independent transfections.
(Bottom) Expression levels of the Gal4-MBD2 proteins (in Middle) were determined by 
Western blot using total protein collected from the assay.
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Using the reporter plasmid with 5X GaM binding sites, I quantitated the 
expression of the reporter gene in the presence of either GaM protein or Gal4-MBD2 
(wild-type) fusion protein at various time points (Figure 3-18, Top). When only the 
GaM protein is co-expressed with the reporter plasmid, it was observed that there was 
a linear increase in the amount of reporter gene product from 23 to 68 hours. This is in 
contrast to cells that were co-expressing Gal4-MBD2, where expression of the reporter 
gene product was at least four-fold lower than the unrepressed state at 23 hour, and the 
values differed even more at subsequent time points.
Since wild-type MBD2 protein is such a potent repressor in this assay, it 
would be difficult to test whether the non-methylated mutant (MBD2-RG41) has 
enhanced repression activity. Thus, I tested whether the repression activity was 
impaired in the hypermethylated (MBD2-RG23) mutant (Figure 3-18, Middle). 
Indeed, the hypermethylated mutant that interacts with the HDAC silencing 
components with less avidity biochemically (see Figure 3-6) was less competent in 
repression (all time points). The most dramatic difference is at 68 hours where the 
wild-type MBD2 was repressing the reporter gene to 4.5 fold lower than the mutant. 
To ensure that the Gal4-MBD2 fusion proteins were expressed at equal levels, total 
protein collected from the assay was analyzed by Western blot (Figure 3-18, Bottom). 
At all time points, the expression levels of Gal4-MBD2 (WT) protein were comparable 
to that of the mutant.
Despite the observed difference in the repression activity of wild-type MBD2 
protein and the hypermethylated MBD2 mutant, some doubts about the experimental 
setup still have to be addressed, namely whether the values obtained were a direct 
measure of HDAC activity in cells and whether the expression of reporter genes 
responded to the GaM fusion proteins in a dosage dependent manner.
3.4,4.2 Generation o f MBD2 TRD mutants
In various cell-based studies, HDAC inhibitors (237) were administered to 
transfected cells and relief of the repression of the reporter was correlated to the 
HD AC-dependent silencing of the GaM-fusion protein (166, 170). However, in many 
cases, it was noted that treating cells with the inhibitors did not fully relieve the 
repression (105, 166). Therefore, I removed the transcriptional repression domain of
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wild-type MBD2 protein to show that the mutation removes the repression function of 
the protein.
MBD2 
141-prgprates
MBD2
1 4 1 -p rg p ra te s g k r m d c p a lp p g w k k e e v i r k s g ls a g k s M M ^ H H H H H H M H H H
MBD2 (TRD-15)
141-prgpratesgkrmdcpalppgwkkeevirksglsagksdvyyfspsgkkfrskpqlarylgnavdlssfdfr- 
MBD2 (TRD-32)
141-prgpratesgkrmdcpalppgwkkeevirksglsagksdvyyfspsgkkfrskp--------------------
rekpqlarylgnafdlssfdfrtgkmmpsklqknkqrlrndplnqnkgkp-240
MBD2 (TRD-94) 
133----------------
qnkgkp-240 
- lrndplnqnkgkp-240 
rlrndplnqnkgkp-240 
-rlrndplnqnkgkp-240
Figure 3-19 MBD2 TRD mutants.
The MBD (Green) and TRD (Red) of MBD2. Three deletion mutants of the MBD2 
protein were created in attempt to disrupt the repression function of the protein.
Within the amino acid sequence of MBD2, the MBD was identified by 
bioinformatics (85), and the TRD was defined biochemically (23). As the two 
domains of the protein overlap (Figure 3-19), deletion of the TRD should be kept at a 
minimum to avoid disruption of the MBD. Therefore, a few TRD deletion mutants 
were generated and the most subtle deletion mutant that illustrates the lost in 
repressive function in cells was chosen.
3.4.4.3 Redefining the TRD o f MBD 2 protein
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Figure 3-20 Characterization of MBD2-TRD mutants.
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293T cells were transfect with the luciferase/renilla reporter plasmid as for Figure 3-18 
and the indicated ng of test plasmids. RLU was obtained 48 hr post transfection and 
MBD2 proteins expression was quantified as for Figure 3-18. Each value obtained is a 
result of one transfection.
With the generation of TRD deletion mutants, I tested whether transcription 
repression activity of MBD2 protein could be relieved. Furthermore, to ascertain 
whether the expression of the repressor gene is correlated to the dosage of wild-type 
MBD2, all test plasmids encoding their effector proteins were titrated in the cellular 
systems (Figure 3-20).
In addition to the plasmid that only encodes the Gal4 protein, a plasmid 
encoding the FLAG-MBD2 (WT) was also included as the negative control. Both 
plasmids did not repress the expression of the reporter gene because the Gal4 protein 
lacks a repression domain and the FLAG-MBD2 (WT) was not tethered to the 5X 
Gal4-DNA binding site on the reporter plasmid. However, the TRD deletion mutants 
(MBD2-TRD15 and MBD2-TRD32, see Figure 3-19) did not show any significant 
loss of repression activity compared to Gal4-MBD2 (WT) protein (Data not shown for 
MBD2-TRD15).
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Figure 3-21 Characterization of MBD2-TRD mutants.
(Top) 293T cells were transfected with the luciferase/renilla reporter plasmid as for 
Figure 3-18 and the indicated amount (ng) of test plasmids. RLU and expression levels 
of the Gal4-MBD2 proteins were analyzed as for Figure 3-20.
(Bottom) Various RG deletion mutants in Figure 3-5 were combined with the -TRD94 
mutation in Figure 3-19 and were expressed as FLAG proteins in 293T cells. The 
proteins were purified and normalized as for Figure 2-15 and were analyzed for co- 
purifying HDAC silencing complex as for Figure 3-1.
As the deletion of 15 to 32 residues within the TRD of MBD2 did not 
eliminate the repression function of the protein, a much larger deletion mutant 
(MBD2-TRD94, see Figure 3-19) was used (Figure 3-21, Top). From the graph, it was 
observed that increase transfection of Gal4-MBD2 (WT) resulted in a correlated 
decrease in RLU of the reporter plasmid. Beyond 200 ng of Gal4-MBD2 (WT), the 
RLU did not decrease any further as the maximum limit of the repression was reached 
(RLU « 20). For Gal4-MBD2 (-TRD94), it was unexpected that the mutant protein 
possessed higher repression activity than wild-type MBD2. At 25 ng of transfection, 
Gal4-MBD2 (-TRD94) was able to fully repress the expression of the reporter plasmid. 
Judging from the Western blot of the two Gal4-MBD2 proteins (Figure 3-21, Top), the 
-TRD94 mutant protein was produced at a much lower level compared to Gal4-MBD2 
(WT).
The TRD of MBD2 protein was defined based on its interaction with Sin3A 
protein in yeast two hybrid and GST pull down assay (23). However, I was unable to 
co-purify Sin3A with MBD2 (see Figure 3-3). Therefore, to ascertain whether the 
TRD really exists in the region described (23) (Figure 3-19), I tested whether the 
HDAC-silencing complex interacts with the MBD2-TRD94 mutant. The -TRD94 
mutation was introduced into FLAG-MBD2 WT, -RG41 and -RG23 constructs and 
the proteins were expressed and purified from 293T cells. Normalized proteins were 
checked for their levels of co-purifying HDAC silencing complex by Western blot 
(Figure 3-21, Bottom).
In the situation where there is no deletion in the TRD (Lane 1 and 2), the 
proteins followed the rule that MBD2 proteins with less methylarginine content 
interact more strongly with the HDAC-silencing components. When the -TRD94 
mutation was introduced (Lane 3 and 4), it was surprising to observe that the proteins
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interacted even more strongly with the HDAC-silencing components than those 
containing an intact TRD (Lane 1 and 2).
To ensure that the effect of arginine methylation still holds true, I compared 
the -TRD94 versions of non-methylated MBD2 (-RG41) and hypermethylated MBD2 
(-RG23) for their association with HDAC interacting components (Lane 5 and 6). 
Arginine methylation still controls the levels of co-purifying HDAC-silencing 
complex, but it was observed that the -TRD94 mutation introduced into MBD2-RG23 
also increased its affinity for HDAC silencing components. I did not further 
characterize this unexpected effect of-TRD94 mutation but I speculate that it could be 
caused by the removal of the MBD domain from the MBD2 protein (Figure 3-19).
Applying the data from the biochemical analysis to the cell based assay, 
(Lane 2 and 4 are FLAG version of Gal4-MBD2 (WT) and Gal4-MBD2-TRD94 
respectively), I can appreciate why deletion of the 94 residues from the presumed TRD 
resulted in the increase in repression activity of the MBD2 protein.
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Figure 3-22 Repression activity of the MBD2 truncation mutant.
(Top) Map of MBD2 truncation mutant (MBD2 1-131) cloned to abolish the ability of 
the protein to interact with the HDAC silencing complex.
(Middle) Various RG deletion mutants in Figure 3-5 were combined with the -TRD32 
deletion in Figure 3-19 and the MBD2 truncation mutant (Above). These constructs 
were expressed as FLAG proteins in 293T cells. The proteins were purified and 
normalized as for Figure 2-15 and were analyzed for the amount of co-purifying HDAC 
silencing complex as for Figure 3-1 (Left). The normalization of the FLAG proteins was 
illustrated by Western blot (Right, similar lane number indicate similar sample).
(Bottom) To test the repression activity of the MBD2 truncation mutant, 293T cells were 
transfected with the luciferase/renilla reporter plasmid as for Figure 3-18 and the 
indicated amount (ng) of test plasmids. RLU were analyzed as for Figure 3-20.
Since my data suggest that the TRD of MBD2 is not located at the region 
previously reported (see Figure 3-19) (23), the most straightforward approach to 
generate a Gal4-MBD2 transcription repression mutant was to create a C-terminus 
truncation mutant (Figure 3-22, Top).
Before using the protein in the cell based repression assay, the MBD2 1-131 
mutation was expressed as a FLAG-tagged protein to verify its ability to recruit the 
HDAC-silencing complex (Figure 3-22, Middle). MBD2 proteins containing the -  
TRD32 mutation was also included in the immunoprecipitation assay to check whether 
the data obtained from Figure 3-20 could be supported by the biochemical behavior of 
the mutants. Indeed, the -TRD32 mutation did not abolish the interaction of the 
MBD2 proteins with HDAC silencing complex (Lane 1-3 vs. Lane 4-6). This explains 
the retention of repression activity of Gal4-MBD2-TRD32 in cells (see Figure 3-20). 
From the proteins tested, the only MBD2 mutations that fully abolished the interaction 
with the HDAC silencing complex were those that were truncated after residue 131 
(Lane 7 and 8). Combined with the previous interaction assay, I deduced that the bona 
fide  HDAC complex interacting domain in MBD2 protein should be localized within 
residues 227-414, the region of MBD2 protein that I had not tested.
Using the array of mutants, I checked whether deletion of amino acids beyond 
residue 131 of MBD2 had any effect on the interaction with PRMT1 and PRMT5. In 
agreement with previous data, interaction of the PRMTs with MBD2 protein relies on 
a wild-type RG domain in MBD2 (Lane 2, and 5); deleting regions outside the RG 
domain does not affect the interaction.
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With the biochemical properties of the MBD2 1-131 protein characterized, I 
tested whether the Gal4-MBD2 (1-131) displayed any loss in repression function in the 
cell based repression assay (Figure 3-22, Bottom). From the graph, it was observed 
that that the truncation mutant was less competent than wild-type MBD2 in repressing 
the expression of the reporter plasmid. Therefore, MBD2 1-131 serves as a suitable 
negative control for the assay. However, the expression levels of the Gal4-MBD2 
proteins could not be checked in this experiment because the epitope of the MBD2 
antibody was deleted by the truncation.
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Figure 3-23 Hypermethylated MBD2 mutant have impaired repression activity.
(Top) 293T cells were transfect with the luciferase/renilla reporter plasmid as for Figure 
3-18 and the indicated Gal4-MBD2 plasmids. RLU and expression levels of the Gal4- 
MBD2 proteins were analyzed as for Figure 3-18.
(Bottom) Gal4-MBD2 proteins were quantified by Western blot with the indicated 
antibodies. (*) Denotes the position of non-specific band and Ran indicate normalized 
protein loading.
After testing commercially available antibodies against the Gal4-MBD2 1- 
131 mutant, the best antibody that detects the presence of the protein was used to 
repeat the cell-based assay (Figure 3-23). As the Gal4 antibody was still quite 
insensitive, it detected only the highly expressed Gal4-MBD2 1-131 (Bottom, lane 7),
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and a ~60kDa nonspecific protein that migrates very similarly to Gal4-MBD2-RG23. 
Therefore, the MBD2 antibody, which does not recognize the truncation mutant, was 
used to determine the expression levels of Gal4-MBD2 (WT) and Gal4-MBD2-RG23.
While the Western blot revealed that the expression level of the Gal4-MBD2 
proteins were in the order of 1-131 > -RG23 > WT, it was observed that the wild-type 
MBD2 protein had more repression activity than the hypermethylated mutant MBD2- 
RG23. The HDAC-interacting mutant (MBD2 1-131) had no (or basal) repression 
activity.
3.4.4.4 Repression activity o f  hypermethylated MBD2 mutant can be rescued in 
PRMT deficient cells
T ranscrip tion  activity of pG5.DNA pol in p re sen ce  of MBD2 p ro te ins 
and  in different siRNA c lo n es
siRNA
c lo n e s _______ pRS_______  PRMT1 PRMT5
Figure 3-24 Rescue of MBD2-RG23 repression activity in siRNA clones.
The siRNA clones in Figure 2-22 were transiently co-transfected with reporter plasmids 
as for Figure 3-23. As these cells are more sensitive to repression by Gal4-MBD2, the 
Gal4 plasmids are co-transfected at a tenth of the amount used in Figure 3-23 and at the 
same ratio corresponding to Lane 1 (WT), Lane 4 (-RG23) and Lane 7 (MBD2 1-131).
RLU were obtained as for Figure 3-18 and the variation in expression of firefly 
luciferase in different cells are compensated by calculating the percentage expression 
against the MBD2 (1-131) repression mutant.
To test whether the loss of repression function of Gal4-MBD2-RG23 is a true 
reflection of hypermethylation at arginine residues, I repeated the assay in the PRMT
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siRNA clones to test whether the transcriptional repression activity of the mutant 
proteins could be rescued in the PRMT deficient cells (Figure 3-24).
While the repression activity of Gal4-MBD2-RG23 was still impaired in the 
control siRNA clone (pRS), depletion of both PRMT1 and PRMT5 in cells resulted in 
the ability of the hypermethylated mutant to repress the reporter to levels comparable 
that of the wild-type MBD2.
Wild-type MBD2 was also expected to repress transcription more efficiently 
in these cells. I find that the difference in repression activity of wild-type MBD2 in 
control cells versus PRMT-deficient cells was slight. This is because the 
methylarginine content of the wild-type protein in control cells is much lower than that 
of the hypermethylated MBD2-RG23 mutant. Therefore, further lowering the 
methylarginine content of wild-type MBD2 in PRMT-depleted cells has a much less 
dramatic effect compared to the effect on the MBD2-RG23 mutant.
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C hapter 4 D iscussion
4.1 MBD2 and MeCP2 are methylated in vitro and in vivo
Using the commonly employed in vitro and in vivo methylation assay (141), I 
deduced that MBD2 and MeCP2 are post-translationally modified by protein 
methyltransferases. In vitro, these modifications are localized towards the N-terminal 
portion of both proteins (Figure 2-2), the region that contains the highest concentration 
of arginine in the context of RG or GR (14 in MBD2, 5 in MeCP2, Figure 4-1). 
Therefore, the modifications are possibly catalyzed by protein arginine 
methyltransferases.
MBD2 r ~ 1 1 1 414
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241 dlnttlpirq tasifkqpvt kftnhpsnkv ksdpqrmneq prqlfwekrl qglsasdvte
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Figure 4-1 The RG repeat domain.
The RG repeat domain of MBD2 (Top) and MeCP2 are shown (Yellow box). Outside 
the RG repeat domain, there are several other arginines (Red) and some are positioned 
next to a glycine (Green).
As arginine residues positioned beside glycine are the preferred substrates for 
most PRMTs (16, 126, 154), I removed the RG repeat domain of both proteins and 
subjected them to metabolic labeling in cells (Figure 2-5). Only full-length MBD2 and
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MeCP2 are acceptors of the post-translationally added 3H-methyl groups. Outside the 
RG repeat domain, additional RG motifs exist in both proteins (2 in MBD2, 8 in 
MeCP2, Figure 4-1). Although, these arginines are possible targets of PRMT, I did 
not observe any incorporation of 3H-methyl groups after long-term exposure of the 
Fluorograph in Figure 2-5. Judging by the distribution of RG repeats in MeCP2 and 
the corresponding 3H-labelling signals, I established that the RG repeat domain is the 
major site of PRMT modification in this protein. For MBD2, it was more 
straightforward as far fewer RG repeats exist outside the domain.
Based on the methylation assays and my laboratory’s interest in the RNA 
binding function (mediated by RG repeat domain) of both proteins (102), I focused on 
characterizing the post-translational modifications within the RG domains.
4.2 MBD2 interacts with PRMT
When expressed as GST-tagged proteins, the amino acid sequences of RG 
repeat domain in MBD2 and MeCP2 are sufficient for methylation by mammalian 
methyltransferases in vitro (Figure 2-6). This observation suggests the possibility of 
identifying the arginine methyltransferases responsible for these modifications by 
interaction assays. The hypothesis is supported by the fact that some PRMTs are 
reported to associate with their substrates in a relatively stable manner (48, 77). This 
point was further illustrated by my finding that the increased stringency of protein- 
protein interaction conditions resulted in the corresponding increase in co-purifying 
PRMT activity with GST-MBD2 baits (Figure 2-9) and the PRMT were subsequently 
determined to be PRMT1 and PRMT5 (Figure 2-10). However, similar experimental 
setups did not identify the co-purifying PRMT for MeCP2. Therefore, heavy emphasis 
was placed on the characterization of MBD2-PRMTs complexes.
While the data from binding assays consistently and convincingly show that 
the RG domain of MBD2 interacts with PRMT1 (Figure 2-10) and PRMT5 (Figure 
2-11), various other experiments were also employed to substantiate this finding. This 
is because the highly basic RG domain of MBD2 (pi = 13.31) might interact non- 
specifically with the acidic PRMT1 (pi = 5.29) and PRMT5 (pi = 6.24).
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4.2.1 PRM T5
A more physiological immunoprecipitation system revealed that endogenous 
MBD2 interacts stably with PRMT5 and MEP50 but exhibited weak or insignificant 
interaction with pICIn (Figure 2-13). These three proteins form the 20 S methylosome, 
a complex that controls the proper biogenesis of pre-mRNA splicing machinery 
through methylation of Sm proteins. In the case of Sm proteins, MEP50 is required for 
the methyltransferase activity of PRMT5 whereas pICIn is postulated to direct 
substrate specificity (71, 72). The region on Sm protein that binds pICIn is different 
from the region that mediates the Sm-PRMT5 interaction. Unlike the endogenous 
MBD2, the recombinant RG domain of MBD2 interacts strongly with pICIn. This 
observation is possibly an artifact due arising from the huge amount of PRMT5 that is 
attracted to the peptide (Figure 2-11).
It may be argued that the association between PRMT5 and MBD2 is be due to 
the existence of both proteins in the Sin3A containing repression complex (23, 178). 
However, using the purification scheme for MBD2 protein complexes, I was unable to 
co-purify Sin3A protein (Figure 3-3). It was demonstrated that the MBD2-PRMT5 
interaction is mediated by the RG domain and removal of the domain from MBD2 
results in the loss of interaction between PRMTs and MBD2. (Figure 2-15)
By thorough characterization of antibodies against dimethylarginines, I 
confirmed the presence of asymmetric and symmetric dimethylarginines within the RG 
domain of MBD2 (Figure 2-18 to Figure 2-20). This observation correlates with the 
finding that MBD2 arginine methylation is mediated by a type I and a type II PRMT 
(PRMT1 and PRMT5 respectively).
MBD2 is also reported to be a putative type II PRMT substrate in a large- 
scale proteomics study that used the Syml 1 antibody to immunoprecipitate candidate 
proteins that contain symmetric dimethylarginines (25). When probing the Symll 
antibody against MBD2 in Western blot, I was unable to identify the symmetric 
dimethylarginine modification present (Figure 2-18). This might be due to the 
structural difference between native MBD2 used for immunoprecipitation compared to 
the denatured MBD2 protein in Western blots.
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4.2.2 PRMT1
In comparison with MBD2-PRMT5, the endogenous MBD2-PRMT1 
complex seemed to be less stable (Figure 2-14). The physical association between 
MBD2 and PRMT1 can only be illustrated with the recombinant RG domain protein 
(Figure 2-10) or the overexpressed MBD2, which binds PRMT1 and PRMT5 but not 
PRMT 3 or PRMT4 (Figure 2-15). In both instances, the dimethylarginine contents on 
MBD2 are either very low or not present. Endogenous MBD2 (Figure 2-28) or MBD2 
expressed at endogenous levels (Figure 2-20) displayed higher asymmetric 
dimethylarginine content and did not co-purify stably with PRMT1.
Most bona fide PRMT1 substrates reported do not form endogenous 
complexes with the arginine methyltransferase and the molecular interactions are 
usually demonstrated by less physiological experiments (48, 90, 211). This is further 
illustrated by the inability of endogenous hnRNP A1 protein to co-purify with the 
enzyme (Figure 2-14). Therefore, to ascertain the relationship between PRMT1 and 
MBD2, I partially depleted PRMT1 from cells to demonstrate the corresponding 
reduction in asymmetric dimethylarginine content of the protein (Figure 2-25). 
Further characterization in PRMT1 null ES cells also revealed the total elimination of 
asymmetric dimethylarginine in the endogenous MBD2 proteins (Figure 2-28). These 
data are in agreement with another report, which states that PRMT1 is indispensable 
for the asymmetric arginine methylation of its substrate proteins (179).
The weak interaction between the highly methylated species of MBD2 and 
PRMT1 most probably reflects on the dynamics of the methyltransferase. In a study 
by Herrmann et a l , the accumulation of hypomethylated substrates caused the 
predominantly cytoplasmic PRMT1 proteins to be immobilized in the nucleus. When 
methylation was resumed, mobility of PRMT1 increased and the protein equilibrated 
back to the cytoplasm (91). As the majority of PRMT 1 substrates such as histones and 
hnRNPs are nuclear proteins, Herrmann et al. speculate that PRMT1 only stably 
associate with unmethylated substrates and release them after the methylation event. 
This could explain the observable interaction of PRMT 1 with the recombinant MBD2 
RG domain or the overexpressed MBD2 protein.
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4.3 Complexity of MBD2 arginine methylation
4.3.1 Asymmetric versus symmetric dimethyiation
Similar to the MBD2, some PRMT substrates are reported to contain both 
asymmetric and symmetric dimethylarginine modifications, examples include SmDl, 
SmD3 and SmB, B' from the splicesosome protein family (71, 160) and the high 
mobility group A la protein (244). Notably, two proteins that are involved in 
transcription regulation, the histone H4 (177, 226) and the SPT5 (121), are reported to 
be substrates of PRMT1 and PRMT5. Mass spectrometry analysis of these two 
proteins revealed that asymmetric or symmetric dimethyl groups can be targeted onto 
the same arginine residue and this led to speculations on the possible antagonistic 
actions between PRMT1 and PRMT5 (16).
As the mass spectrometry analysis was unable to resolve the RG domain 
peptide digested from full-length MBD2 (Figure 2-4), I do not have information 
regarding the position of asymmetric dimethylarginine versus symmetric 
dimethylarginine or even the bona fide sites of arginine methylation in the mammalian 
MBD2 protein. I can only speculate on how these two species of dimethylarginines 
may distribute along the RG domain of MBD2 based on the common observation that 
RGG motifs can only contain asymmetric dimethylarginine while RG motif may 
contain both (154) (Figure 4-2, Top).
Nevertheless, with the highly specific Asym24 and SymlO antibody, I was 
able to perform semi-quantitative assays to determine the nature of arginine 
methylation on MBD2 purified from different cellular systems. In siRNA cells with 
partially depleted PRMT1 activity, the total population of MBD2 protein purified had 
reduced asymmetric and symmetric dimethylarginine content (Figure 2-25). On the 
other hand, in prmtl ES cells, the asymmetric dimethylarginine in endogenous MBD2 
are totally abolished while the symmetric dimethylarginines are significantly increased 
(Figure 2-28 and Figure 2-29).
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MBD2 RG Domain
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Figure 4-2 Species of dimethylarginine present on MBD2 protein.
(Top) The amino acid sequence of MBD2 RG domain. The most likely arginine 
substrates for PRMT are in red. Possible sites for asymmetric dimethylarginine 
modification are shown (Blue box).
(Bottom) Predicted mechanisms of MBD2 arginine methylation in different mammalian 
cell systems. Models are based on the methylarginine content of MBD2 observed in the 
cells and the knowledge of deficiency in PRMT1 or PRMT5.
The difference can be explained by the remaining PRMT1 in siRNA cells 
binding to MBD2 protein but not methylating them. It must be noted that normal level 
of endogenous PRMT1 may be crucial for its dimerization in cells, a feature that is 
essential for the methyltransferase activity (239, 240). Since unmethylated substrates 
are known to have tighter association with PRMT1 (91), the unmethylated MBD2- 
PRMT1 complex might deny the efficient methylation of MBD2 by PRMT5. This 
resulted in the decrease in both species of dimethylarginines on the MBD2 protein.
For the case of prmtl ES cells, symmetric methylation of MBD2 by PRMT5 
is not interfered by PRMTl. Therefore, the type II methyltransferase may modify 
substrate proteins more efficiently, resulting in an MBD2 protein with high symmetric 
dimethylarginine content. To my knowledge, this is the first example of the widely 
speculated antagonism between type I and type II PRMT (16) (Figure 4-2).
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4.3.2 Stoichiometry of MBD2 arginine methylation
In some studies, overexpression of PRMT in cells resulted in a stoichiometric 
increase in the methylarginine contents of the overexpressed substrate protein (26). 
Neither asymmetric nor symmetric dimethylarginine content of MBD2 was observed 
to increase with the overexpression of PRMT 1 and PRMT5 respectively (Figure 6-6).
Most PRMT substrates are reported to achieve a highly methylated state in 
cells (90, 179) but there are some evidence that show that within the pool of cellular 
MBD2, only a subset of the population is methylated. Endogenous MBD2 co-purified 
with methyltransferases in cells readily accepts 3H-methyl groups when radioactive 
methyl donor was added in vitro (Figure 2-12). Albeit overexpressed, FLAG-MBD2 
bound to methyl-CpG DNA demonstrated that the majority of the proteins are 
unmethylated and have a better affinity for the DNA (Figure 3-12 and Figure 3-13). 
Partially disrupting the RG domain of MBD2 results in hypermethylation, and this is 
illustrated by probing the proteins with methylarginine antibodies and post- 
translationally labeling in vivo (Figure 3-6). Reassuringly, the hypermethylated 
mutants exhibit a higher degree of protein expression compared to wild-type MBD2. 
This indicates that the low methylarginine content observed in wild-type MBD2 is not 
because there was insufficient PRMT available in cells to execute the modification. 
The hypermethylated mutants do not interact stably with PRMT and this supports the 
hypothesis regarding the dynamics of PRMT1-MBD2 interaction (see Chapter 4.2.2). 
This is the first demonstration that a PRMT substrate with extensive RG repeats can 
have an increase in methylarginine contents by removal of some arginine residues that 
are the possible sites of this modification.
4.3.3 Can MBD2 arginine methylation be reversed?
The apparent complexity of MBD2 arginine methylation suggests that factors 
other than PRMT1 and PRMT5 might participate in the overall regulation of arginine 
residues within the RG domain. The most obvious candidate would be an arginine 
deiminase.
It is generally believed that arginine methylation does not alter the appearance 
of proteins in one or even two dimensional gel electrophoresis (77, 97). To my
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knowledge, there is only one report that briefly describes the anomalously slow 
migrating properties of RGG motif containing proteins (231). However, for arginine 
deimination, two independent groups reported on a more believable alteration in 
electrophoretic mobility of citrullinated histone due to the loss of one positive charge 
on the modified end product (54, 227).
Although no direct evidence is available at the moment, the low stoichiometry 
of methylarginine contents on MBD2 and the change in electrophoretic mobility of the 
protein that is dependent on genetic background or Adox treatment of cells (Figure 
6-5) suggest that this PRMT substrate might be subjected to arginine deimination as 
well.
4.4 The consequences of MBD2 arginine methylation
Although the numbers of newly identified PRMT substrates are increasing at 
an exponential rate, little is known about the cellular events that trigger arginine 
methylation of the proteins (16, 126). A few pieces of evidence suggested that PRMT 
are possibly required for cellular development (111) and treatment of cells with growth 
factors increase arginine methylation of cellular proteins (44, 45).
As the nature of this study is more directed towards protein biochemistry, 1 
did not investigate the possible cellular cascades that might increase the arginine 
methylation of MBD2 protein. In addition, pharmacological intervention of MBD2 
arginine methylation is useful only to a certain extent. This is because decreasing the 
methylarginine content of MBD2 by Adox has the undesirable effect of disrupting the 
integrity of the NuRD complex (Figure 3-4), the 1 MDa co-repressor partner of MBD2 
(65, 242). However, with various deletion mutants that produce an assortment of 
MBD2 with different amount of methylarginines (Figure 3-5 and Figure 3-6), I was 
able to probe the molecular effects of arginine methylation on this protein.
4.4.1 Arginine methylation decreases MBD2-NuRD interaction
Deleting the RG domain, or expressing the wild-type MBD2 protein in PRMT 
deficient cells revealed that MBD2 with a reduced methylarginine content have a 
higher affinity for components of the NuRD complex. The increase of co-purifying
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HDAC silencing complex is demonstrated by Western blot (Figure 3-1) and in vitro 
HDAC assay (Figure 3-2).
When MBD2 hypermethylation mutants were tested for the quantity of co- 
purifying HDAC silencing complex, the correlation between increasing arginine 
methylation and decreasing affinity for the corepressor complex become evident 
(Figure 3-6). Among seven hypermethylated mutants, six were incapable of efficient 
interaction with the components of NuRD complex compared to the wild-type MBD2 
(Figure 3-7). The significance of how one hypermethylated MBD2 mutant (MBD2- 
RG18) avoids the effect of methylation and interacts stably with the NuRD complex is 
not known and will be best explored by structural analysis.
With regard to protein-protein interactions, asymmetric dimethylation of 
arginines are illustrated to be detrimental for the interaction between proline rich and 
SH3 domain (15) whereas symmetric dimethylation facilitates Tudor domain 
interaction (30, 70) (see Chapter 1.7.1). In all cases, the effects were determined 
empirically. While the MBD2/NuRD interaction may serve as an ideal case study for 
such molecular dissection, certain issues must be addressed before putting arginine 
methylation into the equation. At least ten proteins exist in the NuRD complex (65) 
and which protein comes into direct contact with MBD2 remains unknown. Within 
the MBD2 protein, the region that is reported to recruit the Sin3A corepressor complex 
(23) is not the region required for association with the NuRD. After the deletion of 
Sin3A binding region, the TRD mutants were still capable of co-purifying MTA2 and 
core HDAC components (Figure 3-21). Subsequent experiments localized the NuRD 
interacting domain to residues 227-414 on the MBD2 protein (Figure 3-22). Thus, 
more characterization is required to pinpoint the specific domain.
4.4.2 Arginine methylation decreases MBD2-methyl-CpG DNA interaction
MBD2 proteins assembled on methyl-CpG DNA and eluted in a stepwise 
manner with increasing concentrations of NaCl revealed that arginine methylated 
species of MBD2 have less affinity for the DNA and eluted earlier than the majority of 
the proteins that are unmethylated (Figure 3-12 and Figure 3-13). This control is 
found to be exclusive to wild-type MBD2 proteins as arginine methylated species of 
RG mutants exhibited similar elution pattern with the total population of the protein.
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Such differences in affinity between arginine methylated proteins and nucleic 
acids are seldom demonstrated in the characterization of nucleic acids binding PRMT 
substrates, the major class of proteins that are subjected to this modification (154). In 
1994, Rajpurohit et al. used a continuous gradient elution to remove hnRNP Al 
proteins that were non-specifically binding to single stranded DNA and RNA. They 
found that arginine methylated species of hnRNP Al required slightly lesser 
concentration of NaCl to be eluted from DNA (40 mM) and RNA (35 mM) compared 
to their unmethylated counterpart (185). In a subsequent report by Valentini et al., the 
specific RNA binding partners of yeast hnRNP were identified, and measuring the 
dissociation constant between the hnRNP and the RNA showed that arginine 
methylation does not alter the affinity of the protein towards the RNA (222).
While Rajpurohit et al. demonstrated the difference in affinity between 
hnRNP Al protein and nucleic acids using non-specific targets (185), my experiments 
used the specific DNA partner of MBD2. Furthermore, I illustrated that my assay 
system was highly stringent and only allowed binding of MBD2 to methylated CpG 
DNA but not the unmethylated DNA comprising the same sequence (Figure 3-10 to 
Figure 3-11). However, my experiment used a step salt elution gradient while 
Rajpurohit et al. used a continuous gradient, which may more accurately measure the 
difference in affinity between each species of protein. This is because, at 200 mM 
increments of NaCl, methylated MBD2 proteins eluted at 400 mM and the majority of 
proteins eluted at 600 mM (Figure 3-12). When the salt increments were reduced to 
100 mM, methylated MBD2 proteins eluted at 500 mM while unmethylated MBD2 
remains unchanged (Figure 3-13). Thus, only the continuous salt gradient elution is 
able to pinpoint the exact elution requirement of arginine methylated MBD2. If 
performed, the elution difference between modified and unmodified species of MBD2 
is predicted to be as subtle as the values reported by Rajpurohit et al.
The subtle difference in methyl-CpG DNA binding affinity of arginine 
methylated MBD2 probably does not reflect on the total elimination of MBD2 
repressive functions. In cells, MBD2 was demonstrated to have a wider substrate 
specificity than MeCP2. It could occupy genomic loci of MeCP2 when the latter 
protein was depleted (117). While the methyl-CpG DNA probe used in my study 
contains a high proportion of methyl-cytosine (Figure 3-10), the presence of one
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methylated CpG is sufficient for MBD2 binding (85). Therefore, proper investigation 
of arginine methylated MBD2 binding sites in the genome might reveal that this 
modification influences the sequence specificity of MBD2 protein.
Another important point to consider with regard to the conclusion drawn from 
the methyl-CpG DNA binding experiment (Figure 3-12) is that the MBD2 proteins 
used were overexpressed in cells and therefore had low methylarginine content. As it 
is unfeasible to purify a large quantity of endogenous MBD2 in native form, I can only 
predict the outcome of such experiment. In the process of characterizing MeCPl 
(MBD2/NuRD), Meehan et al. pointed out the negligible methyl-CpG DNA binding 
activity of embryonic stem cells extracts compared to HeLa and various primary cells 
(157). I did not perform parallel comparisons but my attempts to detect the 
methylarginine contents of endogenous MBD2 purified from HeLa13 cells did not yield 
positive signal in Western blot compared to the MBD2 from the ES cells (Figure 2-28 
and Figure 2-29). Therefore, I speculate that the lack of MeCPl activity observed in 
ES cells might be due to by the higher methylarginine contents of the MBD2 proteins 
from these cells.
MBD2
HDAC
complex.
PRMT
PRMT1
PRMT5
PRMT5
. HDAC 
complex.
Figure 4-3 The overall molecular effects of MBD2 arginine methylation.
(Left) The exact cellular location for the PRMTs to methylate MBD2 is not known; the 
preferred forms of MBD2 proteins for recognition by PRMTs also need to be 
investigated.
(Right) At molecular level, MBD2 arginine methylation decreases the affinity of the 
repressor to interact with the HDAC co-repressor complex (NuRD) and methyl-CpG 
DNA.
13 Data not shown for determination of methylarginine contents of MBD2 from HeLa cells.
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4.4.3 Independent regulation of MBD2-NuRD and MBD2-methyl-CpG DNA 
interaction by PRMT
While MBD2 arginine methylation has inhibitory effect on the affinity of this 
protein towards NuRD complex and methyl-CpG DNA, I believe that the control of 
MBD2 interaction with these factors by PRMT activity is two independent events.
For MBD2-methyl-CpG DNA interaction, the inhibitory effect of arginine 
methylation is exclusive for wild-type MBD2 proteins (Figure 3-12). 
Hypermethylated MBD2 mutants that display compromise affinity for NuRD complex 
(Figure 3-6 and Figure 3-7) do not elute faster than the total population of protein in 
methyl-CpG DNA interacting column (Figure 3-13). Removal of the MBD domain 
from the MBD2 protein (MBD2-TRD94) produces mutants that have high affinity for 
the NuRD complex (Figure 3-21). This mutation, when combined with various RG 
domain mutations, show that arginine methylation still controls the affinity of MBD2 
for the NuRD complex when a functional MBD domain is not present.
4.5 Hypermethylated MBD2 has impaired repression activities in 
cells
Since all molecular contacts required for MBD2 mediated repression are 
weakened by arginine methylation (Figure 4-3), I tested whether these modifications 
affect the in vivo repression function of MBD2. Using the RG domain mutants of 
MBD2 (Figure 3-5), I measured the repression activities of the proteins in cell-based 
assays. In the experiment that measured both the methyl-CpG DNA binding affinity 
and HDAC recruitment ability of MBD2, the mutant protein with on methylarginine 
content (MBD2-RG41) was demonstrated to be slightly more competent than the wild- 
type MBD2 in mediating the repression of CpG-methylated reporter plasmid (Figure 
3-15 and Figure 3-17). The subtle difference, and the irresponsiveness of the reporter 
plasmid expression towards the dosage of MBD2 transfected led me to refine the 
experiment.
Taking the DNA binding ability of MBD2 out of the picture, I measured 
repression capability of Gal4-MBD2 fusion protein. I found that hypermethylated 
MBD2 mutant (MBD2-RG23) is at least 2.5 times less competent compared to wild-
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type MBD2 in mediating HDAC dependent transcription repression (Figure 3-18 and 
Figure 3-23). The loss of function in the MBD2-RG23 mutant was rescued when the 
experiment was repeated in PRMT deficient siRNA cells that were less capable of 
executing arginine methylation on MBD2 proteins (Figure 3-24).
Though consistent with the biochemical effects MBD2 arginine methylation, 
the cell-based repression assays are not the best methods to measure the repression 
activity of MBD2. This is because transfected reporter plasmids in the cells assemble 
into chromatin with structures and histones compositions that are dissimilar to cellular 
chromatin (209). This is relevant to repressor proteins such as MBD2, which mediates 
transcription silencing by chromatin remodeling.
A more representative reporter system may be produced by integration of the 
reporter plasmids into the genome. This was not done due to the time constraints and 
the fact that the plasmid expression would be tightly controlled by the position of the 
genome at which it integrated, and becomes unresponsive to MBD2 mediated 
repression. Alternatively, genes controlled by MBD2 in cells can be quantified with 
respect to MBD2 arginine methylation. However, GSTP1 (an MBD2 controlled gene 
in MCF-7 cells (140)) was demonstrated to maintain normal protein levels in cells 
cultured from mice with homozygous deletion of MBD2 gene (Figure 3-17)14.
4.6 Can MBD2 be responsible for histone arginine methylation?
Almost all reported transcription-regulating PRMT substrates are classified as 
transcription activators or transcription factors, and repressor proteins are seldom 
identified as PRMT substrates (126). Nucleolin, a possible transcription repressor 
(234), is reported as a PRMT substrate (163) but the significance of this modification 
has not been investigated.
Nevertheless, PRMTs are known to interact with transcription repression 
complexes. However, the usual targets for methylation are not within the complexes 
(6, 177, 178). PRMT5 interacts with the SWI/SNF (177, 178), and with the Blimp 1 
repressor, both of which are implicated with HDAC containing chromatin remodeling
14 Data not shown for GSTP1 expression level in mbd2 and WT mtf.
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complexes (6). In both instances, histone arginines (H4R3 and H2AR3 for (6) only) 
are the reported substrates of these interactions and the evidence was provided by in 
vitro methylation assays using the co-purified methyltransferase activities. Activities 
of PRMT5 in these complexes are speculated to contribute to transcription repression.
When this thesis was in preparation, Le Guezennec et al. reported on the 
association between PRMT5 and MBD2 proteins expressed in stable cell lines (125). 
While their investigations were mainly focused on the mutual exclusiveness of 
MBD2/NuRD and MBD3/NuRD complexes (see Chapter 1.4.2), they had also co- 
purified PRMT5 with MBD2 and illustrated the in vitro methylation of MBD2. In a 
further experiment, they used ChIP to illustrate that MBD2 and PRMT5 co-localized 
on the pl6/INK4A and pl4/ARF (INK4a/ARF) locus and the specific genomic region 
contains dimethylated histone H4 arginine 3. The H4R3 modification could be 
significantly reduced when cells were treated with DNA methylation inhibitors
It must be noted that besides associating with the MBD2 (146), the 
INK4a/ARF locus is subjected to transcription regulation by many other chromatin 
remodeling complexes (46). Well-characterized examples of regulatory factors 
binding to the INK4a/ARF locus include protein members from the E2F family (59) 
and the SWI/SNF complex (35). Both E2F and SWI/SNF are capable of synergistic 
interaction with PRMT5, and the resultant H4R3 methylation was observed (62, 177, 
178).
Based on my observation on the stable association between MBD2 and 
PRMT5 (Figure 2-13), I do not exclude the possibility that the INK4a/ARF-MBD2- 
PRMT5 association identified by ChIP is a real physiological complex, and not an 
artifact arising from the independent binding of both proteins on the locus. However, 
with regard to H4R3 methylation in the INK4a/ARF locus, Le Guezennec et al. proved 
the presence of dimethylated H4R3 by ChIP assay using an antibody that was 
generated against asymmetrically methylated H4R3 peptide (125). The 
asymmetrically methylated H4R3 is highly unlikely to be the end product of PRMT5 
catalysis.
Since this study shows that MBD2 also associates with PRMT1, it may be 
tempting to speculate that the methyl-CpG DNA dependent asymmetric methylation of
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H4R3 observed by Le Guezennec et al. could be a result of this interaction. If proven, 
this could support the findings that speculate the H4R3 asymmetric methylation by 
PRMT1 to be an early transcription activation event that leads to the acetylation of 
histone tail by the p300 acetyltransferase (5, 226). Such conclusions would be 
consistent with my overall observation of how arginine methylation of MBD2 relieves 
transcription repression activity.
4.7 Future perspectives
While the possibilities that MBD2 mediates the PRMT modification of 
histone arginine may be appealing, there are unanswered questions regarding the 
PRMT modification of MBD2.
I need to know the specific cellular localization of MBD2 protein when it is 
modified by PRMT1 or PRMT5. Both PRMT are reported to be predominantly 
cytoplasmic (48, 91, 188) but evidence exists to show that they can be found in the 
nucleus (62, 91, 121). Newly translated MBD2 may be methylated as it emerges from 
the ribosome, but it is also possible that the modification can occur in the nucleus. 
With such knowledge, I would be able to predict and test for the preferred forms of 
MBD2 substrate for each PRMTs, whether it is monomeric MBD2, MBD2 associating 
with NuRD complex or methyl-CpG DNA, or both (Figure 4-3).
The MBD2-7SK RNA complex is another form of MBD2 that is most likely 
to have altered preference for PRMT methylation. As 7SK RNA binds MBD2 directly 
through the RG domain (102, 114), whether the RNA-protein interaction can affect, or 
be affected by, MBD2 arginine methylation can be addressed by preexisting 
techniques acquired for this study. The significance of MBD2 arginine methylation in 
the context of its interaction with 7SK RNA will be a completely new topic that may 
answer many speculations and probably can open up many perspectives in the study of 
PRMTs.
Unmethylated MBD2 binding to PRMTs may also serve important functions. 
Blimp 1 repressor and PRMT5 translocate from the nucleus to the cytoplasm of mice 
embryonic stem cells when the cells are undergoing extensive epigenetic 
reprogramming. This causes the expression of Blimp 1 controlled genes (6). As
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MBD2 with low methylarginine content binds both PRMTs stably, functions of these 
MBD2-PRMT complexes should be characterized.
For methylated species of MBD2, I have not yet addressed whether an 
individual MBD2 molecule contains both asymmetric and symmetric dimethylated 
arginine, or whether asymmetric and symmetric modifications are mutually exclusive. 
If MBD2 containing only asymmetric or symmetric dimethylarginine can be separated, 
and purified with their interacting partners, I may be able to identify novel protein- 
protein interactions mediated by the modifications. This is supported by recent 
evidence, which indicates that dimethylated arginine is also involved in protein 
binding (30, 49, 70).
These results may provide us with clues to the mysteries surrounding the 
importance of MBD family members. Here, I find that arginine methylation of MBD2 
serves one purpose of relieving its transcription repression activity, and currently, the 
significance of having two different PRMTs that interact with, and produce different 
end products on MBD2, remains to be elucidated. Can this be related to the control of 
cellular development process? Recent reports have already show that MBD2 (98, 99), 
the NuRD complex (108), PRMT1 (180) and PRMT5 (6) may be involved in gene 
expressions which are critical during development. Can these factors work together to 
control developmental gene expression?
If so, I would need to check at which developmental stages are the MBD2 
proteins specifically methylated at the arginines. If MBD2 protein generally contains 
methylated arginine throughout all stages of cellular differentiation, maybe the down 
regulation of MBD2 repressive functions by arginine methylation can explain the 
apparent lack of obvious disease phenotype in the initial characterization of the MBD2 
-/- mice (86). To test such hypothesis, generation and characterization of mice that 
express only the MBD2b protein (85), which can escape regulation by arginine 
methylation will be most appropriate for addressing this question (Figure 4-4).
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Figure 4-4 The MBD2b.
The MBD2b protein is an isoform of MBD2 that arise from the alternative translation 
of the MBD2 mRNA using the internal methionine located at the N-terminus of the 
MBD domain (Green). As it also contains the TRD (Red) that is required for 
repression, MBD2b is predicted to be functionally active. MBD2b lacks the RG domain 
(Yellow).
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Chapter 5 Materials and Methods
5.1 General techniques, solution and buffers
Most media and commonly used solutions were provided by Cancer Research 
UK central services.
Media/solution Composition
L-Broth (LB)
PBSA
TE
10 X DNA loading
10XTBE 
(Ambion) 
50XTAE 
DEPC water
170 mM NaCl, 0.5% w/v yeast extract, 1% w/v 
bactotryptone and antibiotics 
170 mM NaCl, 3 mM KC1, 10 mM Na2HP04 and 2 
mM KH2P 0 4
10 mM Tris-HCl pH 7.0 and 1 mM EDTA
60% w/v sucrose, 0.1% w/v bromophenol blue and
0.1% w/v xylene cyanole FF
0.89 M Tris, 0.89 M Borate and 20 mM EDTA
2 M Tris-Acetate and 50 mM Na2EDTA
0.1% diethyl pyrocarbonate in water, autoclave after
mixing
Table 5-1 List of common solutions provided by Cancer Research UK central services.
5.1.1 SDS polyacrylamide gel electrophoresis (PAGE)
Solution Composition
Separating gel 
acrylamide 
Separating gel 
buffer
Stacking acrylamide 
Stacking acrylamide 
buffer
2x SDS sample 
buffer
MW markers 
(100 pg/ml each)
4x Running buffer
33.5% acrylamide and 0.3% bis
380 mM Tris pH 9.1, 0.1% SDS 0.075% APS
and 0.05% TEMED
30% acrylamide and 0.44% bis
120 mM Tris pH 6.8, 0.1% SDS, 0.03% APS
and 0.2% TEMED
125 mM Tris pH 6.8, 4% SDS, 20% glycerol, 
0.02% bromophenol blue and 10% (3- 
mercaptoethanol
lysozyme (14.3 kDa), carbonic anydrase (29 
kDa), egg albumin (45 kDa), bovine albumin 
(66 kDa), phosphorlyase (97.4 kDa) and p- 
galactosidase (116 kDa)
12 g/L Tris-base, 57.6 g/L glycine and 4% SDS
Table 5-2 Components for SDS-PAGE in this study.
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Separating acrylamide was prepared at final concentrations of 7.5 - 15% and stacking 
acrylamide was always at 4%.
5.1.2 SDS PAGE staining
5.1.2.1 Coomassie staining
Solution______________ Composition____________________________________
Fixing solution 50% v/v methanol and 10% glacial acetic acid
Coomassie stain 2.2 g/L Coomassie blue R250 in fixing solution
Destaing solution 20% methanol and 10% glacial acetic acid
Table 5-3 List of general solutions required for Coomassie staining
SDS-PAGE gels were stained with Coomassie for 25 min and were destained 
until appropriate.
5.1.2.2 Silver staining
SDS-PAGE gels were stained in Silver Quest (Invitrogen LC6070) silver 
staining kit according to manufacturer’s instruction.
5.1.3 Western blotting
SDS-PAGE gel and Protran (Schleicher and Schuell) nitrocellulose transfer 
membrane were immersed in 50 mM Tris, 14.5 mM glycine and 20% methanol 
(transfer buffer) for 15 min. Proteins in the gel were transferred onto the membrane by 
semi-dry transfer unit (Hoefer) according to manufacturer’s instructions. Transferred 
membranes were stained with Ponceau S to reveal MW markers and were then washed 
briefly with 0.1% Tween in PBS (washing buffer) and blocked with 5% non fat dried 
milk (w/v) in washing buffer for 1 hr. Primary and secondary antibodies were diluted 
in washing buffer and were incubated with the membrane according to the antibody 
protocol. Membranes were washed for 30 min with 5 changes of washing buffer after 
each antibody staining. For visualization, the membranes were incubated in enzymatic 
chemiluminescent (ECL, Amersham) reagents and exposed to Kodak BioMax MR 
film (Sigma) according to manufacturer’s instruction.
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Fluorography was used for visualization of proteins with 35S or 3H-labels in 
this study. After Coomassie staining, SDS-PAGE gels were immersed in Amplify 
Fluorographic reagent (Amersham) for 15 min and were dried in a gel dryer (Bio-Rad) 
for 1 hr. Gels were exposed to Kodak BioMax MS film (Sigma) for at least 24 hr 
before developing the film.
5.2 Cloning
5.2.1 DNA preparation
Most plasmid DNA used for this study were raised in Max Efficiency 
(Invitrogen) E. coli DH5a cells. Gateway vector plasmids containing the lethal ccdB 
gene were raised in E. coli DB3.1 (Invitrogen). All plasmid DNA were isolated using 
Qiagen Mini or Maxi kit according to manufacturer’s instruction and were 
resuspended in TE buffer.
5.2.2 Bacterial transformation
Plasmid DNA (1-10 ng) were incubated with competent cells on ice for 30 
min and were subjected to heat shock at 42°C for 90 sec. Cells were returned on ice 
for 3 min and warm LB was added to the cells for incubation on a shaker at 37°C for 
40 min. After incubation, the cells were centrifuged at 1000 g for 30 sec to remove the 
LB and were plated onto LB agarose with appropriate antibiotic.
5.2.3 Annealing of oligos for cloning
5'-phosphorylated oligos (sense and antisense strands) were ordered from 
Sigma Genosys and 10 ng of each strand was resuspended in a buffer containing 30 
mM HEPES-KOH pH 7.4, 100 mM K-acetate and 2 mM Mg-acetate. The reactions 
were incubated at 95°C for 4 min and then 75°C for 10 min after which they were 
equilibrated to room temperature by standing on the bench for 1 hr. Reactions were 
ready for ligation thereafter.
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Ligation reactions for cloning purpose were carried out using Rapid DNA 
ligation kit (Roche Applied Science) according to manufacturer’s instruction.
Clones were verified by sequencing. Purified DNA was incubated with 
BigDye Terminator v3.1 (Applied Biosystems) and appropriate primer. Sequences 
were obtained from 3730 DNA Analyzer (Applied Biosystems) operated by CRUK 
equipment park.
5.2.5 pRetro.Super plasmid for siRNA expression
To create insert encoding siRNA against the PRMT genes, mRNA sequences 
of human PRMT1 (NM 001536) and PRMT5 (NM 006109) were analyzed by 
Extractor 5 software. Four sets of sequences were selected for each PRMT gene and 
were synthesized and annealed as described in Chapter 5.2.3.
The pRetro.Super plasmid was digested with Bglll and Hindlll (New England 
Biolabs) and was ligated with the annealed oilgos to obtain the desired siRNA 
expression plasmids.
5.2.6 Gateway cloning
All FLAG and Gal4 fusions of MBD2 genes were generated using the 
Gateway (Invitrogen) cloning system.
pGal (1-94) Gateway destination plasmid was created by digesting the 
original plasmid with BamHI (New England Biolabs). T4 DNA polymerase (New 
England Biolabs) was used to blunt the ends of the linearized vector. To prevent 
recircularization, plasmid DNA was treated with calf intestinal phosphatase (New 
England Biolabs) and reading frame B from the Gateway vector conversion system 
(Invitrogen) was cloned into the vector. Ligated plasmids were raised and maintained 
in E. coli DB3.1 cells.
The gene of interest in the Gateway pDONR vector (see Table 5-7) can be 
easily transferred into any gateway destination vector by recombination reactions
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carried out using gateway LR clonase (Invitrogen) and according to manufacturer 
instruction.
5.2.7 MBD2 deletion mutants
5.2.7.1 RG deletion mutants
Plasmids encoding MBD2 RG mutants were obtained by digestion of full- 
length MBD2 in pDNOR221 with FspI and SacII (New England Biolabs) to delete 
nucleic acids corresponding to residues 50-94 of the MBD2 protein. Double stranded 
mutagenic oligos were annealed and ligated into the remaining plasmid fragment to 
obtain the desired mutation.
5.2.7.2 TRD deletion mutants
To create MBD2 with a deletion of 15 residues in the TRD, full-length MBD2 
in pDONR221 was digested with BbvCI and BspEI (New England Biolabs) to delete 
nucleic acid corresponding to residues 195-226 of the MBD2 protein. For larger 
deletion mutants, the plasmid was digested with BamHI and BspEI (New England 
Biolabs) to delete nucleic acids corresponding to residues 126-226. For MBD2 1-131, 
pDONR221-MBD2 was digested with BamHI and a mutagenic oligo was cloned into 
the plasmid to introduce a stop codon after residue 131 of the MBD2 protein
5.3 Production of proteins from bacteria cells
All recombinant proteins from bacteria were prepared and purified as 
described in Jeffery and Nakielny (102).
5.4 Mammalian cell culture
5.4.1 Cell types and media
Cell type Medium
293T, HeLa, 
Ramos, 
Neuronal 2A, 
PCI and all 
mouse tail 
fibroblast
Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 4500 mg/L glucose, 2 mM L- 
glutamine, 0.1 units/ml penicillin, 0.1 pg/ml 
streptomycin and 10% fetal calf serum (Normal DMEM).
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All siRNA Normal DMEM with 2 pg/ml puromycin (Sigma)
stables
All Flp-In T- Normal DMEM with 2.5 pg/ml blasticidin, 50 pg/ml
Rex stables hygromycin and induce with 1 - 25 ng/ml tetracycline for
protein expression. All antibiotics mention were 
purchased from Invitrogen.
All embryonic DMEM supplemented with 4500 mg/L glucose, 4 mM L-
stem cells glutamine, 0.12 units/ml penicillin, 0.12 pg/ml
streptomycin, 15% ES screened fetal bovine serum 
(Hyclone), 50 pM |3-mercaptoethanol and 50 units/ml 
ESGRO (Chemicon International).
Table 5-4 List of mammalian cells used in this study and the media used for their 
maintenance.
All mammalian cells were cultured in Costar 100 mm tissue culture dish or 6 
well plates unless otherwise stated. For ES cells, culture dish was pretreated with 
0.1% gelatin (Sigma) for 30 min before addition of trypsinized ES cells. Incubation 
conditions were set at 37°C in 5% CO2 incubator throughout.
5.4.2 Transfection
Effectene transfection reagent (Qiagen) was used for all transfection assays in 
this study. Cells in 100 mm plates were typically transfected when they were at 30 -  
40% confluence. Unless otherwise stated, 6 pg of plasmid DNA, 48 pi EC buffer and 
60 pi effectene reagent was used for each plate and cells were harvested 48 hr after 
transfection.
5.4.3 Generation of stable clones
5.4.3.1 Stable siRNA clones
To generate stable siRNA clones, 293T cells in 100 mm plates were 
transfected with pRetro.Super plasmids (1 pg DNA, 8 pi EC and 10 pi Effectene) 
encoding siRNA. Two days after transfection, normal medium was removed and 
replaced with selective medium (see Table 5-4). The cells were maintained in the 
selective medium for one week and replaced with fresh selective medium every two 
days until colonies were formed. Colonies were picked from each plate and were 
cultured in one well of a 6 well plate until confluence. Stable cells with significant 
knockdown of target protein in Western blot were subcultured. Clones displaying
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highest level of knockdown for each protein after 2 months were kept for further 
analysis.
5.4.3.2 Stable Flp-In TREx clones
Expression plasmids (1 pg) encoding FLAG-MBD2 proteins were co­
transfected with 9 pg of pOG44 into Flp-In TREx 293T (Invitrogen) cells using 
Effectene (Qiagen) transfection reagent (10 pg total DNA / 80 pi EC / 100 pi 
Effectene). 48 hr after transfection, the normal medium was replaced with selective 
medium (see Table 5-4) and the cells were maintained for 1 to 2 weeks until the 
appearance of colonies. Selected cells were checked for their tetracycline-induced 
expression of FLAG-MBD2 protein by Western blot (as described in Chapter 5.4.3.1).
5.4.4 Cell lysis buffers
All mammalian cell lysate and protein assay buffers were supplemented with 
10 pg/ml of aprotinin, leupeptin and pepstatin, 0.5 mM PMSF and 2 mM DTT and 
were prepared at 4 °C.
Buffer Contents
RIPA 10 mM Na2HP04, 150 mM NaCl, 2 mM EDTA, 0.1%
SDS, 1% sodium deoxycholate and 1% NP40
TCE 50 mM HEPES-KOH pH 7.5, 150 mM K-acetate, 5 mM
Mg-acetate and 0.1% digitonin
RSB 10 mM Tris pH 7.4 and 2.5 mM MgCl2 (NaCl
concentration can be variable)
Detergents 0.5% Triton X (for protein complex) or 0.5% Empigen
for RSB (for pure proteins)
NaCl for 100 mM to 1.6 M NaCl with 1 X RSB. Usually at 800
RSB mM NaCl.
PRMT 20 mM Tris-HCl pH 8.0, 200 mM NaCl and 0.4 mM
EDTA
Table 5-5 List of cell lysis buffers used in this study.
5.4.5 Preparation of cell lysate
Cells (~1 X 106) were washed once in ice cold PBS A and were lysed in 1 ml 
of the appropriate buffer (see Table 5-5). The lysates were sonicated with 5 x 10 sec 
blast with 5 min interval on ice between each blast, lysates were left on nutator for at 
least 30 min. Insoluble proteins were removed by centrifuging at 14,000 g for 10 min.
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For Western blots, the lysates were normalized by Bradford assay to enable equal 
loading of proteins. For purification of endogenous proteins or GST pull down assay, 
lysates were subjected to a further centrifugation step of 100,000 g for 1 hr and the 
supernatant was passed through 0.22 pM filter to obtain a clear colorless lysate. 
Otherwise, cell lysates were used directly for immunoprecipitation or other 
biochemical assays. Unused lysates were flash frozen in liquid nitrogen and stored at - 
80 °C.
5.4.6 Purification of FLAG-tagged proteins from 293T cells
Cells lysates were prepared from transfected 293T cells using RSB-800 with 
0.5% Triton X-100 lysis buffer (see Table 5-5). To purify FLAG-proteins without any 
interacting partners, the same lysis buffer was used with 0.5% Empigen BB 
(Calbiochem) in place of Triton X-100.
Anti-FLAG antibody M2-agarose beads (Sigma; 25 pi bead volume/plate of 
cells, washed with lysis buffer) were added to the cell lysate and the slurry was rotated 
for 2 -16 hr. After that, FLAG-tagged proteins bound to the beads were washed 4 
times with RSB800-0.5% Triton X-100 buffer and once with PRMT buffer, each wash 
involved a centrifuging step of < 500 g for 30 sec and rotation at 4°C for > 2 min after 
addition of fresh buffer. Washed beads were eluted with 2 X SDS sample buffer for 
Western analysis or resuspended in PRMT buffer for biochemical assays.
To obtain unbound FLAG-tagged proteins in native form, 80 pg of 3X FLAG 
peptide (Sigma) in 20 mM Tris-HCl pH 7.4, 100 mM NaCl and 2.5 mM MgCh was 
added to the beads and the slurry was rotated at 4°C for 1 hr. The proteins were eluted 
by passing the slurry through a Micro Bio-Spin column (Bio-Rad). FLAG-proteins 
purified in this way were quantified by comparing against BSA standards in SDS- 
PAGE/Coomassie. All FLAG- proteins were > 90% pure as judged by SDS-PAGE 
and Coomassie staining.
5.4.7 Purification of endogenous proteins/enzymatic activity from cells
Antibodies ( 2 - 5  pg) for immunoprecipitation were incubated with 1 ml cell 
lysate at 4°C for 3 to 16 hr. 50 pi of protein G sepharose (Amersham) beads washed
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once in cold PBS was added to capture the antibody-protein complex for at least 1 hr. 
The beads were washed 4 times with the lysis buffer and twice with PRMT assay 
buffer. For Western blot analysis, the protein complexes were eluted from the protein 
G beads by boiling in SDS-sample buffer, and then separated by SDS-PAGE. To 
assay for co-purifying PRMT activity, the protein complexes on the beads were 
resuspended in 30 pi of PRMT assay buffer containing 2 pCi of 3H-S-adenosyl- 
methionine. The labeling was carried out at 37°C for 90 min and the proteins were 
separated by SDS-PAGE and visualized by means of Western blot and Fluorograph.
5.4.8 Immunofluorescence
Cells (HeLa) on glass coverslips in a 6 well plate were transfected with 
plasmids (1 pg DNA/ 8 pi EC /10 pi Effectene per well) and were harvested after 18 
hr. The cells were fixed with 2% formaldehyde in PBS at room temperature for 30 
min and were permeabilized with acetone for 3 min at -20 °C. Blocking was carried 
out in 3% BSA in PBS A for 1 to 16 hr and the coverslip was covered with primary 
antibody diluted in blocking buffer for 1 hr. After primary antibody staining, the 
coverslips were washed 3 times in PBS A with 5 min incubation at room temperature 
between each wash. Secondary antibody diluted in blocking buffer was applied to the 
coverslips for 30 min and the coverslips were washed as previously. Stained 
coverslips were mounted onto glass slides with Vectashield mounting medium 
containing DAPI (Vector laboratories) and edges of the coverslip were sealed with nail 
varnish.
5.5 Specialized techniques used in this study
5.5.1 In vitro methylation assay
For all in vitro methylation assay, 0.5 pg of GST-tagged protein was used as 
substrate, 2 pCi o f 3H-S-adenosy 1-methionine as the methyl donor, and 15 pg of cell 
lysate or rabbit reticulocyte lysate (Promega) as the source of methyltransferases. Cell 
lysate was pretreated with 0.1 mM S-Adenoysl-homocysteine (Sigma) at 37°C for 20 
min when inhibition of methyltransferase activity was required. All methylation 
reactions were carried out in PRMT assay buffer described in Table 5-5 for 1.5 hr.
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Methylated substrates were separated on SDS-PAGE, stained with Coomassie and 
analyzed by Fluorography.
5.5.2 In vivo labeling assay
Transfected 293T cells expressing FLAG proteins were starved in methionine 
deficient DMEM supplemented with 10% fetal calf serum, 100 pg/ml cyclohexamide 
(Sigma) and 40 pg/ml chloramphenicol (Sigma) for 30 min. The medium was 
removed and replaced with the same medium with 100 pCi of 3H-L-methyl- 
methoinone (Amersham) or 10 pCi of 35S-methionoine (Amersham) and in the 
presence or absence of protein synthesis inhibitor. The labeling reaction was allowed 
to proceed for 3 hr and FLAG proteins were purified by immunoprecipitation as 
described in 5.4.6. Proteins were eluted by boiling in SDS-PAGE sample buffer and 
were separated by SDS-PAGE, analyzed by Coomassie staining and Fluorography.
The in vivo labeling experiments were sometimes performed with cells treated 
with methylation inhibitors. Methylation inhibitors, Adox (Sigma) and MTA (Sigma) 
were used at a final concentration of 20 pM and 300 mM respectively and were added 
to the cells 12-36 hr prior to or during the labeling assay.
5.5.3 Precipitation of proteins
Proteins in solution were precipitated by addition of 6 volumes of a mixture 
of 50% ethanol, 25% methanol and 25% acetone. The mixture was vortexed 
vigorously and was incubated at -  20°C overnight or -80°C for 30 min. The mixture 
was centrifuged at 14,000 g for 20 min at 4 °C. The supernatant was removed and the 
pellet containing the precipitated protein was dissolved in 2 X SDS sample buffer.
5.5.4 GST pull down
To remove cellular proteins bound unspecifically to the sepharose beads, 2 ml 
of cell lysates described in Chapter 5.4.5 was added to 100 pi of washed glutathione 
sepharose beads (Amersham) and was rotated at 4°C for 1 hr. The GST-beads were 
removed by centrifuging at < 500 g for 30 sec. The supernatant was added with 2 - 5  
pg of GST-tagged proteins and was left on the rotator at 4°C for 4 -  16 hr. After that, 
50 pi of GST beads were added and the mixture was incubated for a further 1 hr to
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capture the GST-tagged proteins. Proteins bound to the beads were then washed with 
4 changes of lysis buffer or buffer containing higher salt content, see Table 5-5. Each 
wash consisting of centrifuging at 500 g for 30 sec and incubation on rotator at 4°C for 
> 2 min with addition of fresh buffer. In the last wash, the proteins were resuspended 
in PRMT buffer. To visualize the proteins by Coomassie/silver staining, PRMT buffer 
was removed from the beads by centrifugation and the proteins were eluted from the 
beads by addition of 2 X SDS sample buffer. Distinct bands on the SDS-PAGE gel 
were excised and were sent to CRUK protein analysis service for mass spectrometry 
identification.
5.5.5 HDAC assay
Biotinylated histone H4 peptide was acetylated with 3H-Acetyl-coenzyme A 
(Amersham) using reagents and instructions provided in the Histone Deacetylase Kit 
(Upstate). After labeling and coupling to strepavidin agarose, the 3H-histone H4 
peptide was quantified by scintillation counting in Ultima Gold LLT (Perkin Elmer) 
scintillation fluid. Labeled peptides (30,000 to 40,000 CPM) were used for each assay 
to detect for HDAC activity in normalized FLAG-MBD2 protein complexes. The 
reaction was incubated, stopped and assayed for 3H-Acetate release according to 
manufacturer’s instruction. Sodium Butyrate (250 mM) was included as a control for 
unspecific release of H-Acetate molecules.
5.5.6 Gel shift assay
Methylated DNA probe was labeled at the 5' end using polynucleotide kinase 
(New England Biolabs) and y P-ATP (Amersham) according to manufacturer’s 
instructions. For labeling of RNA probes, plasmid DNA encoding the RNA was 
linearized with an appropriate restriction enzyme and transcribed in vitro with SP6 
RNA polymerase (Promega) and in the presence of a 32P-UTP according to 
manufacturer’s instruction. The reaction was treated with DNase I for 15 min at 37°C 
and the RNA was purified using G-50 spin column (Qiagen).
FLAG-tagged proteins purified as for Chapter 5.4.6 were incubated with the 
32P-labelled nucleic acids in the presence of buffer consisting of 40 mM HEPES pH 
7.3, 110 mM K-acetate, 6 mM Mg-acetate, 250 mM sucrose, 1 mM DTT and 0.1%
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NP40. All incubations were carried out on ice for 20 min. In RNA interaction 
experiments, 20 units of RNasin (Promega) were used, whereas in DNA interaction 
experiments, 0.1 mg/ml yeast tRNA (Ambion) was used. After incubation, the 
reactions were separated on a 1% agarose gel electrophoresis and the gels were 
resolved at 4°C using 0.5% TBE in DEPC water. The gel was dried and analyzed as 
for Fluorography in 5.1.4.
5.5.7 Biotin DNA interaction assay
DNA was synthesized by CRUK oligo services in the sequence of 5’- 
GATCJGAJGAJGAJGAJGAJGAJGAJGAJGAJGAJGAJGA-3’ where J represents 
the cytosine base that can be methylated or unmethylated accordingly. A 5'-biotin 
label was coupled to the first base. Complementary strands of the sequences were 
synthesized and 1 pg of the sense and antisense strand was annealed as described in 
Chapter 5.2.3.
Blocking of the Strepavidin agarose (Sigma) beads was carried out by adding 
50 pi of beads to 500 pi of 3% BSA in PBS for 1 hr. The beads were then washed 3 
times with 1 ml of DNA wash buffer containing 40 mM Hepes.KOH pH 7.5, 350 mM 
KC1 and 0.01% NP40. Beads were then added to the annealed oligos in binding buffer 
containing 40 mM Hepes.KOH pH 7.5, 100 mM KC1 and 6 mM MgCh to bind at 4°C 
on rotator for 12 -  16 hr. Non-specific binding of DNA was avoided by washing 4 
times in DNA wash buffer. The strepavidin-agarose-DNA complex was added to 5 pg 
of FLAG-MBD2 (Empigen purified) in 250 pi buffer containing 30 mM Hepes.KOH 
pH 7.5, 100 mM NaCl, 5% glycerol, 0.25 mg/ml tRNA, 0.5% Triton X-100, 2 mM 
DTT and protease inhibitors15. The binding was carried out for 2 hr 30 min before the 
proteins were sequentially eluted from the beads. Wash buffer for the elution 
consisted of a base buffer containing 40 mM Hepes.KOH, 2 mM EDTA and 0.5% 
Triton X, the strepavidin-agarose-DNA-FLAG MBD2 complex was washed 6 times 
with a stepwise increase in NaCl concentration. Each wash consisted of 10 min 
incubation with rotation at 4°C and centrifugation at 500 g for 30 sec. The proteins 
were recovered as described in 5.5.3. The final fraction of proteins present on the
15 For protease inhibitors, refer to Chapter 5.4.4.
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beads was eluted with SDS-sample buffer, all fractions were loaded onto SDS-PAGE 
for analysis by Coomassie, and Western blots.
5.5.8 Luciferase assay using pGL2-promoter reporter plasmid
Unmethylated reporter plasmid (pGL2-promoter, Promega) was raised from 
E. coli JM109 and was subjected to mock or CpG-methylation using M.SssI (New 
England Biolabs). Completion of methylation was verified by digestion with Fspl.
Cells of 50% confluence in a 6 well plate were transfected with 2.45 pg total 
plasmid and 24.5 pi Effectene Transfection reagent (Qiagen). Each transfection 
consisted of 2 pg of methylated or unmethylated reporter plasmid expressing the 
firefly luciferase gene and 200 ng of control plasmid encoding the Renilla reniformis 
luciferase (pRL-TK, Promega). 250 ng of FLAG-MBD construct was included to test 
their repression activity.
Luciferase levels were measured after 12-15 hr using the Dual-Luciferase 
Assay Kit according to manufacturer’s instruction (Promega). Corrected values were 
obtained by calculation of firefly/renilla luciferase. Relative transcription was 
obtained by calculating methylated/unmethylated reporter using the corrected values. 
Relative transcription activity is the average of three independent experiments.
5.5.9 Luciferase assay using pG5-DNA polymerase-P reporter plasmid
Reporter plasmid (2 pg of pG5 DNA polymerase-(3) encoding the firefly 
luciferase protein and 5 ng of control plasmid encoding the Renilla reniformis protein 
(pRL-TK, Promega) were cotransfected with 45 - 405 ng of Gal4-MBD2 fusion 
proteins to assay for their repression activity. The total DNA mix was topped up with 
empty pGal vector to 2.45 pg and transfected with 24.5 pi of Effectene Transfection 
reagent (Qiagen) to 293T cells at 70% confluence in a well of the 6 well plates. 
Firefly and renilla luciferase activities were measured 48 hr post transfection using the 
Dual-Luciferase Assay Kit (Promega) and according to the manufacturer’s instruction. 
Relative luciferase unit (RLU) was expressed as a ratio of luciferase/renilla activity 
and each sample usually represents the average of 3 independent transfections. 
Proteins used for the assay were collected by precipitating the supernatant as described
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in Chapter 5.5.3 and resuspending the pellet in SDS sample buffer, both fractions were 
pooled and analyzed for expression of Gal4 fusion proteins by Western blot.
5.6 Antibodies used in this thesis
All information on 
following table.
Antibodies Product 
number
antibodies used 
Host animal
for this study is 
Manufacturer
summarized in
Applications 
in this thesis
Control IgG SC-2025 Mouse Santa Cruz control for IP
Control IgG SC-2027 Rabbit
Biotechnology 
Santa Cruz control for IP
Control IgG SC-2717 Sheep
Biotechnology 
Santa Cruz control for IP
Control IgG SC-2028 Goat
Biotechnology 
Santa Cruz control for IP
Flag M2 A8592 Mouse
Biotechnology
Sigma WB
HRP
Flag-M2 F3165 Mouse Sigma WB, IF
Flag-M2 A2220 Mouse Sigma IP
Agarose
Gal4 SC-577 Rabbit Santa Cruz WB
HDAC1 2E10 Mouse
Biotechnology
Upstate IP
HDAC1 PC-544 Rabbit Calbiochem IP, WB
HDAC2 H54 Rabbit Santa Cruz IP, WB
hnRNP A1 4B10 Mouse
Biotechnology
Dreyfuss WB
hnRNP A1 Y15 Goat Santa Cruz IP, WB
IgG Goat Sc-2020 Donkey
Biotechnology 
Santa Cruz HRP
IgG Mouse 115-035-068 Goat
Biotechnology
Jackson
conjugate
secondary
HRP
IgG Rabbit 62-6120 Goat
Immuno
Research
Zymed
conjugate
secondary
HRP
IgG Sheep 12-342 Rabbit Upstate
conjugate
secondary
HRP
MBD2 S923 Sheep Upstate
conjugate
secondary
IP
MBD2 N18 Goat Santa Cruz IP, WB
Biotechnology
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MBD2 D15 Goat Santa Cruz 
Biotechnology
IP, WB and 
IF
MEP50 MC1F5 Mouse Gideon
Dreyfuss
WB (1:2000)
Methylargini
nes
7E6 Mouse Abeam WB
Methylargini
nes
21C7 Mouse Abeam WB
Methylargini
nes
16B11 Mouse Abeam WB
Methylargini
nes
5D1 Mouse Abeam WB
Methylargini
nes
SymlO Rabbit Upstate WB
Methylargini
nes
Asym24 Rabbit Upstate WB
Methylargini
nes
Syml 1 Rabbit Upstate WB
Mi2 H242 Rabbit Santa Cruz 
Biotechnology
WB
MTA2 C20 Goat Santa Cruz 
Biotechnology
IP, WB
p53 pAB1801 Mouse Cancer Research 
Technologies
WB
pICIn P88320 Mouse BD
Transduction
Laboratories
WB
PRMT1 07-404 Rabbit Upstate IP, WB and 
IF
PRMT3 07-256 Rabbit Upstate WB
PRMT4 07-080 Rabbit Upstate WB
PRMT5 6G8 Mouse Gideon
Dreyfuss
WB (1:100)
PRMT5 07-405 Rabbit Upstate IP, WB and 
IF
Ran 610341 Mouse BD
Transduction
Laboratories
WB and IF
RbAp46 PC-546 Rabbit Oncogene IP, WB
RbAp48 PC-545 Rabbit Oncogene IP, WB
Sin3A AK11 Rabbit Santa Cruz 
Biotechnology
WB
Table 5-6 Detail list of all antibodies used in this study.
Unless otherwise stated, all antibodies were used according to the manufacturer’s 
instruction. IP = immunoprecipitation, WB = Western blot and IF = 
immunofluorescence.
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5.7 Plasmids used in this thesis
All information on antibodies used for this study is summarized in the 
following table.
Plasmids Tag Provider Gene
sequence
from
Usage in this study
GAR GST Tina
Braschome
NA Expression of 
proteins in bacteria
MBD2 C-terminus GST Brain
Hendrich
Mouse cells
MBD2 full-length GST Brain
Hendrich
Mouse
MBD2 N-terminus GST Brain
Hendrich
Mouse
MBD2 RG domain GST Sara
Nakielny
Mouse
MeCP2 C-terminus 
MeCP2 full-length
GST
GST
Xingsheng
Nan
Xingsheng
Nan
Rat
Rat
MeCP2 N-terminus GST Xingsheng
Nan
Rat
MeCP2 RG 
domain
GST Sara
Nakielny
Rat
pCDNA3.1 -Flag-
Gateway
destination
Linda Jeffery Gateway cloning
pCDNA5/FRT/TO-
Flag-Gateway
destinaion
Flag Janet
Cronshaw
pDONR221 - Invitrogen -
pGal (1-94)
Gateway
destination
This study Mouse
MBD2 (1-131) Flag This study Mouse Expression of
MBD2 (-RG14a) Flag This study Mouse proteins in
MBD2 (-RG14b) Flag This study Mouse mammalian cells
MBD2 (-RG18) Flag This study Mouse
MBD2 (-RG23) Flag This study Mouse
MBD2 (-RG29a) Flag This study Mouse
MBD2 (-RG29b) Flag This study Mouse
MBD2 (-RG36) Flag This study Mouse
MBD2 (-RG41) Flag This study Mouse
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MBD2 (-RG9) Flag This study Mouse
MBD2 (-TRD15) Flag This study Mouse
MBD2 (-TRD32) Flag This study Mouse
MBD2 (-TRD94) Flag This study Mouse
MeCP2 (R106W) Flag Linda Jeffery Rat
PRMT1 GFP Mark Human
Bedford
PRMT3 GFP Mark Human
Bedford
PRMT4 GFP Mark Human
Bedford
PRMT5 Flag Westley Human
Friesen
MBD2 (-RG) Flag Linda Jeffery Mouse
MBD2 full-length Flag Saori Kitao Mouse
MBD3 Flag Brain Mouse
Hendrich
MeCP2 (-RG) Flag Linda Jeffery Rat
MeCP2 full-length Flag Xingsheng Rat
Nan
SmDl Flag Westley Human
Friesen
pG5DNA - J. Millbrandt - Reporter gene
polymerase Beta expression studies
pGL2-promoter - Promega -
pRL-TK - Promega -
MBD2 (1-131) Gal This study Mouse
MBD2 (-TRD15) Gal This study Mouse
MBD2 (-TRD32) Gal This study Mouse
MBD2 (-TRD94) Gal This study Mouse
pGal (1-94) Gal Caroline Hill -
pRetro.Super - Miguel - siRNA stable cells
Martins generation
PRMT 1A - This study Human
PRMT IB - This study Human
PRMT 1C - This study Human
PRMT ID - This study Human
PRMT5A - This study Human
PRMT5B - This study Human
PRMT5C - This study Human
PRMT5D - This study Human
Table 5-7 Detail list of plasmids used in this study.
Further information can be provided upon request.
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Chapter 6 Supplementary results
6.1 Determine of the optimal SAH concentration for in  v itr o  
methylation assay
[SAH]
MBD2 5 uM 20 uM 50 uM
ee N C + - + - +D O -------
45— « a »
29 —
3H Fluorograph
Figure 6-1 Determination of best inhibitor concentration for methylation assay.
GST-MBD2 (N and C-terminus) were subjected to methylation assay as for Figure 2-1 
and GST-MBD2 N-terminus methylation was titrated with an increasing concentration 
of SAH or control.
SAH concentration was titrated from 5-50 pM (Figure 6-1) instead of the 10 
pM used in previous assays. It was found that even at the presence of 50 pM SAH, the 
GST-MBD2 N-terminus protein was still labeled by the methyltransferases in 
mammalian cell lysate. Therefore, 100 pM of SAH was used in all methylation assays 
thereafter.
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6.2 Immunopurifying endogenous MBD2 for mass spectrometry 
analysis
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Figure 6-2 Immunopurification of endogenous MBD2 protein.
(Top) Determination of cell types that express the highest amount of MBD2 protein. 
Different cells types (1 X 106 cells each) were lysed in RIPA buffer and the Bradford 
normalized lysates were checked on Western blot for their endogenous levels of MBD2.
(Bottom) Determination of the suitable antibody for the immunopurification of MBD2 
protein. The indicated cell lysate were used for immunoprecipitation by incubating 
with the indicated antibodies and the antibody-i\IBD2 complexes were captured by 
Protein G agarose. Immunopurified complex were washed 6 times with the lysis buffer, 
eluted with SDS-PAGE sample buffer and analyzed by Western blot. (*) Denotes 
antibody heavy chain.
To immunopurify endogenous MBD2 proteins, expression levels of the 
protein in several cell types were compared in Western blot (Figure 6-2, Top). Similar 
to other reports, endogenous MBD2 always resolves as a doublet band (170). It was 
found that MBD2 protein level was highest in Ramos cells, in other cells (eg. 293T) 
MBD2 proteins were not detectable (data not shown).
Various MBD2 specific antibodies were also tested for their 
immunoprecipitation efficiencies (Figure 6-2, Bottom), it was found that the D15 
antibody immunoprecipitate MBD2 proteins most efficiently. Therefore, all
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subsequent MBD2 immunoprecipitations uses this antibody. As MBD2 migrates at 48 
kDa, to ensure that the immunoprecipitated bands observed were not the degradation 
products of the 50 kDa antibodies heavy chain, control experiments of antibodies in 
lysis buffer without cellular protein were included.
Since protein samples collected from immunoprecipitations need to be 
relatively pure for mass spectrometry analysis, the lysis buffer and wash buffer used 
for the immunoprecipitation were optimized to obtain a good balance between yield 
and purity.
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Figure 6-3 Optimization of washing condition for IP.
Endogenous MBD2 protein was immunopurified from Ramos cells lysed in RIPA buffer 
and the captured antibody-MBD2 complexes were washed with the indicated 
concentrations of Empigen BB. Half of the IP products were analyzed by silver staining 
(Left) and the remaining was analyzed by Western (Right). (*) Denotes antibody heavy 
chain.
Wash conditions for the immunoprecipitation of MBD2 were titrated with 
increasing amounts of detergent. Empigen BB, the zwitterionic detergent was chosen 
for this purpose because it is known to solublize proteins effectively but yet preserves 
the epitope and maintains the reactivity of antibodies (142). However, when the 
complexes prepared in increased percentages of Empigen BB, there were no increase 
the cleanliness of the samples (Figure 6-3, silver staining). Moreover, increasing the
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percentage of Empigen beyond 0.2% decreases the yield of MBD2. Therefore, 
purification of the endogenous MBD2 protein was carried out without addition of 
Empigen BB.
6.3 GST pull down assay using HeLa and Ramos cell lysates
HeLa lysate Ram os lysate
MW t
s s
GST GST GST
= only MeCP2 MBD2
c  RG RG
dom ain dom ain
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118 —  
9 7 — I
66 —
45 —
29 —
GST GST 
MeCP2 MBD2 
RG RG 
dom ain dom ain
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1 2  3 4
C oom assie
5 6 7 8 9 10 11 12
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Figure 6-4 Identifying the interacting partners of the RG domain of MBD.
GST protein or the GST-tagged RG domain of MeCP2 and MBD2 proteins were 
incubated in the absence or presence of the indicated cell lysates at 4°C for 4 hr and the 
proteins were captured by Glutathione Sepharose. After extensive washing, proteins 
were eluted from the Sepharose beads by SDS-PAGE sample buffer, resolved by SDS- 
PAGE and visualized by Coomassie. Selected protein bands were excised from the gel 
and were sent for mass spectrometry identification.
In Figure 6-4, proteins from HeLa and Ramos cell lysates were allowed to 
interact with various GST proteins, the complexes and were washed under stringent 
conditions to enrich for proteins that were specifically interacting with the RG 
domains (Lane 4, 6, 10 and 12).
To ensure all protein bands on the gel were from the cell lysate were not 
bacterial proteins carried over from the recombinant protein, controls samples without 
addition of cell lysate were included (3, 5, 9 and 11). Also, to eliminate bands that
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were result of the unspecific interaction between the mammalian proteins with the 
GST-tag or glutathione sepharose beads, the GST proteins were incubated with the 
lysates (Lane 1, 2, 7 and 8). From this experiment, a total of 35 protein bands were 
selected and excised from the gel for mass spectrometry identification (Data not 
shown). However, none of the bands identified was protein methyltransferase.
6.4 MBD2 from prmtl ES cells migrate differently in SDS-PAGE
75 V
______________ Cell lysate_______________
WT prmtl WT prmtl WT prmtl WT prmtl
150 V
7.5% ‘ 
15% *  
4-12% 
*7.5% 
15%
wb wet ***
4-12%
1 2 3 4 5 6 7 8
Western MBD2
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p rm tl WT
Adox :
9 10 11 12
Western MBD2
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+
4 5 —
29 —
-Western MBD2
-Western Ran
11 12 9
Figure 6-5 Analysis of the migration of MBD2 in SDS-PAGE.
(Top) Wild-type and prmtl normalized cell lysate were separated on different SDS- 
PAGE conditions and analyzed by Western blot. The optimum condition selected is 
indicated with an (*).
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(Middle) The indicated cells were treated in the absence or presence of Adox for 30 hr 
and normalized cell lysates prepared were separated with the optimum condition 
indicated above.
(Bottom) Samples from above were reanalyzed with MBD2 and Ran antibody probing 
on the same Western blot.
Various gel systems were used to separate the wild-type and prmtl ES cell 
lysates to determine if there was any observable difference in gel mobility of the 
MBD2 proteins obtained from different cells. Gels with the lowest (7.5%) and highest 
(15%) concentration of polyacrylamide were compared with 4-12% gradient gels in 
their ability to illustrate the difference in mobility between the MBD2 protein obtained 
from different sources. The voltage used for the electrophoresis was also varied in this 
instance (Figure 6-5, Top). To ensure that any mobility difference observed was not 
artificially produced by a gel “smiling” effect, equal amount of wild-type ES lysate 
(Lane 1, 3, 5 and 7) were compared alongside prmtl lysate (2, 4, 6 and 8).
With the exception of the 7.5% and 15% SDS-PAGE gel running at constant 
75 V, all other conditions revealed a difference in mobility of the MBD2 proteins in 
the prmtl cell lysate versus the wild-type cell lysate. The most distinctive difference is 
achieved by running in 7.5% polyacrylamide gel at 150 V (*), where the upper band of 
the MBD2 proteins in wild-type ES cells (Lane 1, 3, 5 and 7) was almost separated 
into two bands while the MBD2 bands from prmtl cells maintained their normal 
appearance.
To test whether the slower migrating MBD2 protein from wild-type ES cells 
is an effect of a methyltransferase event, both ES cells were cultured in the absence or 
presence of Adox. The resultant lysates were analyzed using the optimized SDS- 
PAGE conditions (Figure 6-5, Middle). There was not much difference in mobility of 
MBD2 protein from untreated and treated prmtl cells (Lane 9 vs 10) but untreated 
MBD2 proteins from wild-type ES cells (Lane 11) migrated slower than their Adox 
treated counterpart (Lane 12), and the MBD2 proteins from prmtl cells (Lane 9 and 
10).
The samples were reanalyzed using the same SDS-PAGE conditions and the 
Western blot was probed with antibodies against MBD2 and Ran (Figure 6-5, Bottom).
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As observed, migration of all Ran proteins in the same gel (Lane 11,12 and 9) was not 
affected by the genetic background or Adox treatment of the cells, but MBD2 from 
untreated wild-type ES cells (Lane 11) was migrating slower than in the rest of the 
samples (Lane 12 and 9).
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6.5 Increasing MBD2 arginine methylation by increasing PRMT 
contents of the cells
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Figure 6-6 Cotransfecting PRMTs with MBD2.
(Top) 293T cells were transfected with FLAG-MBD2 and the indicated PRMT plasmids 
for 48hr. The cells were then lysed, Bradford normalized and Western with the
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indicated antibodies to assay for the expression of the transfected plasmids, Ran levels 
indicates protein loading.
(Bottom) The FLAG proteins were then prepared and normalized as for Figure 2-15 and 
normalized proteins were subjected to Western to detect for dimethylarginines.
Western blot with FLAG antibody indicates protein loading.
As arginine methylation of MBD2 involves at least two PRMTs, various type 
I PRMTs were transfected either alone, or in combination with PRMT5, the type II 
PRMT. At 48 hr post transfection, the FLAG-MBD2 and FLAG-PRMT5 proteins 
were checked for their expression levels in the lysate (Figure 6-6, top) and were 
immunoprecipitated to quantify for the methylarginine contents of MBD2.
It was found that MBD2 raised in cells that expressed FLAG-PRMT5 did not 
display an increase in level of symmetric dimethylarginine (Figure 6-6, bottom, Lane 
14-18). Similarly, expression of all PRMT1 in cells did not increase the levels of 
asymmetric dimethylarginine on MBD2 (Lane 11 and 15). MBD2 proteins with the 
highest level of arginine methylation were those raised in cells without overexpression 
of PRMT proteins (Lane 10). Thus, the experiment shows that it is unfeasible to 
increase arginine methylation of MBD2 by overexpressing PRMTs.
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